

AUTHOR INDEX

VOLUME 42

- Aarestrup, Frank M., 3331
 Abbott, Karen H., 813
 Abdel-Rahman, Susan M., 2706
 Abe, Kenji, 1340
 Abe, Koh, 1866
 Abe, Shigeru, 1587
 Abudullah, Noor Rain, 37
 Achour, Ammar, 2482
 Adams, John M., 409, 821
 Addis, Antonio, 1336
 Adebij, Antoinette-Mary A., 502
 Adrian, Peter V., 2221
 Aeschlimann, Jeffrey R., 254, 721, 981, 2188, 2710
 Agnani, H., 540
 Aguesse-Germon, Stéphanie, 369
 Aguilar, C., 1601
 Aguilar, L., 1574
 Aguilar, Lorenzo, 1361
 Ahmad, Imran, 767
 Aihara, Miki, 1895
 Aikawa, Masamichi, 1985
 Air, Gillian M., 801
 Aitken, Ingrid A., 83
 Akasaka, Takaaki, 1284
 Akeb, Fatima, 2656
 Akiyama, Yoshiko, 2492
 Al-Abdely, Hail M., 2542
 Alak, Ala, 2391
 Alangaden, George J., 1295
 Alaoui-Jamali, Moulay A., 779
 Alarcón, Balbino, 2668
 Alcaide, Fernando, 2792
 Alcalá, Luis, 2452
 Alcina, Antonio, 2668
 Alder, J. D., 2385
 Alder, Jeffrey D., 2674
 Al-Hattawi, K., 2799
 Alifano, Pietro, 571
 Allan, Paula W., 1045
 Allery, A., 2125
 Allignet, Jeanine, 1794
 Alliot, Pierre, 1093
 Allocco, Alessandra, 1745
 Almela, M. J., 2863
 Al-Mohsen, Ibrahim, 2399
 Alonso, M. A., 1306
 Alós, Juan-Ignacio, 989
 Alovero, Fabiana, 1495
 Alpert, Nathaniel M., 2048
 Amano, Ken-ichi, 1895
 Ambrosetti, P., 2966
 Amicosante, Gianfranco, 1459
 Amoroso, Ana M., 228
 Amsden, Guy W., 695, 927, 1578
 Amyes, Sebastian G. B., 2221
 Anaissie, Elias, 1512
 Anaissie, Elias J., 129, 606
 Ananth, Sandya L., 801
 Anderson, Barry D., 1815
 Anderson, Jennifer, 1985
 Anderson, Kevin P., 971
 Andersson, Siv G. E., 1845
 Andes, D., 2375
 Andrei, Graciela, 216, 3285
 Andreoni, Massimo, 2017
 Andreou, Roseann, 1336
 Andrés, María T., 3022
 Andrews, J. M., 428
 Angarano, Gioacchino, 1346
 Angus, P. W., 3130
 Annaert, Pieter, 1568
 Annis, Charles G., 2456
 Ansorg, R., 725
 Anton, K. E., 1620
 Antonakis, Kostas, 779
 Aoki, Hiroyuki, 3251
 Aoki, Miho, 1666
 Aouad, Arlette, 1295
 Appelbaum, P. C., 624, 1503
 Appelbaum, Peter C., 495, 589, 857, 953, 1253, 1263, 1269, 2002, 2459, 2914, 3028, 3032
 Appelmelk, B. J., 3073
 Aquino, A., 550
 Arai, Sei-Ichi, 1298
 Arata, Jirō, 3141
 Araujo, Fausto G., 2284
 Archer, Gordon L., 306, 1355
 Ardanuy, Carmen, 53, 1636
 Argème, Maxime, 1093
 Argenson, Jean Noel, 3086
 Arimilli, Murty N., 1568
 Ariza, Javier, 53
 Arlet, Guillaume, 464, 2352
 Arnett, Gussie, 1045
 Arnfinnsson, Jóhann, 2290
 Arpin, C., 2125
 Arranz, M. E., 618
 Asahi, Yasuko, 2267
 Asai, Masaki, 2178
 Asaka, Masahiro, 1895
 Ashton, C. H., 1256
 Astier, Alain, 2141
 Atkinson, Jill D., 682
 Aubry-Damon, Hélène, 2590
 Augustijns, Patrick, 1568
 Austria, Natasha E., 88
 Avery, Mitchell A., 1454
 Aymon, D., 2966
 Azad, Abdu F., 1845
 Azad, Raana F., 971
 Azijn, Hilde, 269
 Azoulay-Dupuis, Esther, 862
 Babczinski, Peter, 2197
 Babich, John W., 2048
 Babini, Gioia S., 1168
 Babu, Y. Sudhakar, 801
 Bacchi, Cyrus J., 2718
 Bacher, John, 2399, 2700, 2898
 Bader, Augustinus, 1052
 Baillie, A. J., 2722
 Baillie, George S., 1900, 2146
 Bajaksouzian, Saralee, 3032
 Bajic, Marina, 2495
 Bajic, Miroslav, 2495
 Baker, Carol J., 1517
 Bakker-Woudenberg, Irma A. J. M., 1677, 2431, 2437
 Bala, Shukal, 2336
 Balas, Delia, 2792
 Balcabao, I. P., 1574
 Baldanti, Fausto, 444
 Balis, Frank M., 1815, 3187
 Balkovec, James M., 1985
 Ballesta, Sofia, 1850
 Ballet, Jean J., 818
 Ballou, Charles H., 521
 Ballweber, L. M., 1239, 1726
 Baltch, Aldona L., 2405, 2564, 3153
 Balzarini, J., 618
 Banach, Mary, 631
 Banerjee, Goutam, 348
 Banerjee, Partha, 1105
 Bannam, Trudi L., 1563
 Banovic, Linda, 921
 Bantia, Shanta, 801
 Baquero, F., 3279
 Baquero, Fernando, 1042
 Baragwanath Ciprofloxacin Study Group, the, 2235
 Barbaut, X., 1731
 Barbet, J. P., 1334
 Barbuch, R., 1160
 Barchiesi, Francesco J., 151
 Bard, M., 1160
 Barditch-Crovo, Patricia, 2380
 Barenholz, Yechezkel, 3092
 Barg, Neil L., 3317
 Barker, Helen, 2171
 Barnaud, Guilene, 2352
 Barone, Joseph A., 1862
 Barret, John, 2391
 Barrett, John F., 1529
 Barrow, Esther L. W., 2682
 Barrow, William W., 2682
 Barry, A. L., 945
 Barry, Arthur L., 1213, 1274, 2138, 2765
 Barthélémy, Michel, 1323
 Bartlett, Marilyn S., 934
 Bartlett, M. S., 282
 Barzilai, Asher, 473
 Basco, Leonardo K., 1811, 2347
 Bassetti, Matteo, 2017, 3014
 Basu, Indira, 206
 Basu, Mukul K., 348
 Bataille, Jean Francois, 3086
 Bateson, J. H., 436
 Battersby, Luann C., 675
 Battisti, James M., 2906
 Bauchet, Jacqueline, 862
 Bauer, Madeline, 528
 Bauernfeind, Adolf, 514, 827
 Baum, Kenneth F., 1139
 Bayer, Arnold S., 1837, 3169
 Beauchamp, Belinda, 1315
 Bébear, C., 703
 Bébear, Cécile M., 2024, 2304, 2474
 Bébear, Christiane, 2024, 2304, 2474
 Bébear, C. M., 703
 Beccani-Argème, Mireille, 1093
 Bédos, Jean-Pierre, 862
 Behn, Ingrid, 1911
 Bejaoui, Noureddine, 1966
 Bekersky, Ihor, 263, 2391
 Bekkering, Michelle, 59
 Bell, Aaron, 2898
 Benali, Karim, 942
 Benbow, John W., 339
 Bender, Brendan C., 666
 Benedi, Vicente Javier, 1636, 1850
 Benhamou, P. H., 1334
 Bennett, John E., 1695
 Bennett, L. Lee, Jr., 1045
 Bennett, P. M., 436
 Berche, Patrick, 108
 Berg, Jeanne, 2784
 Berger-Bachi, Brigitte, 564, 936
 Bergeret, M., 1334
 Bergeron, Michel G., 2527, 3309
 Bergeron, Yves, 2527, 3309
 Bergsson, Gudmundur, 2290
 Berman, Adam L., 1098
 Bermudez, Luiz E., 180
 Bernberg, Erin L., 339
 Berry, Valerie, 3193
 Bertin, Philippe, 209
 Bertino, J. S., Jr., 1842
 Bertrand, Guylène, 1068
 Betebenner, David, 3218
 Bethel, James, 631
 Beutner, Karl R., 789
 Beveridge, Terry J., 1476
 Bhachech, Niraja, 1671
 Bhakdi, Sucharit, 2569
 Bhattacharjee, Apurba K., 583
 Bhattacharya, M. K., 206
 Bhattacharya, S. K., 206
 Bhavnani, Sujata M., 521
 Bhinderwala, Naseema S., 1447
 Biava, Mariangela, 3035
 Bickii, Jean, 2347
 Biddle, James W., 3024
 Bierbaum, Gabriele, 154
 Bierman, Robert H., 1862
 Bijsterbosch, Martin K., 1146
 Bilello, J. A., 2153
 Bilello, P. A., 2153
 Bille, J., 2966
 Bille, Jacques, 241
 Billon, Marie A., 352
 Bingen, Edouard, 942
 Biot, C., 540
 Biron, Karen K., 444
 Bischofberger, Norbert, 612, 640, 647, 1568
 Björkman, Anders, 1222
 Blagburn, Byron L., 2877
 Blampain, G., 540
 Blanton, Ronald E., 601
 Blaser, Jürg, 895
 Blázquez, Jesús, 1042
 Bleton, Rémy, 2830
 Bleyzac, N., 1731
 Blokpoel, Marian C. J., 1931
 Blondelet-Rouault, Marie-Hélène, 2612
 Bloor, Stuart, 269
 Blouin, Robert A., 2602
 Bocanegra, Rosie, 2371, 2467, 2542
 Boden, Daniel, 2775
 Bodnar, Ulana R., 734
 Boldrini, E., 2434
 Boman, Nancy L., 45
 Bonab, Ali A., 2048
 Bonacorsi, Stephane, 942
 Bonati, Maurizio, 1336
 Bonay, Pedro, 2668
 Bonino, Alessandro, 1745
 Bonmassar, E., 550
 Bonnafous, Pascale, 2066
 Bonnefoy, Alain, 1392
 Bonner, Daniel P., 313

- Bopp, Lawrence H., 2564
 Bordon, Florence, 209
 Borel, Christelle, 369
 Borg, Natalia, 2174
 Borin, Marie, 3014
 Borner, K., 459
 Borner, Klaus, 1470
 Borucki, Michael J., 1139
 Boschman, Cynthia R., 734
 Boswell, Garry, 2391
 Boswell, Garry W., 263
 Botha, P. L., 2752
 Boucher, Bradley A., 930
 Boudjadja, A., 703
 Bouffard, F. Aileen, 1985
 Bouquet, Serge, 2756
 Bouthors, A. T., 3113
 Bouvier d'Yvoire, M. Y., 1731
 Bouza, Emilio, 2452
 Bové, Joseph M., 2304
 Bové, Joseph Marie, 2024
 Bowden, Raleigh A., 2584
 Bowker, K. E., 419
 Boyaka, Prosper N., 2607
 Boyer, Paul L., 447
 Boykin, David, 2495
 Boykin, David W., 2503, 2877
 Bracchi, Valerie, 2456
 Bracey, Dani, 2160
 Bradford, Patricia A., 1671, 1980
 Bradley, Suzanne F., 1305
 Braga, Pier Carlo, 18
 Brandt, M. E., 3242
 Branzoni, Manuela, 1931
 Brasseur, Philippe, 818
 Brasseur, Robert, 209
 Bray, Patrick G., 682, 2973
 Bredberg, Anders, 1923
 Breisch, S., 114
 Breitschwerdt, Edward B., 362
 Brenner, Zigman, 2549
 Brenner, M. B., 550
 Brenwald, Nigel P., 2032
 Bret, L., 1110
 Breyer, Stefan, 2417
 Bridges, Edward G., 1799, 1805
 Brien, Jo-anne E., 1370
 Brink, Douglas N., 1073
 Brinkman, A. B., 2749
 Briones, Marcelo R. S., 2731
 Brocard, J., 540
 Brockman, A., 135
 Brooks, Jason V., 3047
 Brötz, Heike, 154
 Brown, Melissa H., 475
 Brown, Scott L., 583
 Brown, S. D., 945
 Brown, Steven D., 1213, 1274, 2138, 2765
 Bruce, A. Gregory, 1133
 Brück, W., 1397
 Brueckner, Ralf P., 675, 1293
 Brummer, Elmer, 907, 2299
 Brun, Reto, 2858
 Bruni, Carmelo Bruno, 571
 Bruno, Antonella, 2232
 Brun-Pascaud, Monique, 1068
 Bruzzese, T., 3012
 Bryant, Martin L., 478
 Bryskier, A., 1944
 Bryskier, André, 965, 1509
 Bu, Ming, 487
 Bucci, Cecilia, 571
 Bucke, W., 459
 Buckheit, Robert W., Jr., 487
 Buckner, Frederick S., 3245
 Budhani, R. K., 2521
 Buell, Donald, 263, 2391
 Buiting, A., 1233
 Bukrinsky, Michael I., 1133
 Burch, Daniel J., 589
 Burger, Richard M., 709
 Burgmann, Heinz, 2417
 Burke, John P., 1402
 Bush, Karen, 1671
 Bushman, F., 2245
 Butters, Jenny A., 2171
 Bye, A., 2153
 Byers, Thomas J., 2144
 Byrne, William R., 675
 Cacho, Juana, 989
 Callahan, Ronald J., 2048
 Callender, Diana, 2700
 Callender, Diana P., 2898
 Callery-D'Amico, Susan V., 885
 Calvo, Raquel, 1028
 Cambau, Emmanuelle, 2084
 Camp, Mary J., 3103
 Campa, M., 2434
 Campbell, David A., 1447
 Canada, Todd W., 930
 Caniça, M. Manuela, 1323
 Cantoni, Rita, 1931
 Cao, Guoliang, 2784
 Cao, Y., 2637
 Capa, Laura, 2694
 Capobianco, John O., 389
 Capparelli, Edmund, 808
 Cappelletty, Diane M., 721
 Carattoli, Alessandra, 3053
 Carbon, C., 289
 Carbon, Claude, 468, 862, 2607, 2830, 2950
 Carias, Lenore L., 963
 Carides, A., 223
 Carlone, Nicola A., 1745
 Caroff, Nathalie, 1323
 Carosi, Giampiero, 1346
 Carothers, Lori, 2784
 Carr, Robert A., 1176
 Carrano, Lucia, 571
 Cars, O., 2739
 Cars, Otto, 2365
 Carter, K. C., 2722
 Carvalho-Oliveira, Leonardo, 2549
 Casadevall, Arturo, 1437
 Casari, Salvatore, 1346
 Casassus, Philippe, 849
 Casazza, Rosetta, 3014
 Casetta, Anne, 2074, 2889
 Casin, L., 3113
 Casin, Isabelle, 209
 Cassidy, Shawn M., 1878, 3146
 Catamo, G., 3000
 Cato, Allen, III, 1788
 Cavaleyra, M., 3097
 Cavanaugh, John H., 3107
 Celandroni, F., 2434
 Cenfor, Carlos, 1361
 Centrón, Daniela, 1506
 Cerami, Anthony, 1133
 Cerceau, C., 2184
 Cercenado, Emilia, 2452
 Cerwinka, S., 1088
 Cesana, Marina, 2359
 Cevini, Claudia, 2232
 Chaibi, E. B., 1110
 Chakrabarti, Debopam, 2456
 Chalkley, L. J., 2752
 Chambers, Henry F., 3325
 Chanal-Clarís, C., 1110, 2184
 Chanal-Clarís, Catherine, 2771
 Chandrasekar, Pranatharthi H., 3018
 Chanock, Stephen, 2391
 Chantot, Jean-François, 1392
 Chapman, S., 2637
 Chapman, Stanley W., 978
 Charleston, Bryan, 83
 Charron, Alain, 2024, 2304, 2474
 Chau, Françoise, 1068
 Chauhan, Sharda, 2299
 Chaves, J., 1524
 Chelstrom, Lisa M., 383
 Chen, Chih-Ming, 3218
 Chen, Lan Bo, 1340
 Chen, Ming S., 640, 647
 Chen, Minjun, 2633
 Chen, V., 1397
 Chen, Xiaojie, 3218
 Cheng, Angela, 521
 Cheng, Augustine F. B., 440, 3051
 Cheng, Darwin, 3169
 Cheng, Kit L., 927, 1578
 Cheng, Yung-Chi, 369, 833, 1799, 1805
 Cherrington, J. M., 1620
 Chevallier, Michèle, 369
 Chien, Shu-Chuan, 885
 Chillemi, Antoinette C., 2923
 Chiodo, Francesco, 1346
 Chiolerio, R., 2966
 Cho, Eun Hee, 190
 Cho, Yoon, 2206
 Chodosh, S., 114
 Choi, Myeong Jun, 2534
 Cholody, Wieslaw M., 487
 Chopra, Ian, 3282
 Choromanska, Olga, 3315
 Chou, Jenny Wen-Lin, 3146
 Chow, Andrew T., 885, 1098
 Chow, Joseph W., 1229
 Chow, J. W., 705
 Chow, Lucien L., 3325
 Christ, William J., 2824
 Christofalo, Barbara, 2295
 Christophers, Jacqueline, 868
 Chu, Chung K., 369
 Chu, Daniel, 2674
 Chu, Yiu-wai, 440, 3051
 Chuang, Yin-Ching, 1319
 Chung, Gavin A. C., 795
 Chung, Whasun O., 3022
 Church, Joseph A., 3187
 Ciferri, Orio, 1931
 Cihlar, Ronald L., 2342
 Cirioni, O., 3320
 Citron, Diane M., 1127
 Claeys, Geert, 3329
 Clancy, Cornelius J., 509
 Clark, J. M., 3209
 Classen, David C., 1402
 Claydon, Elizabeth, 2919
 Clayton, Julie, 868
 Cleare, Wendy, 1437
 Clemons, Karl V., 899
 Clewell, Don B., 1229
 Climo, Michael W., 306, 1355
 Cloud, Gretchen A., 1139
 Clumeck, A. N., 903
 Clumeck, N., 223
 Cockerill, Franklin R., III, 202
 Coen, Donald M., 971
 Coffin, Jill M., 1447
 Cohen, Jeffrey D., 916
 Cohn, David, 631
 Coira, A., 1524
 Colaizzi, John L., 1862
 Cole, Peter J., 772
 Coleman, David C., 1819
 Collado, I., 1524
 Collatz, E., 3113
 Collatz, Ekkehard, 209
 Colledge, Danni, 2132
 Colledge, D. L., 3130
 Collins, Jerry M., 1592
 Collins, L., 1853
 Collins, L. A., 344
 Collins, Peter, 868
 Colonna, Richard J., 3200, 3209
 Cometta, A., 2966
 Conant, Marcus, 269
 Content, Jean, 483
 Contreras, Lellys M., 1771
 Conway, Sameul C., 3179
 Cook, Gregory, 959
 Cookson, Barry D., 502
 Coote, Peter J., 2160
 Cordeiro, Carol, 2511
 Cordingley, Michael G., 1629
 Corey, E. J., 2731
 Corey, G. Ralph, 3169
 Cormet-Boyaka, Estelle, 2607
 Cornaglia, Giuseppe, 1459, 2848
 Cornu, Guy, 404
 Corrado, Michael, 1098
 Correia, John A., 2048
 Corti, Emiliana, 571
 Corvaisier, S., 1731
 Cossum, Paul A., 1646
 Coster, Trinka, 1293
 Côté-Richer, Mélanie, 3309
 Cotin, Agnès, 1093
 Coudron, Philip, 596
 Couet, William, 2756
 Courtois, Philippe, 2756
 Courvalin, Patrice, 2557, 2590, 2759
 Coutrot, Anne, 209
 Cove, Jonathan H., 1702
 Cox, J., 1256
 Coyette, Jacques, 534
 Craft, J. Carl, 1176
 Craig, W. A., 2375
 Craske, John, 868
 Crellin, Paul K., 1563
 Crémieux, Anne Claude, 2830
 Creti, Roberta, 712
 Cross, Alan S., 583
 Crowder, Michael W., 921
 Cruciani, Mario, 3014
 Crumacker, Clyde S., 1139, 2326
 Cuffini, Anna Maria, 1745
 Cundliffe, Eric, 715

- Cundy, Kenneth C., 647, 687, 2380
 Cunliffe, William J., 1702
 Curvale, Georges, 3086
 Cutright, Jessica L., 3018
 Cuvelier, Catherine, 468
 Cynamon, Michael H., 462, 3315
 Czarny, Agnieszka, 2495
- Dagan, Ron, 589
 Daikoku, Tohru, 2095
 Dalhoff, A., 1397, 2060
 Dalhoff, Axel, 1868
 Dal-Ré, R., 1574
 Danel, Franck, 3117
 Daniel, Barbara E., 528
 Dankert, Jacob, 319
 Dankner, Wayne, 808
 Darby, Graham, 868
 Dardenne, Olivier, 534
 D'Argenio, D. Z., 2153
 Dargis, Michèle, 3296
 Das, I., 428
 Dautrey, S., 289
 Dautrey, Sophie, 468, 2830
 Davidson, Terry G., 3103
 Davies, Todd A., 2914
 Davis, Kelly J., 675
 Davis, Patrick J., 2405
 de Azavedo, Joyce C., 2425
 de Barbeyrac, Bertille, 2474
 de Béthune, Marie-Pierre, 269, 3123
 Debets-Ossenkopp, Y. J., 2749
 De Baere, Thierry, 3329
 De Beule, Karel, 404
 Debier, M., 223
 de Cespédès, Gilda, 2889
 De Clercq, E., 618
 De Clercq, Erik, 170, 216, 1568, 3285
 Declercq, R., 618
 Deeks, Steven G., 2380
 Deguchi, Takashi, 433, 3293
 DeHertogh, Deborah A., 1139
 Deidda, Delia, 3035
 De La Campa, Adela G., 2792
 de las Heras, Federico Gómez, 2694
 Delbos-Bocage, Laurence, 2950
 Dellling, Ulrike, 1034
 Delon, Annie, 2756
 Del Poeta, Maurizio, 2495, 2503
 DeLuca-Flaherty, Camille R., 1447
 Delucia, Jennifer L., 2122
 Dempsey, Walla L., 2336
 den Hollander, Jan G., 377, 744, 749
 Deniau, Michele, 2141
 Denning, David W., 873, 2726
 Dennis, Suzana, 2784
 De Pascalis, Roberto, 571
 DeRemer, Mary, 409, 821
 de Repentigny, Louis, 404
 De Ridder, K., 2070
 De Rossi, Edda, 1931
 Derouin, Francis, 1068
 Derse, David, 487
 Deslauriers, Anne-Marie, 2527
 De Smet, Koen A. L., 1931
- De Smet, M., 223
 Desmyter, J., 618
 Dessus-Babus, Sophie, 2474
 Deutsch, P., 223
 Deutsch, Paul J., 332
 De Wit, S., 223, 903
 Déziel, Robert, 1629
 Dially, O., 1012
 Diamond, DeAnn M., 528
 Diarra, B., 1012
 Diaz, J. A., 618
 Diaz-Mitoma, Francisco, 2996
 Dibirdik, Ilker, 383
 Di Bonaventura, G., 3000
 Dick, Christian, 2569
 Diderot, Vimala, 1115
 Dieterich, H.-J., 2421
 Dietze, Beate, 2440
 DiFrancesco, Robin, 409
 Ding, James C., 528
 Dinh, Nhu-Nguyen, 2206
 Dionisi, Anna Maria, 3053
 Dix, Suzanne P., 3103
 Dodge, Richard K., 2630
 Doern, Gary V., 1762
 Doern, G. V., 3242
 Doit, Catherine, 942
 Doktor, Stella Z., 88
 Domagala, John, 956, 2978
 Domarle, I., 540
 Domínguez, Juan Manuel, 2274, 2279
 Domínguez, María Angeles, 1636
 Domon, Haruki, 555, 785
 Donabedian, S., 705
 Donabedian, Susan M., 1229
 D'Onfro, Jennifer, 1959
 Dong, Yuzhi, 956, 2978
 Donisi, Alessandra, 1346
 Donnelly, Samantha M., 1819
 Donnenfeld, Alan E., 1336
 Donskey, Curtis L., 963
 Dorenbaum, Alejandro, 1315
 Dornseif, Bruce, 1098
 Dorr, M. B., 2262
 Doshi, Vatsal, 3269
 Douglas, John M., Jr., 789
 Douglas, L. Julia, 1900, 2146
 Dowling, Ruth, 772
 Dowzicky, M., 1088
 Drabick, Joseph J., 583
 Drain, Kathryn L., 2877
 Drancourt, Michel, 3086, 3301
 Drlica, Karl, 709, 956, 2978
 Dropinski, James F., 1985
 Droppert, R. M., 3266
 Drusano, George L., 358, 631, 1098, 1105, 1417, 1512, 2153, 2326
 Duan, Jianmin, 1629
 Dubin, Donald T., 2122
 Duboc De Almeida, Gisele Madeira, 2630
 Dubreuil-Lemaire, Marie-Laure, 2141
 Duchene, Patrick, 2602
 Dudley, Michael N., 72
 Dufresne, Julien, 1245
 Dumas, Rafael, 298
 Dunn, J. P., 2240
 Dunn, Michael, 1290
 Duong, Michel, 3309
- du Plessis, Mignon, 2221
 Dupont, C., 1334
 Dupret, Jean-Marie, 1323
 Duran, M., 2637
 Durán-Chica, Isabel, 2668
 Durand, Remy, 2141
 Dutschman, Ginger E., 1799, 1805
 Dykstra, Christine C., 2495, 2503
- Eady, E. Anne, 1702
 Easmon, C. S. F., 2799
 Eaton, K. A., 1549
 Ecker, David J., 2113
 Edmonds, Anthony, 1176
 Ednie, Lois M., 1269, 2459
 Edwards, David I., 1973
 Edwards, J., 903
 Edwards, Kathryn M., 1375
 Eerola, Erkki, 2443
 Egron, Marie-Jose, 779
 Ehlers, S., 459
 Ehrhardt, A. F., 1350
 Ehrhardt, Anton F., 596
 Eiffert, H., 277
 Eisenberg, Eugene J., 647
 Eisler, M. C., 1012
 El-Farrash, Mohamed, 1340
 Elford, Howard L., 2456
 Eliopoulos, G. M., 1088, 1520
 Ellison, W., 2262
 El Menyawi, Ibrahim, 2417
 El-Shourbagy, Tawakol, 2784
 el Solh, Névine, 1794
 Endo, Masahiro, 755
 Endoh, Y. S., 3333
 Enger, Cheryl, 2240
 Engler, Michael, 1151
 Englund, Kristin, 734
 Entenza, J. M., 1889
 Erdman, Keith, 2784
 Eriksson, Staffan, 2620
 Erlendsdóttir, Helga, 1005
 Erley, C., 2421
 Ernst, Erika J., 1207, 1382, 1387
 Ernst, Michael E., 1207, 1387
 Escarpe, Paul A., 640, 647, 3234
 Esnouf, R., 618
 Espersen, Frank, 377
 Espinel-Ingroff, A., 129, 282
 Estes, Randee, 2036
 Evans, Martin E., 727
 Ewing, Patty, 2674
 Ewing, P. J., 2385
 Ezzell, John W., 675
- Facca, Bryan, 1783
 Fairfield, Alexandra, 1959
 Falconer, Derek, 2645
 Falconer, Derek J., 1695
 Falla, Timothy J., 3282
 Fantin, Bruno, 468
 Farinotti, R., 289
 Farinotti, Robert, 468, 2950
 Farley, Maureen, 3187
 Farley, Maureen Q., 1815
 Farnet, C. M., 2245
 Farris, M. G., 1088
 Fattorini, Lanfranco, 712
 Favennec, Loic, 818
 Fayz, Shirin, 1654
- Feldman, Charles, 772
 Feldmesser, Marta, 1437
 Fenoll, Asunción, 2768
 Ferdinando, Dudley P., 2160
 Fernandez, Marisol, 1517
 Fernández-Roblas, Ricardo, 1028
 Ferraro, M. J., 1520
 Ferreira, Ludmila R. P., 2549
 Ferrua, Bernard, 654
 Feuerstein, Erwin, 2399
 Fey, Paul D., 306
 Field, Hugh J., 1555
 Fierro, José F., 3022
 Filler, Scott G., 2645
 Finegold, Sydney M., 984
 Fingerioth, Joyce D., 2923
 Finlay, B. Brett, 2511
 Fioravanti, Rossella, 3035
 Fiori, GianPaolo, 1346
 Firsov, Alexander A., 659, 2841, 2848
 Fischman, Alan J., 2048
 Fisher, L. Mark, 2810
 Fishman, Jay Alan, 995, 1309
 Fitoussi, Frederic, 942
 Fitzgibbon, Joseph E., 2122
 Fluit, Ad, 1249
 Flynn, Pat, 3157
 Follansbee, Stephen, 631
 Fontana, Roberta, 2055
 Foote, Edward F., 456
 Ford, Clyde D., 1402
 Forman, Michael, 2240
 Forrat, Rémi, 298
 Forrest, Alan, 521
 Forsgren, Arne, 1923
 Förster, Christian, 1470
 Fortney, Kate, 2690
 Foster, Tim J., 564
 Fothergill, Annette, 147
 Fourel, Isabelle, 1045
 Fournier, Bénédicte, 121, 2109
 Fowler, Cynthia L., 885, 1098
 Fowler, Vance G., Jr., 3169
 Fox, Terry L., 789
 Frame, Bill, 1783
 Franceschini, Nicola, 1459
 Francois, Patrice, 564
 Franke, Mary A., 3153
 Frankenburg, Shoshana, 3092
 Franz, Renate, 3065
 Franzblau, S. G., 344
 Frech, Gabriele, 1288
 Freifeld, Alison, 2391
 French, Gary, 2771
 French, Martyn, 3038
 Fresno, Manuel, 2668
 Freys, Guy, 425
 Fridland, Arnold, 612, 1484, 2656, 3157
 Friedland, Ian R., 199, 2650
 Friedlander, Arthur M., 675
 Frimodt-Møller, Niels, 377, 1706
 Froesch, Matthias, 1052
 Frost, David J., 389
 Froyman, Robrecht, 83
 Fuchs, P. C., 945
 Fuchs, Peter C., 1213, 1274, 2138, 2765
 Fuentes, F., 414
 Fuhr, Uwe, 2359

- Fujie, Akihiko, 37
 Fujihira, Shiro, 37
 Fujii, Nobuhiro, 1895
 Fujimoto, Keisaku, 1597
 Fujioka, Hisashi, 1985
 Fujita, Naohisa, 2150
 Fujiwara, Tamio, 1340
 Fukuda, Hideyuki, 1917, 2678
 Fukuoka, Takashi, 23
 Fung-Tomc, Joan C., 313
 Furr, J. R., 2151
 Furuta, Takahisa, 37
 Furuya, Nobuhiko, 555, 1858, 2853
 Fuursted, Kurt, 377, 749
 Gaillot, Olivier, 2352
 Gama, Vivian, 1990
 Gangadharam, P. R. J., 1853
 Ganoza, M. Clelia, 3251
 Gantt, Soren M., 2731
 Gao, Hong-Qiang, 447
 García, Isabel, 1850
 García-Bermejo, Isabel, 989
 García-Bustos, José F., 2694
 García-Calvo, Gloria, 1028, 1361
 García-Garrote, Fernando, 2452
 García-Rodríguez, J. A., 1306
 Gardovska, Dace, 1980
 Gargallo-Viola, D., 2863
 Garry, Louis, 1068, 2830
 Gate, John J., 83
 Gates, Hiram, 545
 Gathmann, I., 135
 Gatti, Giorgio, 2017, 3014
 Gatti, Simonetta, 2232
 Gaudreau, Christiane, 1847, 2106
 Gauthier, Jean, 1629
 Gazouli, Maria, 1259, 1281
 Gazzard, Brian G., 293
 Gazzinelli, Ricardo T., 2549
 Geber, Antonia, 1695
 Geerts, S., 1012
 Geller, Robert B., 3103
 Gemperli, B., 135
 Gendrel, D., 1334
 Genovesi, E. V., 3209
 Georges, A. J., 540
 Georgiou, Marios, 2792
 Gerardo, Sharon Hunt, 1127
 Gerckens, Lynn S., 1996
 Gerin, John L., 2804
 Gerna, Giuseppe, 444
 Geryk, Bruce, 1542
 Geslin, Pierre, 942
 Ghaffar, Faryal, 2650
 Ghannoum, M. A., 282
 Ghannoum, Mahmoud A., 2645
 Ghate, Anita A., 801
 Ghelardi, E., 2434
 Ghuysen, Jean-Marie, 534
 Giacometti, A., 3320
 Giakkoupi, Panagiota, 1281
 Giamarellou, Helen, 939
 Gibreel, Amera, 3059, 3276
 Gieffers, Jens, 2762
 Gikas, Achilleas, 2747
 Gilbert, David N., 2259
 Gilbert, Deborah, 72
 Gilbert, Huguette, 2106
 Gill, Charles J., 1996
 Gill, Martin J., 2032
 Gill, M. J., 2799
 Gillis, T. P., 1853
 Gilmore, Claire E., 3103
 Giménez, María José, 1361
 Giménez, M. J., 1574
 Girard, Pierre-Marie, 1068
 Giraud, Annick, 1093
 Giri, Neelam, 2399, 2700
 Giuliani, A., 550
 Glatman-Freedman, Aharona, 1437
 Glauser, M. P., 1889, 2966
 Glick, Dvora, 3092
 Gnann, John W., Jr., 1139
 Gniadkowski, Marek, 514, 827, 3079
 Godwin, Karen, 1815
 Gold, H. S., 1088
 Goldberg, Burt, 2718
 Goldman, David L., 1437
 Goldman, Robert C., 389
 Goldsmith, Jonathan C., 3187
 Goldstein, Beth P., 1355
 Goldstein, Ellie J. C., 1127
 Gomez De Las Heras, F., 2863
 Gómez De Las Heras, Federico, 2274
 Gómez-Garcés, Jose-Luis, 989
 Gómez-Gómez, J. M., 1042
 Gomez-Lus, M. L., 414, 1574
 Gonzalez, Corina E., 2391, 2399, 2700
 González, Irene, 2792
 Gonzalez-Torres, Concepción, 3009
 Gooch, W. Manford, 1073
 Gordon, Morris A., 2405
 Gore, Medini A., 1447
 Gorman, Sean P., 3002
 Gotoh, Naomasa, 65, 1938
 Gottfredsson, Magnús, 1005
 Gourmelen, Anne, 2612
 Gous, A. G. S., 2235
 Grabowski, Brian, 3218
 Graham, Lisa, 487
 Granneman, G. Richard, 2784, 3107, 3218
 Granneman, Richard, 1788
 Grant, Juliana, 1454
 Grasela, Thaddeus H., 409, 821
 Grasselier, Henny, 319
 Grassi, Jacques, 2656
 Gratzl, Otmar, 2626
 Graybill, John R., 147, 151, 2371, 2467, 2542, 2938
 Graybill, J. Richard, 528
 Graziani, G., 550
 Greganti, G., 3320
 Gregis, Giampietro, 1346
 Griffin, Linda, 687
 Griffiths, Jeffrey K., 1959
 Groeneveld, Paul H. P., 739
 Groeneveld, P. H. P., 3073
 Groll, Andreas H., 2399, 2700, 2898
 Grope, Ilze, 1980
 Gropper, Michael A., 3269
 Grosse-Siestrup, Christian, 2440
 Grosset, Jacques, 1115, 2066
 Groulier, Pierre, 3086
 Grousson, Dominique, 654
 Grove, Kristie L., 833
 Grzesiowski, Pawel, 3079
 Guarnieri, Joseph, 1862
 Guarro, J., 1601
 Guay, Gordon G., 88
 Gudiol, Francisco, 53
 Gudmundsson, Sigurdur, 1005
 Guedj, Roger, 2656
 Gueylard, Delphine, 2950
 Guillemain, Isabelle, 2084
 Guillevin, Loïc, 849
 Guillen, Elizabeth, 1799
 Gümbel, Hermann, 3332
 Guo, Xin, 1799
 Gur, Deniz, 3117
 Gurwith, Marc J., 606
 Gustafson, Erik A., 2923
 Gustavson, Linda E., 1176
 Guteérrez, M. N., 1306
 Gutkind, Gabriel O., 228
 Gutmann, Laurent, 173
 Hacker, Jörg, 2817
 Hadding, Ulrich, 1249
 Haddix, Heidi, 332
 Halfar, Omar K., 1133
 Hafner, Richard, 631
 Hahn, H., 459
 Haimeur, Anass, 1689
 Hajjeh, R. A., 3242
 Hak, Janneke, 2437
 Hale, Ron L., 1447
 Hall, James Edwin, 666
 Hall, Len, 2171
 Hall, Lucinda M. C., 3117
 Hallut, Séverine, 534
 Halstenson, Charles E., 456
 Hamatake, Robert K., 3200
 Hamblin, Michael R., 2595
 Hammerschlag, Margaret R., 194, 951, 1515
 Hammerum, Anette M., 3331
 Hammonds, Timothy R., 889
 Hanaoka, Masayuki, 1597
 Hanberger, Håkan, 1222
 Hancock, Susan I., 362
 Hanes, Scott D., 930
 Hannecart-Pokorni, Eleonora, 483
 Hansen, Birgit, 1249
 Hansen, Eugene B., Jr., 1121
 Hansen, M., 2245
 Hanson, Nancy D., 596
 Hanson, N. D., 1350
 Harada, Hiroshi, 1340
 Haran, M. H., 436
 Harasaki, Tamako, 23
 Harbarth, S., 2966
 Hardin, Thomas, 147
 Harrel, Lizzie J., 3169
 Harris, Stuart I., 1176
 Hasan, Tayyaba, 2595
 Hasegawa, Takaaki, 2178, 3136
 Hashida-Okado, Takashi, 755
 Hassell, Alan E., 1862
 Hastings, Kenneth L., 2336
 Hatanaka, Masakazu, 1340
 Hatch, Richard A., 974
 Hattenbach, Lars-Olof, 3332
 Hattori, Noriaki, 1406
 Hauschildt, Sunna, 1911
 Hawley, Shaun R., 682
 Hayakawa, Isao, 1284
 Hayano, Toshihide, 1597
 Hayasawa, Hiroto, 1587
 Hayashi, Shunji, 1895
 Hazen, Kevin C., 2961
 Hector, Richard F., 2371
 Heefner, Donald, 3256
 Hegarty, Barbara C., 362
 Heidler, Steven A., 1187
 Heifets, L. B., 1853
 Heininger, A., 2421
 Heinz, Hans-Peter, 1249
 Helbig, Jürgen H., 2870
 Hell, Wolfgang, 2817
 Hellmann, Nicholas S., 2380
 Hellmann, N. S., 1620
 Hengerer, Arne, 2870
 Hennigan, Steven H., 1375
 Henriksson, Agneth, 1923
 Henry, D., 2262
 Henry, Daniel C., 1073
 Hernández-Allés, Santiago, 1636, 1850
 Herreros, E., 2863
 Herring, Vanessa L., 930
 Herscovici, Jean, 779
 Hertogs, Kurt, 269, 3123
 Hesney, Michael, 332
 Hess, Mary M., 930
 Hewitt, Ross G., 409, 821
 Heym, Beate, 879
 Hickerson, William L., 930
 Hickman, Melissa E., 1517
 Hidri, Nadia, 3304
 Higginbotham, Lindsey M., 2645
 Higgs, Christopher J., 293
 Hiles, Richard, 263
 Hill, S., 2956
 Hill, Shawn A., 487
 Hincenbergs, Mara, 2113
 Hinuma, Yoriko, 1340
 Hirai, Kei-ichi, 700
 Hirai, Yoshikazu, 1895
 Hirakata, Yoichi, 698, 1722, 2006, 2853
 Hiramatsu, Keiichi, 1917
 Hirota, Katsuhiko, 1083
 Hishida, Akira, 1718
 Hitchcock, Christopher, 1695
 Hitchcock, Christopher A., 2645
 Hiyoshi, Suchiro, 431
 Ho, Elaine, 1336
 Hoagland, Vicki, 332
 Hoban, Daryl J., 184, 2427, 2446
 Hoch, James A., 1529
 Hoellman, Dianne B., 495, 857, 3032
 Hoepelman, I. M., 1233, 3266
 Hoffmann, E., 2421
 Hofheinz, Werner, 2602
 Hofmann, Basia, 1249
 Hogan, Patricia A., 3313
 Hoi, Annie Buu, 2889
 Holland, Kevin P., 2456
 Hollenstein, Ursula M., 2417
 Hollingshead, Melinda, 487
 Hollis, R. J., 3242
 Hollomon, Derek W., 2171
 Holmes, P., 1012
 Holt, H. A., 419

- Holtorf, Lorilynne, 3146
 Holyoak, Caroline D., 2160
 Holzgrabe, Ulrike, 1151
 Hon, H., 2235
 Hong, Sung Yu, 2534
 Hooper, David C., 121, 2109
 Hoover, David L., 583
 Hope, Michael J., 45, 2511
 Hopkins, Marlene K., 202
 Hoppe, Jörg E., 965, 1868
 Horaud, Thea, 2889
 Horgen, Lionel, 3006
 Hori, Satoshi, 1917
 Horio, Takeshi, 3141
 Hosaka, Masaki, 2678
 Hosoya, Yoshiko, 2041
 Hossain, Mohammad Ashraf, 1722
 Hostomsky, Zdenek, 140
 Houang, Elizabeth T. S., 440, 3051
 Hougham, Andrina J., 789
 Houin, Rene, 2141
 Houlahan, Heather H., 254, 981
 Hryniewicz, Waleria, 514, 3079
 Hsu, Ann, 1788, 2784, 3107, 3218
 Hu, André, 971
 Huang, Kun-Yen, 1319
 Huang, Mingjun, 487
 Huang, Wanzhi, 2893
 Huber, O., 2966
 Huczko, Elizabeth, 313
 Hudspeth, Marie, 1127
 Huebner, Robin, 2633
 Hufman, John H., 640
 Huggins, Andrea S., 1563
 Hughes, April, 2996
 Hughes, Stephen H., 447
 Hughes, Walter, 1315
 Huletsky, Ann, 3296
 Huneau, Jean-François, 2607
 Huovinen, Pentti, 257, 1493
 Hurwitz, Selwyn J., 2804
 Hutchison, M., 2421
 Hwang, Frances, 2380
 Hyatt, Judith M., 521
 Ibrahim, Ashraf S., 2645
 Ida, Hirohisa, 431
 Iga, Tatsuji, 691, 1738
 Igno, Felicitas R., 1295
 Ike, Yasuyoshi, 2150
 Inaba, T., 1654
 Ing, Michael, 1837
 Ingate, S. T., 618
 Inglis, Shelly, 2336
 Innaimo, S., 3209
 Inotsume, Nobuo, 453
 Ioannides-Demos, Lisa L., 1365, 1370
 Iona, Elisabetta, 712
 Irvin, James D., 383
 Isaka, Yoshitaka, 1340
 Ischer, Françoise, 241
 Ishida, Hiroko, 1641
 Ishida, Mariko, 325
 Ishida, Yoshihisa, 1641
 Ishiguro, Masaji, 1181
 Ishihara, Satoshi, 3293
 Ishii, Kazuhiro, 555
 Ishii, Yoshikazu, 94, 1181, 1858, 2853
 Ishikawa, Hiroshi, 2943
 Ishimaru, M., 3333
 Ishimatsu, Yuji, 1866
 Ishizuka, Hitoshi, 1738
 Ismael, Farid, 2830
 Isogai, Emiko, 1895
 Isogai, Hiroshi, 1895
 Ison, C. A., 2799, 2919
 Issacs, C. E., 1239
 Itoh, Akio, 2178
 Itoh, Tomoo, 325
 Itokawa, Kenichi, 1751
 Ittarat, Wanida, 2332
 Ivens, Tania, 269
 Iwashita, Tetsuji, 1866
 Iwata, Masayuki, 23
 Iwayama, Satoshi, 1666, 2095
 Izquierdo, J., 414
 Izumikawa, Kin-Ichi, 698
 Izumikawa, Koichi, 698, 2006
 Jabs, Douglas A., 2240
 Jaccard, C., 2966
 Jackson, Jesse J., 1996
 Jacobberger, Bernadette, 425
 Jacobs, Michael R., 495, 589, 857, 953, 1253, 1263, 1269, 2002, 2459, 2914, 3028, 3032
 Jacobs, M. R., 624, 1503
 Jacolot, Anne, 3304
 Jacquemin, Philippe, 404
 Jaffe, Howard S., 2996
 Jafri, Hasan S., 2650
 Jahn, Andreas, 2569
 Jahn, Bernhard, 2569
 Jakeman, Kenneth J., 640, 647
 Jamard, Catherine, 369
 Jams-Dow, Carlos, 1592
 Janoff, Andrew S., 767
 Japour, Anthony, 2784
 Japour, Anthony J., 3218
 Jaramillo, Jorge, 1629
 Jarlier, Vincent, 2084
 Jarosinski, Paul, 1815, 2391
 Jarvis, K., 2385
 Jarvis, Ken, 2674
 Jaspers, C. A. J. J., 1233
 Jayanti, Venkata, 3218
 Jelliffe, R. W., 1731
 Jenkins, John R., 889
 Jensen, Lars Bogo, 2463, 3331
 Jensen-Pergakes, K. L., 1160
 Jerome, Arnaud, 3006
 Jessen, Lois, 1862
 Jett, Bradley D., 1671
 Ji, Baohong, 1115, 2066
 Jiménez-Valera, Maria, 3009
 John, Joseph F., 2122
 Johnson, Cheryl A., 3315
 Johnson, Debra, 528
 Johnson, Elizabeth M., 1412
 Johnson, M., 2956
 Johnson, Robert B., 916
 Johnson, Theresa, 1454
 Johnston, Nicole J., 2425
 Join-Lambert, Olivier, 468
 Jonckheere, H., 618
 Jones, Mark E., 1249
 Jones, R. N., 161, 3242
 Jones, Ronald N., 1762
 Jones, S., 428
 Jones, Susan, 2495
 Jones, Susan K., 666, 2503
 Jorgensen, James H., 2312
 Joseph, W. Patrick, 1139
 Ju, William D., 332
 Jueneman, Shane A., 2914
 Jung, Louis, 425
 Jungheim, Louis N., 916
 Jungwirth, Renate, 514, 827
 Jura, Heike, 1052
 Justice, Steven J., 332
 Kaatz, Glenn W., 197, 254, 721, 981
 Kabani, Amin M., 184, 2427
 Kabayashi, Intetsu, 579
 Kadota, Jun-Ichi, 1866
 Kadurugamuwa, Jagath L., 1476
 Kageruka, P., 1012
 Kahn, James O., 2380
 Kaijser, Bertil, 3276
 Kaiser, Allen B., 545, 2449
 Kakeya, Hiroshi, 1722
 Kaku, Mitsuo, 698, 2006
 Kalach, N., 1334
 Kamai, Yasuki, 23
 Kamali, F., 1256
 Kamihira, Shimeru, 698, 2006
 Kaminsky, Ronald, 2858
 Kampf, Günter, 2440
 Kanamaru, Mitsutaka, 1433, 1718
 Kaneki, Toshimichi, 1597
 Kanematsu, Emiko, 433, 3293
 Kapel, Nathalie, 818
 Karkhanis, Yashwant, 1985
 Karlowsky, James A., 184, 2427, 2446
 Karlsson, Sigfús M., 2290
 Karp, Matti, 1906
 Kasama, Tsuyoshi, 1499
 Kashuba, A. D. M., 1842
 Kataja, Janne, 1493
 Kataoka, Atsuko, 1778
 Katayama, Koichi, 2824
 Kati, Warren, 3218
 Kato, Ikunoshin, 755
 Kato, Tamamo, 1666
 Kauffman, Carol A., 1305
 Kaul, Sanjeev, 2295
 Kaw, Pamela, 1105
 Kawada, Harumi, 23
 Kawada, Yukimichi, 433, 3293
 Kawahara, Yukinori, 1738
 Kawakami, Jun-Ichi, 691
 Kawamura, Takeshi, 433, 3293
 Kawasaki, Shin, 1499
 Kawata, Tsutomu, 2824
 Kazempour, Kazem, 2336
 Kearns, Gregory L., 2706
 Kehrenberg, Corinna, 2116
 Keller, Amy, 3187
 Keller, M. R., 2637
 Kellner, James D., 2425
 Kelly, Diane E., 1756, 3065
 Kelly, Steven L., 1756, 3065
 Kelly, Valerie A., 2274
 Kemp, Sharon, 269
 Kempf, Dale J., 3218
 Kennedy, Allison, 3146
 Kennedy, M. A., 1160
 Kern, Winfried V., 2089
 Kernodle, Douglas S., 545, 1375, 2449, 3163
 Kerrigan, John E., 666
 Keyserling, Constance H., 1073
 Khan, Anis A., 1713, 2284
 Khan, Ikhtas A., 1454
 Khetarpal, Minoo, 1295
 Kieft, H., 1233
 Kikuchi, Mikio, 1895, 2943
 Kim, Choung, 612
 Kim, Choung U., 640, 647, 1568, 3234
 Kim, Hak Yeop, 190
 Kim, Jeong Hoon, 190
 Kim, Kwang Seo, 190
 Kim, So H., 1217
 Kim, Won B., 1217
 Kim, Young Min, 190
 Kim, Young S., 3325
 Kimura, Akifumi, 2824
 Kinard, Rachel G., 2877
 King, Peter J., 140
 King, Robert W., 2128, 3179
 King, Stephen R., 930
 Kinsman, Oonagh S., 2274
 Kinzig, Martina, 1659
 Kinzig-Schippers, Martina, 2012, 2359
 Kippenberger, Stefan, 3332
 Kirikae, Fumiko, 1015
 Kirikae, Teruo, 1015
 Kirkpatrick, Iain D. C., 2427
 Kirkpatrick, William R., 2932, 2938
 Kirst, Herbert A., 1303
 Kishi, Yoshito, 2824
 Kitada, Ayako, 1718
 Kitahara, Shigehisa, 1200
 Kitaichi, Kiyoyuki, 3136
 Kitano, Megumi, 2492
 Kitayama, Akiko, 23
 Kitzis, Marie-Dominique, 173
 Klaus, Sidney, 3092
 Klecker, Raymond W., 1592
 Klein, Larry L., 389
 Klepser, Michael E., 1207, 1382, 1387
 Kline, Bruce, 202
 Klugman, Keith, 2633
 Klugman, Keith P., 1329, 2221
 Knaebel, David, 911
 Knapp, Joan S., 2103
 Knott, Sarah J., 1973, 3193
 Knowles, M., 2637
 Knudsen, Jenny D., 377
 Knudsen, Jenny Dahl, 1706
 Ko, Wen-Chien, 1319
 Kobayashi, Hiroyuki, 1641
 Kobayashi, Kazuo, 1499
 Kobayashi, Nobumichi, 717
 Kobayashi, Seiichi, 2824
 Kobayashi, Toshio, 1597
 Kober, Astrid, 3123
 Kodama, Hiroki, 967
 Kodama, Kazuyo, 1778
 Kodama, Makoto, 1340
 Koegel, C., 1160
 Koffel, Jean Claude, 425
 Koffertitis, Diamantis, 2747
 Koga, Tetsufumi, 23
 Kohlhepp, Sue J., 2259
 Kohlsdorfer, C., 1397
 Kohner, Peggy, 202
 Kohno, Shigeru, 40, 698, 1722, 1866, 2006

- Kohrer, Karl, 1249
 Kohyama, Tadashi, 1499
 Koivisto, Leeni, 1906
 Koizumi, Tomonobu, 1597
 Kojima, Saori, 3136
 Kojima, Somet, 37
 Koller, Klaus-Peter, 2817
 Kolonoski, Peter, 180
 Komatsuzawa, Hitoshi, 1278
 Komori, Toshiaki, 2150
 Kon, Tatiana, 65
 Korba, Brent E., 2804
 Korda, Anna, 339
 Koren, Gideon, 1336
 Korneyeva, Marina, 3218
 Kosuge, Kazuhiro, 1298
 Kotra, Lakshmi P., 1542
 Kourea, Helen P., 840
 Kovach, Danuta, 1290
 Koyama, Junko, 700
 Koyano, Shinichi, 325
 Koymans, Luc, 241
 Kozawa, Osamu, 1433
 Kozel, Thomas R., 1437
 Krakowka, Steven, 1549
 Kreiswirth, Barry N., 1295
 Krishnamoorthy, Rajagopal, 1323
 Kropp, Helmut, 1996
 Krueger, W. A., 2421
 Kubar, Joanna, 654
 Kubitz, D., 2060
 Kubo, Keishi, 1597
 Kubota, Mikie, 23
 Kubota, Satoshi, 1200
 Kugler, Kari, 1762
 Kuipers, E. J., 2749
 Kukhanova, Marina, 1799
 Kumar, Arvind, 2495, 2503
 Kumar, Gondi N., 3218
 Kumar, Princey, 631
 Kumazawa, Joichi, 579
 Kumon, Hiromi, 1083
 Kuo, Chih-Feng, 1319
 Kurahashi, Kiyoyasu, 3269
 Kuritzkes, D. R., 2637
 Kurosaka, Seiko, 1284
 Kurosaka, Yuichi, 1641
 Kusano, Nobuchika, 2193
 Kusters, J. G., 2749
 Kuwahara, Shogo, 23
 Kuzuhara, Naoki, 967
 Kwappenberg, Kitty M. C., 739
 Kwon, Mi yun, 2534
- Labia, R., 1110, 2184
 Labia, Roger, 879, 1323, 2771
 Labro, M. T., 1944
 Lacy, Steven A., 640
 Ladner, Stephanie K., 2128, 3179
 Lagrange, Philippe H., 464, 2352
 Lakey, David L., 1375
 Lakshminarayan, S., 114
 Lal, Ritu, 3218
 Lalezari, Jacob P., 1139
 Lalkin, Arich, 1336
 Lamb, David C., 3065
 Lamb, L., 3209
 Lambert, Michelle, 1629
 Lambert, Thierry, 2557, 2759
 Lambros, Chris, 147
- Lamm, Janet E., 3107
 Lamp, Kenneth C., 231
 Lampe, M. F., 1239, 1726
 Lampis, Giorgio, 3035
 Lamy, P. D., 1620
 Lancaster, Danny, 2656
 Lancaster, M. V., 282
 Land, Tracey M., 2877
 Landay, Alan L., 2326
 Landry, Bernard, 631
 Landureau, Jean-Charles, 2482
 Laneury, Jean Paul, 2602
 Lang, Jean, 298
 Langae, Taimour Yousef, 3296
 Langlie, Mridula-Chandan, 383
 Lant, Ariel F., 293
 Laouari, D., 289
 Larder, Brendan, 269
 Larrick, James W., 3269
 Larsen, Robert A., 528
 Lartey, Paul A., 389
 Lassek, Christoph, 2012
 Lavandera, José L., 2694
 Lavitola, Alfredo, 571
 Lawetz, Carol, 1629
 Leal, Mary Ann E., 528
 Lebibi, J., 540
 LeBlanc, Donald J., 2312
 Le Blancq, Sylvie M., 843
 Leclerc, Jean-Marie, 404
 Leclercq, Roland, 1392
 Lecoublet, Sophie, 818
 Leede, Dolena R., 2144
 Lee, Bok Luel, 2534
 Lee, Chang-Kwon, 2985
 Lee, Ji Hye, 2534
 Lee, Keun Hyeung, 2534
 Lee, Linda N., 2312, 2932
 Lee, Mark, 762
 Lee, Myung G., 1217
 Lee, William A., 687
 Leeds, Janet M., 2113
 Lees, N. D., 1160
 Le Fichoux, Yves, 654
 Legakis, Nicholas J., 1281
 Leggett, James E., 2259
 Lehr, Karl H., 199
 Lehrer, Robert L., 2206, 2690
 Leitner, Ingrid, 1057
 Leitzke, S., 459
 Lelièvre, Alain, 654
 Lemesre, J. L., 3097
 Lemmouchi, Y., 1012
 Lendvai, Nikolett, 1437
 Lenfant, Bernard, 199
 Leonard, John, 1788
 Leonard, John M., 2784, 3107, 3218
 Leopold, Klaus, 154
 Leotard, Sophie, 3304
 Lerner, Stephen A., 1295, 1542
 Lessard, I. A. D., 2215
 Leunk, Robert D., 1549
 Levesque, Roger C., 1245, 1966, 2319, 2576
 Levy, Benjamin, 1788
 Levy, Stuart B., 2089, 3050
 Lew, D., 2966
 Lew, Daniel P., 564
 Lew, Willard, 640, 647, 3234
 Lewin, Alfred, 509
 Lewis, Linda L., 3187
- Lewis, Russell E., 1207, 1382
 Li, Cong, 1837
 Li, Leping, 389
 Li, Tsai-Kun, 1022
 Li, Wei Dong, 2731
 Li, Weixing, 640, 647
 Li, W.-X., 1620
 Li, Xian-Zhi, 399, 1682, 2225
 Li, Yongjun, 712
 Li, Yu-Feng, 2989
 Li, Yuzhou, 911
 Li, Zhiyu, 3293
 Liassine, Nadia, 1794
 Libby, Jeffrey M., 78
 Liberator, Paul, 1985
 Liendo, Andreina, 1771
 Lienhardt, Christian, 1115
 Lietman, Paul S., 2380
 Ligozzi, Marco, 2055
 Lin, Enjarn, 2132
 Lin, Gengrong, 1253, 3032
 Lin, Lillian S., 3103
 Linares, Josefina, 53, 1636, 2792
 Lindsay, David S., 2877
 Ling, Baodong, 936
 Ling, Julia M., 440
 Linquist-Stepps, Valerie, 2113
 Liolios, Lisa L., 1365, 1370
 Lipford, J. R., 2245
 Lipman, J., 2235
 Lister, Philip D., 1610
 Liu, Jien-Wei, 1319
 Liu, Leroy F., 1022
 Liu, Qing-Feng, 1105, 1417, 1512
 Liu, Quingxiang, 3325
 Liu, Shwu-Huey, 369, 833, 1799, 1805
 Liu, Weiguo, 1105, 1417, 1512
 Liu, Wenqiu, 911
 Liu, Xuejun, 911
 Liuzzi, Michel, 1629
 Livermore, David M., 1168, 3117
 Lloyd, D., 1195
 Locarnini, S. A., 3130
 Locarnini, Stephen, 2132
 Lo Cascio, Giuliana, 2055
 Locke, Charles S., 1176
 Loebenberg, David, 1771, 2467
 Loebstein, Ronen, 1336
 Logan, Patricia, 45
 Loimaranta, Vuokko, 1906
 Loiseau, Philippe M., 352
 Lomovskaya, Olga, 2225
 Looareesuwan, S., 135
 Looareesuwan, Sornchai, 2332
 Look, Gary C., 1447
 Lopez-Ribot, Jose L., 2932
 Lortholary, Olivier, 849
 Louie, Arnold, 1105, 1417, 1512, 2405
 Louie, Lisa, 762
 Louie, Marie, 762
 Lounis, Nacer, 2066
 Low, Donald E., 2425
 Löwdin, E., 2739
 Löwdin, Elisabeth, 2365
 Lozano-Chiu, Mario, 129
 Lu, Amy T., 1447
 Luck, Linda, 911
 Lück, P. Christian, 2870
- Lückefahr, Marc, 1249
 Lucumi, Armando, 1990
 Lüthmann, Anja, 1911
 Lund, Brian C., 1382
 Lupetti, A., 2434
 Lurain, Nell S., 2326
 Luscombe, Carolyn, 2132
 Luther, Michael F., 151, 2371, 2938
 Luther, Mike F., 2467
 Lutsan, Irja, 2650
 Lutsch, Charles, 298
 Lütticken, Rudolf, 1509
 Lutwyche, Peter, 2511
 Luxemburger, C., 135
 Luzzi, Ida, 3053
 Lynch, Geoffrey R., 687
 Lyon, Donald J., 440
 Lyons, Christopher N., 2584
 Lyras, Dena, 1563
- Ma, Ling, 1181
 Maass, Matthias, 2762
 MacGowan, A. P., 419, 436
 Maciejewski, L., 540
 Mack, Douglas, 2036
 Maclean, Derek, 1447
 Macleod, Catherine M., 2295
 Madaio, R., 550
 Madaras-Kelly, Karl J., 1266
 Madders, Helen, 2919
 Mader, M., 277
 Madu, Assumpta, 1417
 Maesaki, Shigefumi, 40, 698, 1722, 2006
 Magambo, Japheth K., 601
 Magnaval, Jean-François, 2770
 Magner, D. J., 2262
 Mailard, J.-Y., 2151
 Mainardi, Jean-Luc, 468
 Maire, P. H., 1731
 Malena, Marina, 3014
 Mallet, Marie-Noëlle, 1093
 Mamelok, Richard D., 606
 Manavathu, Elias K., 1295, 3018
 Manna, Filomena, 571
 Manning, Nigel J., 1756
 Mansfield, D. L., 2262
 Manteau, Michel, 2830
 Manzo, Ruben H., 1495
 Mao, Chen, 3225
 Maquaire, S., 3097
 Marchese, Anna, 464
 Marchetti, O., 1889
 Marco, F., 161
 Markowitz, M., 2637
 Markowitz, Martin, 2775
 Marone, Piero, 2017
 Marotti, Keith R., 947
 Marr, Kieren A., 2584
 Marriott, Michael S., 2274
 Marriott, M. S., 2863
 Marsden, Katherine, 1695
 Marsh, Kennan C., 3218
 Marsh, V. R., 1256
 Marshall, C. G., 2215
 Martin, Claude, 1093
 Martin, J. Julio, 2274, 2279
 Martín, M. M., 414
 Martinez, C. M., 2863
 Martínez, J. A., 1306
 Martinez-Bueno, Manuel, 534

- Martínez-Martínez, Luis, 1636, 1850, 3290
 Martin-Munley, Sarah, 293
 Martiny, Heike, 2440
 Marttila, Harri J., 2443
 Maruyama, Kazuo, 40
 Maslo, Caroline, 2066
 Mason, William S., 1045
 Massias, Laurent, 2830
 Massova, Irina, 1
 Matlow, Anne, 1290
 Matsubara, Yuichi, 1866
 Matsuda, Izumi, 2178
 Matsuda, Junichi, 2006
 Matsumoto, Makoto, 2943
 Matsumoto, Syouzou, 1433
 Matsumoto, Tetsuro, 579
 Matsumoto, Tetsuya, 555, 1858, 2853
 Matsumura, Naoki, 176
 Matsuno, Hiroyuki, 1298, 1433
 Matsuo, Hirotoami, 691, 1738
 Matsuo, Takashi, 1083
 Matsuzawa, Hiroshi, 1181
 Mattei, Maurizio, 712
 Matthews, C., 223
 Mattie, Herman, 739
 Mattiuzzi, Gloria N., 606
 Maurin, M., 1537
 Maxwell, Anthony, 889
 Mayers, Martin, 1417, 1512
 Mazabel, E., 2637
 Mazière, Bernard, 2830
 Mazière, Jean-Claude, 2482
 Mazzariol, Annarita, 1459
 Mazzieri, Maria Rosa, 1495
 Mberu, E. K., 164
 Mbongo, Nicolas, 352
 McAtee, Robert K., 2932
 McCaffrey, Ronald P., 1424
 McClelland, R. Scott, 3169
 McCoig, Cynthia C., 2650
 McCracken, George H., Jr., 2650
 McCrea, J., 223
 McCully, Cindy L., 1815
 McCune, Joseph M., 2113
 McCutchan, Thomas F., 715
 McDonald, Edith, 3218
 McDougal, Linda K., 2312, 3024
 McDougall, Brenda, 140
 McDowell, J., 2153
 McElhaney-Feser, Gail E., 2342
 McEvoy, Maureen, 2391
 McFadden, Diane, 1985
 McGuire, Brian, 2996
 McLean, A. J., 1365
 McLeod, Rima, 2036
 McMahon, J., 705
 McMillian, Carl L., 2898
 McMurray, Walter J., 1076
 McMurry, Laura M., 3050
 McNamara, James, 1315
 McSharry, James J., 2326
 Mead, Jan R., 339
 Medda, Swapna, 348
 Medina, I., 3209
 Mégraud, Francis, 2836
 Melby, Peter C., 2542
 Melnick, Laurence, 3256
 Mendel, Dirk B., 640, 647, 3234
 Mendoza, Alfonso, 2694
 Menzies, Barbara E., 1375
 Mercier, Renee-Claude, 981, 254
 Merker, Hans Joachim, 1470
 Merriam, C. Vreni, 1127
 Merson, James, 640, 647
 Mertz, Gregory J., 1139
 Merz, Michael, 298
 Meshnick, Steven R., 934, 1454, 2332
 Messer, S., 161
 Messer, S. A., 3242
 Messer, Shawn A., 1387
 Meulbroek, Jon, 2674
 Meyers, W. M., 2070
 Mian, Umar, 1417
 Michailowsky, Vladimir, 2549
 Michejda, Christopher J., 487
 Michelsen, Phyllis B., 3153
 Middlemas, David, 3157
 Miki, Shigeru, 1340
 Mikiewicz, Barbara, 827
 Miller, Carole B., 606
 Miller, Kenneth, 2405
 Miller, L. P., 1853
 Miller, M. D., 1620
 Miller, Michael H., 1105, 1417, 1512
 Miller, Thomas J., 2128, 3179
 Miller, Veronica, 269, 3123
 Millet, P., 540
 Mills, John, 3038
 Mimoz, Olivier, 3304
 Minami, Rumiko, 453
 Minami, Shinzaburo, 176
 Minamoto, Masahiko, 1433
 Minassian, Beatrice, 313
 Mindermann, Thomas, 2626
 Mine, Tomoyuki, 1778
 Minnick, Michael F., 2906
 Miriagou, Vivi, 1281
 Mirochnick, Mark, 808
 Mistry, Anita, 2225
 Mitchell, Bernadette A., 475
 Mitsuhashi, Susumu, 176
 Mitsuya, Hiroaki, 1815
 Mitten, M., 2385
 Mitten, Mike, 2674
 Miyahara, Takayuki, 1597
 Miyake, Yoichiro, 1083
 Miyama, Tetsuo, 1738
 Miyamae, Shin, 2119
 Miyamoto, Kaname, 2824
 Miyazaki, Haruko, 1695
 Miyazaki, Shuichi, 94, 555, 785, 1858, 2853
 Miyazaki, Tsuneo, 967
 Miyazaki, Yoshitsugu, 40, 1695
 Mizen, Linda W., 813
 Mizuoka, Keiji, 431
 Mizushima, Tohru, 1778
 Mobashery, Shahriar, I., 1542
 Moellering, R. C., Jr., 1088, 1520
 Moesker, H. L., 3266
 Moghazeh, Soraya L., 1295
 Moland, E. S., 1350
 Moldovan, Tabitha, 721
 Mole, Larry, 631
 Molina, Judith, 1771
 Molitoris, Denise, 984
 Molitoris, Eric, 984
 Molla, Akhteruzammen, 3218
 Möller, Lieke V. M., 319
 Montalbo, Eleanor, 2542, 2938
 Montalbo, Eleanor M., 151
 Montgomerie, J. Z., 188
 Monzillo, Vincenza, 564
 Moon, Hong Mo, 2534
 Moore, Caroline B., 2726
 Moore, P. Hutton, 2877
 Morales, Vivian E., 583
 Moran, Gary P., 1819
 Mordrelle, Agnès, 2607
 Morcillon, P., 1889
 Moreno, Encarnación, 3009
 Moreno, Mary Beth, 2113
 Moretti, Myla, 1336
 Moribe, Kunikazu, 40
 Morita, Yuji, 1778
 Morita, Yutaka, 1499
 Morosini, Maria-Isabel, 1042
 Morrissey, Graham, 873
 Morrissey, Jacqui, 873
 Morschhäuser, Joachim, 3065
 Morse, Gene D., 409, 821
 Morton, Teresa M., 1305
 Moskovitz, Bruce L., 1862
 Moss, Neil, 1629
 Mouton, Johan W., 377, 744, 749
 Moye, John, 1315
 Mueller, Brigitta U., 1815, 3187
 Muffat-Joly, Martine, 862
 Mugnier, P., 3113
 Mugnier, Pierre, 108
 Mukherjee, Jean, 1437
 Mukhopadhyay, Asish Kumar, 206
 Mulamba, Gilbert B., 971
 Mulato, A. S., 1620
 Muli, F., 1428
 Mullen, A. B., 2722
 Müller, Carola, 2359
 Müller, R., 459
 Munghin, Mathirut, 682, 2973
 Muñoz, J. L., 1306
 Murakami, Kinya, 1083
 Muramatsu, Hideyuki, 37, 2041
 Murphy, Philip G., 3002
 Murphy, Robert, 1815
 Murray, Barbara E., 2883
 Murray, Robert W., 947
 Murta, Silvine M. F., 2549
 Musafija, Albert, 473
 Mushatt, David, 631
 Myers, Dorothea E., 383
 Myung, Joon Mo, 2731
 Naas, Thierry, 2074
 Naber, Kurt, 1659
 Nabeshima, Toshitaka, 2178, 3136
 Nadai, Masayuki, 2178, 3136
 Nadler, H. L., 1088
 Nadler, Steven G., 1133
 Naesens, Lieve, 1568
 Nafziger, Anne N., 695, 927, 1578, 1842
 Nagahara, Naoki, 2492
 Nagashima, Satoru, 1433, 1718
 Nagata, Aya, 691
 Nagata, Kumiko, 700
 Nair, G. Balakrish, 206
 Naito, Mikihiko, 1738
 Najvar, Laura, 528
 Najvar, Laura K., 147, 151, 2371, 2467, 2542
 Nakahara, Kazuhiko, 1499
 Nakahashi, Masaaki, 1938
 Nakajima, Moto-O, 1406
 Nakamura, Chizuko, 453
 Nakamura, Hidenori, 1499
 Nakano, Masahiro, 453
 Nakano, Masayasu, 1015
 Nakano, Michiko, 2006
 Nakao, Masafumi, 2492
 Nakashima, Mitsuyoshi, 1298
 Nakayama, Issei, 431
 Nakazawa, Harumi, 1666, 2095
 Naruhashi, Kazumasa, 2178
 Nash, Theodore, 1488
 Nasr, Mohamed, 2284
 Natarajan, Jaya, 1098
 Nau, R., 277, 1397
 Nau, Roland, 2012
 Nauta, J. J. P., 3266
 Navre, Marc, 1447
 Nayak, Ramchandra, 885
 Negri, Maria-Cristina, 1042
 Nelson, Gene O., 675
 Nelson, M., 729
 Nelson, Page W., 129
 Nemoto, Ken, 1083
 Neuhard, Jan, 2620
 Neville, W. A., 436
 Neyts, Johan, 170, 216, 3285
 Ng, Samson P., 1646
 Ng, Tak-keung, 440
 Ng, Winston, 2650
 Nguyen, M. Hong, 471, 509
 Nicas, Thalia I., 1303
 Nichols, Brian P., 88
 Nicola, Federico G., 3024
 Nicolas-Chanoine, Marie-Hélène, 879
 Nicolau, David P., 840, 991
 Nicoll, A. J., 3130
 Nie, Lin, 840
 Nieto, Eva, 1361
 Nieto, Marcelo, 1495
 Nightingale, Charles H., 840, 991
 Nihira, Takuya, 2985
 Niida, Yoshito, 1433
 Nikaido, Hiroshi, 2119
 Niki, Yoshihito, 1751
 Nilius, A. M., 2385
 Nilsson, Lennart E., 1222
 Nilsson, Maud, 1222
 Nishino, Takeshi, 1938
 Nishino, Yoshinori, 433, 3293
 Nishiyama, Yukihiko, 1666, 2095
 Niu, Ping, 3218
 Niwa, Masayuki, 1433
 Niwano, Yoshimi, 967
 Nixon, James R., 3002
 Njoroge, Ernest M., 601
 Noda, Tetsuhiro, 1722
 Nomura, Atsuko, 1938
 Nonomiya, Tomoko, 431
 Noormohamed, Faruq H., 293
 Norbeck, Daniel W., 3218
 Nordmann, Patrice, 2074, 3304
 Noskin, Gary A., 606, 734

- Nosten, F., 135
 Notka, Mostafa, 2326
 Nouaille-Degorce, B., 289
 Nukkula, Mike, 2674
 Nussenzeig, Victor, 2731
 Nzadiyabi, T., 540
 Nzila-Mounda, A., 164
- Oakley, Karen L., 873, 2726
 Obara, Masao, 1718
 Obias, Arlene A., 734
 Occhialini, Alessandra, 2836
 Ochi, Kozo, 2041
 Odds, F. C., 282
 Odenholt, I., 2739
 Odenholt, Inga, 2365
 O'Doherty, E., 903
 Oethinger, Margret, 2089
 Ogawa, Atsuko, 755
 Ogawa, Yasuyuki, 2492
 O'Gorman, Maurice R. G., 2326
 Oguma, Keiji, 1895
 Oh, Jong Eun, 2534
 Ohara, Kenji, 3141
 O'Hara, Koji, 431, 1406
 Ohara, Maria, 3269
 Ohashi, Kyoichi, 1298
 Ohishi, Kazuhisa, 1718
 Ohlsen, Knut, 2817
 Ohmura, Yuko, 1666
 Ohno, Akira, 94, 555, 1858, 2853
 Ohta, Kouji, 1278
 Ohtoshi, Takayuki, 1499
 Ohya, Satoshi, 23
 Oikawa, Miki, 1666
 Ojwang, Joshua O., 1412, 1646
 Okada, Kazuyoshi, 1597
 Okamoto, Kiyomi, 1938
 Okamoto, Susumu, 2041
 Okazaki, Osamu, 1751
 Okonogi, Kenji, 2630
 Okunishi, Masahiko, 1666, 2095
 Oleksijew, A., 2385
 Oleksijew, Andy, 2674
 Olink, A. G., 1233
 Olivier, Martin, 2527
 Olson, J. E., 2254
 Omura, Satoshi, 2731
 O'Neill, Paul M., 682
 O'Neill, P. M., 2410
 Ono, Nobukazu, 1666, 2095
 Ono, Tsuneko, 1083
 Onodera, Yoshikuni, 3044
 Oomori, Yasuo, 2678
 Orani, Anna, 1346
 Orden, Beatriz, 989
 Orefici, Graziella, 712
 Orme, Ian M., 3047
 Orozco, Alison S., 2645
 Ortiz, G., 1306
 Osborne, Barbara, 332
 Østergaard, Christian, 1706
 Osterling, M. Clayton, 487
 Otani, Tsuyoshi, 1641
 Otsubo, Takakazu, 40
 Otten, Tatjana F., 2443
 Otto, Michael J., 3179
 Ouassii, A., 3097
 Ouellet, Daniele, 3107
 Ouellet, Nathalie, 2527, 3309
 Ouellette, Marc, 1689
- Owens, Mary L., 789
- Padoin, C., 1463
 Pactznick, Victor L., 129
 Paige, L., 2385
 Paige, Lenette, 2674
 Palamone, Carla, 487
 Palarchio, Angela Ianni, 1745
 Palepou, Marie-France I., 502
 Pallares, Roman, 53
 Palmer, Michael, 2569
 Palmer, Robert, 1176
 Palucha, Andrzej, 3079, 827
 Palzkill, Timothy, 2319, 2576, 2893
 Pan, Xiao-Su, 2810
 Pankuch, G. A., 624, 1503
 Pankuch, Glenn A., 1263, 2914, 3028, 3032
 Pannecouque, C., 618
 Papa, Pietro, 2017
 Paradise, Michael R., 959
 Pariat, Claudine, 2756
 Paris, William, 1629
 Park, B. K., 2410
 Park, Chang, 3218
 Park, I.-S., 2215
 Parker, William B., 1045
 Parkinson, Tanya, 1695, 2645
 Parra, Araceli, 1361
 Parrott, Steven C., 1646
 Pascual, Alvaro, 1850, 3290
 Pastuszak, Anne, 1336
 Patel, Robin, 202
 Paterson, Jesse, 779
 Patrick, A. K., 2637
 Patrick, Donald A., 666, 2877
 Patrick, Sheila, 3002
 Patron, Roberto L., 1355
 Patterson, Jan E., 1305, 2312
 Patterson, Thomas F., 2932, 2938
 Patton, D. L., 1239
 Paul, Gérard, 1323
 Paul, Muriel, 2141
 Pauwels, Rudi, 269, 3123
 Payares, Gilberto, 1771
 Payne, D. J., 436
 Pearce, James A., 2160
 Peeters, Frank, 269
 Pelak, Barbara A., 1996
 Peloquin, Charles A., 927, 1578
 Peña, Carmen, 53
 Penso, Gabriella, 2232
 Perani, Evelyn, 1115
 Perea, Evelio J., 3290
 Pereira, Maria E. S., 2549
 Perez, Norma, 1771
 Perfect, John R., 2495, 2503, 2630
 Perilli, Mariagrazia, 1459
 Perkins, Margaret E., 843
 Perkins, Ruth, 1417
 Perkins, Walter R., 767
 Perni, Robert B., 3179
 Pernodet, Jean-Luc, 2612
 Perret, G., 1463
 Perri, M. B., 705
 Peterson, Lance R., 734
 Petitjean, O., 1463
 Petitjean, Olivier, 849, 3304
 Petraitene, Ruta, 2700, 2898
 Petraitis, Vidas, 2700
- Petraitis, Vidmantas, 2898
 Petrofsky, Mary, 180
 Petrosino, Joseph, 2893
 Petrucca, Andrea, 3053
 Pettit, George R., 2961
 Pettit, Margaret, 921
 Pettit, Robin K., 2961
 Pezzella, Cristina, 3053
 Pfaller, M. A., 161, 282, 3242
 Pfaller, Michael A., 1207, 1382, 1387, 1762
 Pfründer, Dietmar, 1868
 Philippon, Alain, 464, 2352
 Piccolomini, R., 3000
 Pichoud, Christian, 369
 Piddock, Laura J. V., 795, 2956
 Pietrelli, Larry A., 606
 Pinkerton, Frank H., Jr., 2656
 Piper, James R., 3315
 Piras, Marta, 1771
 Piras, Romano, 1771
 Pirofski, Liise-Anne, 1437
 Piscitelli, Stephen, 2399, 2700
 Pitout, J. D. D., 1350
 Pitout, Johann D. D., 596
 Pitt, M. Louise, 675
 Pizzo, Philip A., 1815, 3187
 Plattner, Jacob J., 3218
 Plowe, C. V., 164
 Ploy, Marie-Cécile, 2557
 Podglajen, Isabelle, 209, 2089
 Poggio, Antonio, 1346, 2017
 Pomerantz, Roger J., 1200
 Pompei, Raffaello, 3035
 Ponte, Carmen, 1361
 Poole, Keith, 65, 399, 1682, 2225
 Poole, Robert K., 959
 Pootrakul, Pensri, 2332
 Popov, Serguei, 1133
 Porcelli, S. A., 550
 Porretta, Giulio Cesare, 3035
 Portaels, F., 2070
 Portillo, A., 3279
 Portnoy, Yury A., 2841, 2848
 Posho, Leta, 2950
 Postelnick, Michael A., 734
 Pottecher, Thierry, 425
 Potts, Karen E., 478
 Pouedras, P., 2184
 Power, Maureen, 631
 Powles, Mary Ann, 1985
 Poyart, Claire, 108
 Prange, Hilmar W., 2012
 Pratlong, Francine, 2141
 Praz, G., 2966
 Preira, A., 1944
 Preston, Sandra L., 1098
 Prieto, J., 414, 1574
 Pritchard, P. Haydn, 3146
 Psaroulaki, Anna, 2747
 Pujol, I., 1601
 Pujol, Miquel, 53
 Purdue, Lynette, 1315
 Purimetla, Nayanatara, 907
- Qian, Jiang, 1788, 3107
 Qin, Xiang, 2883
 Quarta, M., 3320
 Quenelle, Debra C., 2682
 Quantin, C., 2125
 Quesne, Gilles, 108
 Quinn, Patricia, 1290
- Quintiliani, Richard, 991
- Raasch, Ralph, 631
 Rabin, Linda, 2113
 Radding, Jeffrey A., 1187
 Radulovic, Suzana, 1845
 Rafii, Fatemeh, 1121
 Rainey, Petrie M., 1076
 Rajacic, Zarko, 895
 Rajagopalan-Levasseur, Premavathy, 1068
 Rama, Paolo, 2232
 Ramachandran, Kishore, 666
 Ramage, Gordon, 3002
 Ramaswamy, Manisha, 1646, 3146
 Ramon, Jacob, 473
 Rampp, Albert, 2569
 Ramsey, Mary A., 1305
 Ranieri, Sergio, 1346
 Raoult, D., 1537
 Raoult, Didier, 3086
 Rasheed, J. Kamile, 2312
 Rastogi, Nalin, 3006
 Ratelle, Johanne, 404
 Ratheiser, Klaus, 2417
 Rather, Philip N., 959
 Rattendi, Donna, 2718
 Rauli, Robert E., 2342
 Ravensbergen, E., 3073
 Raymond, J., 1334
 Raymond, Martine, 1034
 Raymond, Ralph H., 2295
 Rayner, Craig R., 1370
 Raze, Dominique, 534
 Reagan, David R., 1305
 Reeves, D. S., 419
 Regelin, Annette G., 319
 Regen, Steven L., 147, 2542
 Reichelderfer, Patricia S., 2326
 Reichl, Veronica, 1098
 Reilly, William, 1402
 Reinecke, Manfred G., 140
 Reinert, Ralf René, 1509
 Remington, Jack S., 1713
 Renaudin, H., 703
 Renaudin, Hélène, 2304
 Renaudin, Joel, 2024, 2304
 Revankar, Sanjay G., 2938
 Rex, J. H., 282
 Rex, John H., 129
 Reynolds, Peter E., 154
 Reynolds, Robert C., 3315
 Ricart, Asumpta, 53
 Riccardi, Giovanna, 1931
 Ricci, Davide, 18
 Ricci, Maria Luisa, 712
 Ricci, V., 2956
 Rice, Louis B., 963, 1871
 Rice, William G., 487, 1488
 Richards, David M., 1266
 Ricou, B., 2966
 Ridley, Robert G., 2973
 Ridoux, Olivier, 3301
 Riesbeck, Kristian, 1923
 Rietbrock, S., 2359
 Rieux, Véronique, 862
 Rimaroli, C., 3012
 Rinaldi, M. G., 282
 Rinaldi, Michael G., 147, 151, 978
 Ringertz, Signe, 1062
 Ringwald, Pascal, 1811, 2347

- Ritz, William J., 2564
 Rivera, Johanna, 1437
 Rivollet, Daniele, 2141
 Robbins, Brian L., 612, 2656
 Robert-Gero, Malka, 352
 Roberts, Marilyn C., 257, 3022
 Roberts, Patricia, 767
 Roberts, William L., 1076
 Robertson, B. D., 2799
 Robinson, W. E., Jr., 2245
 Robinson, W. Edward, Jr., 140
 Robledo, Sara, 1990
 Roblin, Patricia M., 194, 951, 1515
 Rogers, Michael, 1315
 Rogers, M. John, 715
 Rogers, P. David, 978
 Rolain, J. M., 1537
 Romand, J., 2966
 Romanha, Alvaro J., 2549
 Rood, Julian I., 1563
 Rooney, James F., 2380
 Rosas, Angel L., 1437
 Rosato, Adriana, 1392
 Rosen, H., 1996
 Rosenkranz, Alexander R., 2417
 Rosenthal, Philip J., 2254
 Ross, Jeremy I., 1702
 Rossi, Rick, 3256
 Rossignol, Daniel P., 2824
 Rossignol, Jean François, 2836
 Rousseau, Deborah, 654
 Roy, Paul H., 1506
 Royce, C., 135
 Rubin, Marc, 3187
 Rubin, Robert H., 2048
 Rubinstein, Ethan, 473, 2607
 Rudant, Eric, 2759
 Rudin, Susan D., 963
 Rudy, Jeff, 2996
 Ruette, Sandrine, 654
 Ruhnke, Markus, 3065
 Ruiz, F., 3279
 Ruiz, Joaquin, 2768
 Ruiz-Bravo, Alfonso, 3009
 Ruscoe, J. E., 2410
 Rüsing, Guido, 1151
 Russell, A. D., 2151
 Rustad, Tiger, 2584
 Rutman, Andrew, 772
 Ruys, G. J. H. M., 1233
 Rybak, Michael J., 254, 721, 981, 2188, 2710
 Ryder, Neil S., 1057
 Ryu, Miwako, 691
 Sabbagh, Yves, 2319
 Sacks, Stephen L., 2996
 Sadler, B., 2153
 Sadler, Brian, 1315
 Saenz, Y., 3279
 Safrin, Sharon, 2380, 2996
 Sage, David R., 2923
 Sage, Suzanne, 1336
 Sahl, Hans-Georg, 154
 Sahn, Daniel, 1980
 Sahn, Daniel F., 1229, 1671
 Saika, Takeshi, 579
 Saito, Shinji, 1015
 Sakumoto, Misao, 579
 Sala, J., 1601
 Saldivar, Ayda, 3218
 Saleh Mghir, Azzam, 2830
 Salerno-Concalves, Rosangela, 2482
 Sales, Nicole, 2830
 Salvadó, M., 1524
 Samii, Kamran, 3304
 Samuels, D. Scott, 2906
 Sanders, C. C., 1350
 Sanders, Christine C., 596, 1610
 Sanders, W. Eugene, Jr., 1610
 Sandul, Amy L., 2103
 Sanglard, Dominique, 241, 1819, 2932
 Sanoja, Cristina, 1771
 Sanschagrin, Francois, 2576, 1245, 1966, 2319
 Sarasini, Antonella, 444
 Saravia, Nancy G., 1990
 Sarkkinen, Hannu, 1493
 Sasaki, Eisuke, 1722
 Sato, Akihiko, 1340
 Sato, Kenichi, 236, 1284, 1641, 3044
 Saunders, Marilyn H., 184
 Savov, Orlin, 1659
 Sawa, Teiji, 3269
 Sawada, Yasufumi, 691, 1738
 Sawai, Tetsuo, 431, 1406
 Saxon, Dawn, 45
 Scaglia, Massimo, 2232
 Scalise, G., 3320
 Schaadt, Ronda D., 947
 Schacht, E., 1012
 Schaeffer, Catherine A., 487
 Schantz, Peter M., 601
 Scharff, Matthew D., 1437
 Schaufele, Robert L., 2898
 Schel, Patricia, 269
 Schell, Wiley A., 2495, 2503, 2630
 Schenk, Peter, 2417
 Schentag, Jerome J., 521
 Scheuring, Sibylle, 1249
 Schick, Betsy, 1336
 Schick, D. G., 188
 Schiller, Neal L., 974
 Schinazi, Raymond F., 2804
 Schito, Gian Carlo, 464
 Schlüter, Gerhard, 1831
 Schmatz, Dennis, 1985
 Schmid, E. N., 725
 Schmidt, H., 277, 1397
 Schmitt, J.-C., 618
 Schmitt, Jürgen W., 2870
 Schmitt, Kathy A., 789
 Schmitz, Franz-Josef, 1249
 Schmuck, Gabriele, 1831
 Schneider, Ines, 514, 827
 Schneider, O., 1397
 Schneider, R., 2966
 Scholten, P. C., 3266
 Schönfeld, Wolfgang, 2197
 Schrijver, I. A., 3073
 Schroeder, T. H., 2421
 Schühly, U., 2060
 Schülten, T., 1088, 1520
 Schultz, Marc J., 1605
 Schumann, Jens, 1911
 Schürmann, Anja, 1831
 Schurr, Erwin, 1034
 Schuster, Brian G., 1293
 Schuster, Sheldon M., 2456
 Schwabe, Rudolf, 1470
 Schwank, Silvia, 895
 Schwarz, Stefan, 1288, 2116
 Schweizer, Herbert P., 394
 Scribante, J., 2235
 Seal, David V., 2144
 Segatore, Bernardetta, 1459
 Segovia, M., 1306
 Segura, C., 1524
 Seibel, Nita I., 2391
 Seiberling, Michael, 298
 Seifer, Maria, 3200, 3209
 Sein, Tin, 2399, 2700, 2898
 Sekiguchi, Morie, 1597
 Sekiyama, Takaaki, 2095
 Semaoun, Rémi, 849
 Semenov, Andrey, 2254
 Sempere, Marco, 2768
 Senesi, S., 2434
 Seo, Susan M., 197, 254, 981
 Seppälä, Helena, 257, 1493
 Sereno, D., 3097
 Setacci, Domenico, 1459
 Seytre, Delphine, 849
 Shafran, Stephen D., 2996
 Shah, Nikil H., 1447
 Shakibaei, Mehdi, 1470
 Sham, Hing L., 3218
 Shanley, Diarmuid B., 1819
 Shannon, Kevin, 2771
 Shapiro, Howard M., 2326
 Shaw, Jeng-Pyng, 687
 Shaw, Margaret M., 934
 Shayegani, Mehdi, 1105
 Shealy, Y. Fulmer, 1045
 Shedlofsky, Steve, 2602
 Sheehan, Daniel J., 3313
 Shelton, Mark J., 409, 821
 Sherrill, Lanette C., 1139
 Shetty, Daiva, 2399
 Shetty, Shubhra, 1200
 Shevchenko, Alexander A., 659, 2841, 2848
 Shewach, Donna S., 1045
 Shi, Harry, 1176
 Shigenobu, Fritz, 431
 Shigeri, Yasushi, 2745
 Shim, Hyun J., 1217
 Shimada, Hideyo, 325
 Shimizu, Masaki, 431
 Shimizu, Mayumi, 2745
 Shinabarger, Dean L., 3251
 Shiota, Sumiko, 1778
 Shirai, Chiharu, 1278
 Shmuklarsky, Moshe, 1293
 Shoen, Carolyn M., 3315
 Shugarts, D., 2637
 Sibbald, R. Gary, 2996
 Siber, George E., 583
 Sibley, C. H., 164
 Sidorenko, Sergei V., 1259
 Sidwell, Robert W., 640, 3234
 Siegel, J., 2245
 Sieradzki, Krzysztof, 100
 Sifaoui, Farid, 173
 Sigfusson, Asbjörn, 1005
 Silen, Joy L., 1447
 Simard, Marie, 2527, 3309
 Simarro, Encarnación, 2768
 Simjee, S., 2799
 Simoncini, Lavinia, 444
 Simor, Andrew E., 762
 Singh, Kavindra V., 2883
 Sinnis, Photini, 2731
 Sirot, D., 1110, 2184
 Sirot, Danielle, 2771
 Sirot, J., 1110, 2184
 Sjögren, Eva, 3276
 Sköld, Ola, 1062, 3059, 3276
 Skurnik, Mikael, 257, 1493
 Skurray, Ronald A., 475
 Slifer, Teri R., 1713
 Slight, Thra, 135
 Slocombe, Brian, 813
 Smallwood, R. A., 3130
 Smeijsters, Louis J. J. W., 1146
 Smidt, Mary L., 478
 Smith, Anthony M., 1329
 Smith, Gillian M., 813
 Smith, James W., 934
 Smith, Jean A., 1139
 Smith, Raymond P., 2405, 2564, 3153
 Smith, R. P., 903
 Smitherman, Laura S., 2906
 Smithgall, Molly D., 1133
 Snijders, Susan V., 1677, 2431
 Socransky, Sigmund S., 2595
 Soejima, Rinzo, 3141
 Soini, Hanna, 257, 2443
 Sokal, Étienne M., 404
 Solas, Caroline, 2989
 Solas, Dennis W., 1447
 Solbach, Werner, 2762
 Sommadossi, Jean-Pierre, 2989
 Soong, Seng-jaw, 1139
 Sörberg, Mikael, 1222
 Sörensen, Tina Klitmøller, 1706
 Sörgel, Fritz, 1151, 1659, 2012, 2359
 Soriano, Francisco, 1028, 1361
 Sougakoff, Vladimir, 2074
 Soukos, Nikolaos S., 2595
 Souli, M., 1088
 Souli, Maria, 939
 Soussy, Claude-James, 2590
 Sow, Samba, 1115
 Spangler, Sheila K., 495, 1253
 Sparfloxacin Multicenter UUTI Study Group, for the, 2262
 Spector, Stephen A., 808
 Speelberg, B., 1233
 Speelman, Peter, 1605
 Speirs, Robert J., 462
 Speldooren, Valérie, 879
 Spencer, James, 921
 Speranza, Filippo, 1346
 Sperling, Rhoda S., 808
 Spicer, W. John, 1365, 1370
 Spinola, Stanley M., 2690
 Spring, L., 1853
 Spruance, Spotswood, 789
 Spyridaki, Ioanna, 2747
 Srikumar, Ramakrishnan, 65, 399, 1682, 2225
 Srinivas, Ranga V., 612, 1484, 3157
 Staas, Jay K., 2682
 Ståhle, Lars, 2174
 Stahlmann, Ralf, 1470
 Staib, A. Horst, 2359
 Stamm, W. E., 1239, 1726
 Standiford, Harold C., 631
 Standing, David N., 3200, 3209
 Stanko, Jason P., 666
 Stapleton, Paul, 2771
 Stass, H., 2060

- Staszewski, Schlomo, 269, 3123
 Steckelberg, James M., 202
 Steigbigel, Roy T., 1139
 Stein, Andreas, 3086
 Stein, Daniel S., 358
 Steingrimsson, Olafur, 2290
 Stephan, Bernd, 83
 Sterrett, Andrew T., 332
 Stevens, David A., 767, 899, 907, 2299
 Stevens, Dennis L., 1266
 Stevens, Rachel, 767
 Steward, Christine D., 2661
 Stewart, Kent, 3218
 Stewart, Michael B., 2295
 Stiebel, Thomas R., Jr., 478
 St-Louis, Maryse, 2511
 Stobberingh, Ellen E., 3331
 Stoddart, Cheryl A., 2113
 Stoeckel, Klaus, 2602
 Stoffels, Paul, 3123
 Stone, J., 223
 Stone, Julie A., 332
 Storch, Gregory, 1980
 Storie, Christine, 1563
 Strobel, Frank W., 1878
 Struthers, J. K., 1428, 2521
 Struwig, M. C., 2752
 Stuerz, K., 277, 1397
 Stürmer, Martin, 3123
 Suárez, Ana Isabel, 3290
 Sudbeck, Elise A., 3225
 Sueoka, Cathy, 687
 Sugai, Motoyuki, 1278
 Sugar, Alan M., 1424
 Sugimoto, Hirohiko, 1340
 Suginaka, Hidekazu, 1278
 Suginaka, M., 3333
 Sugita, M., 550
 Sugiyama, Toshiro, 1895
 Sulavik, Mark C., 3317
 Suller, M. T. E., 1195
 Sullivan, Derek J., 1819
 Sullivan, Donna C., 978
 Sullivan, J., 2262
 Sultan, Eric, 199
 Sumpunsirikul, Petchmanee, 2332
 Sun, Eugene, 2784, 3218
 Sundelof, Jon G., 1996
 Sunder-Plassmann, Gere, 2417
 Suriano, Terra, 734
 Sutton, Kym, 45
 Suzuki, Katsuya, 1666, 2095
 Suzuki, Naoyoshi, 2985
 Swaney, Steve M., 3251
 Swarz, H., 114
 Swedberg, Göte, 1062
 Sweet, Clive, 640, 647
 Swenson, Christine E., 767
 Symonds, W., 2153
 Szekely, Adrien, 1412
- Taba, Hideki, 2193
 Taber, Harry, 1105
 Tachedjian, Gilda, 3038
 Tack, Kenneth J., 1073
 Tada, Mayumi, 2492
 Tahar, Rachida, 1811
 Tai, Chun Y., 640, 3234
 Taylor, Sandra A. N., 762
 Takahashi, Koichi, 579
 Takanaga, Hitomi, 1738
- Takei, Masaya, 2678
 Takemura, Hiromu, 698, 2006
 Takesako, Kazutoh, 755
 Takeuchi, Naonobu, 1499
 Takiguchi, Yoshiharu, 1433
 Takizawa, Hajime, 1499
 Takizawa, Tomoko, 40
 Talarico, Christine L., 444
 Talbot, G. H., 1088, 2262
 Tamaoka, Hisashi, 2943
 Tamura, Hirohi, 1015
 Tamura, Shinobu, 1858
 Tamura, Toshihide, 700
 Tanaka, Eitaro, 40
 Tanaka, Hironori, 698, 2006
 Tanaka, Masatoshi, 579
 Tanaka, Mayumi, 236, 1284, 3044
 Tanaka, S. K. T., 2385
 Tanaka, Yoshinobu, 2119
 Taniguchi, Koki, 717
 Tanimoto, Koichi, 2150
 Tashiro, Takayoshi, 40, 1722
 Tateda, Kazuhiro, 555, 1858, 2853
 Tatsu, Yoshiro, 2745
 Tattawasart, Unchalee, 2151
 Täuber, Martin G., 3325
 Tavanti, A., 2434
 Taylor, D., 3209
 Taylor, Diane E., 59, 1952
 ten Kate, Marian T., 1677
 Tennant, Bud C., 2804
 Tenorio, C., 3279
 Tenover, Fred C., 2312, 2661, 3024
 Tenovuo, Jorma, 1906
 Tentori, L., 550
 Teraguchi, Susumu, 1587
 Tessier, F., 2125
 Tessier, Pamela R., 840, 991
 Thackray, Alana M., 1555
 Thal, L. A., 705
 Thalhammer, Florian, 2417
 Then, Rudolf, 1495
 Theodos, Cynthia M., 1959
 Thériault, Esther, 2319
 Therrien, Christian, 2576
 Theuretzbacher, Ursula, 1659
 Thiel, Andreas, 2012
 Th'ng, Cecilia, 1290
 Thölke, Jürgen, 1911
 Thomas, Ann M., 528
 Thomas, Jennifer K., 521
 Thompson, Diane G., 1303
 Thompson, Randall K., 1996
 Thomson, Kenneth S., 596
 Thomson, K. S., 1350
 Thorburn, Christine E., 1973, 3193
 Thoresen, Ove Fredrik, 712
 Thormar, Halldor, 2290
 Tidwell, Richard R., 666, 2495, 2503, 2877
 Tiegs, Gisa, 1911
 Tingle, M. D., 2410
 Titlow, William B., 727
 Tod, M., 289, 1463
 Tod, Michel, 849
 Tolson, D., 436
 Tomasz, Alexander, 100
 Tomé, Daniel, 2607
 Tominaga, Kaoru, 1015
- Tomono, Kazunori, 40, 698, 1722, 2006
 Toole, J. J., 3130
 Tornatore, Michelle A., 734
 Toro, D., 1574
 Torre, Donato, 1346, 2017
 Torrero, M. N., 344
 Torres, C., 3279
 Tosini, Fabio, 3053
 Totten, Patricia A., 2690
 Tovcimak, A., 2385
 Tovcimak, Ann, 2674
 Tran, Thu T., 2656
 Traore, H., 2070
 Trapnell, Carol Braun, 1592
 Trees, David L., 2103
 Tremblay, Carole, 1847
 Trépanier, Eric F., 695
 Trépo, Christian, 369
 Trescher, Gudrun, 59
 Triebler, Catharine A., 59
 Triesenberg, Steve, 1783
 Trieu-Cuot, Patrick, 108
 Trofatter, Kenneth F., Jr., 789
 Troillet, N., 2966
 Trostdorf, F., 1397
 Trotter, Sylvie, 2996
 Trowbridge, Martin, 868
 Troyer, Jill Michelle, 1845
 Truffot-Pernot, Chantal, 2066
 Truong, Lo Anne, 2113
 Tsai, Shane F., 1229
 Tselentis, Yannis, 2747
 Tshukutsoane, S., 2235
 Tsuboi, Isami, 431
 Tsuchiya, Tomofusa, 1778
 Tsuda, Masataka, 1938
 Tsuda, Yasuyuki, 325
 Tsuji, Masakatsu, 94
 Tsuji, Takashi, 2095
 Tsujimoto, Hideto, 1938
 Tsunoi, Tomoko, 325
 Tsuruo, Takashi, 755, 1738
 Tsutsui, Ken T., 1447
 Tucker, Simon T., 478
 Tuel-Ahlgren, Lisa, 383, 3225
 Tullio, Vivian, 1745
 Tunney, Michael M., 3002
 Turik, Michael A., 2446
 Turner, Jeffrey, 2206
 Turner, William W., 1187
 Turpin, Jim A., 487
 Tying, Stephen K., 789, 1139
 Tzelepi, Eva, 1259, 1281
 Tzipori, Saul, 1959
 Tzouveleakis, Leonidas S., 1259, 1281
- Ubeaud, Geneviève, 425
 Ubukata, Kimiko, 2267
 Uchida, Takahiro, 691
 Uchida, Yoko, 1284, 3044
 Uckun, Faith M., 383
 Uckun, Fatih M., 3225
 Uematsu, Toshihiko, 1298, 1433
 Uemura, Yayoi, 1015
 Uh, Mitchell, 2511
 Uhl, Jim R., 202
 Ulrich, Peter, 1133
 Underwood, Mark R., 444
 Unerl, K., 2421
 Urasawa, Shozo, 717
- Urbina, Julio A., 1771
 Uriel, Clara, 779
 Uzzan, Bernard, 849
- Vaccaro, Joseph R., 675
 Vakulenko, Sergei B., 1542
 Valadon, Philippe, 1437
 van Alphen, Lock, 319
 van Berkel, Theo J. C., 1146
 van Boxel, Renée A. J., 3173
 Van Cauwenberge, Anja, 269
 Vandamme, A.-M., 618
 van de Klundert, Jos A. M., 3173
 Vandembroucke-Grauls, C. M. J. E., 2749
 van den Bogaard, Anthony E., 3331
 Van den Eynde, Christel, 269
 Van Den Mooter, Guy, 1568
 van der Poll, Tom, 1605
 van Deventer, Sander J. H., 1605
 van Dissel, Jaap T., 739
 van Dissel, J. T., 3073
 van Dyke, Russ, 808
 van Dyke, Russell, 1315
 Vanechoute, Mario, 3329
 van Etten, Els W. M., 1677, 2431, 2437
 Van Gerven, F., 282
 van Gerven, Veerle, 269
 Vanhoof, Raymond, 483
 van Houtte, Margriet, 269
 van Langevelde, P., 3073
 van Langevelde, Petra, 739
 van Marwijk Kooij, M., 1233
 Van Meervelt, L., 618
 van Vianen, Wim, 2431, 2437
 Van Voorhis, Wesley C., 3245
 van Vugt, M., 135
 Vargas, Marcus, 2718
 Varon, Emmanuelle, 173
 Vasavanonda, Sudthida, 3218
 Vasilyef, Alexandr V., 2443
 Vattanavibool, Phantip, 2332
 Vaudaux, Pierre E., 564
 Vazifeh, D., 1944
 Veau, C., 289
 Vedantam, Gayatri, 88
 Vega, S., 618
 Venkatachalam, T. K., 3225
 Venkateswarlu, K., 1756
 Venzon, David J., 3187
 Verbrugh, Henri A., 377, 744, 749
 Verdet, Charlotte, 2352
 Verhoef, Jan, 1249
 Vermeulen, M. C. A., 1233
 Verschraegen, Gerda, 3329
 Verweij, Paul E., 873
 Vestris, G., 1537
 Viljanen, Matti K., 2443
 Villari, Paolo, 100
 Villarreal, Elcira C., 916
 Vincent, H. H., 1233
 Vincent, John, 2048
 Visalli, M. A., 624
 Visalli, Melissa A., 857, 953, 2002

- Visca, Paolo, 3053
 Vogel, Nicolas, 2036
 Voladri, Rama Kishan R., 1375, 3163
 Vollmer, A., 725
 von Recklinghausen, G., 725
 Vora, Shefali, 907, 2299
 Vostrov, Sergey N., 659, 2841, 2848
 Voyer, Normand, 2319
 Vyshnevskaya, Elena, 2443
 Vyshnevskiy, Boris I., 2443
- Wachira, Timothy M., 601
 Wada, Takao, 1938
 Wada, Yasunao, 700
 Wagner, Sonja, 1057
 Wakabayashi, Hiroyuki, 1587
 Waldman, Scott, 332
 Walker, Scott, 762
 Wallace, Thomas, 1646
 Wallace, Thomas L., 1412
 Walsh, Gerald M., 801
 Walsh, Thomas J., 263, 2391, 2399, 2700, 2898
 Walsh, Timothy R., 921
 Walsh, T. J., 282
 Walsh, T. R., 436
 Wandschneider, Heidi L., 930
 Wang, B., 2245
 Wang, Elaine, 1290
 Wang, Ge, 1952
 Wang, Hui, 2633
 Wang, Jianghai, 2620
 Wang, Jian-Ying, 709, 956
 Wang, Li, 2178, 3136
 Wang, Q. May, 916
 Wang, Shan-Tair, 1319
 Wang, Tong, 236
 Wang, Yan Yan, 2132
 Wang, Yongwen, 1447
 Ward, Douglas J., 1695
 Ward, Rosemary, 868
 Ward, S. A., 2410
 Ward, Stephen A., 682, 2973
 Waring, Alan J., 2206
 Warnock, David W., 1412
 Wasan, Kishor M., 1646, 1878, 3146
 Watanabe, Naoko, 325
 Watkins, W. M., 164
 Webb, Murray S., 45, 2511
 Wehrle, A., 2421
 Weigel, Linda M., 2661
- Weinberg, Adriana, 2326
 Weinstock, George M., 2883
 Welch, John T., 462
 Welkos, Susan L., 675
 Welton, L. A., 705
 Wendt, Constanze, 2440
 Wennersten, C. B., 1088, 1520
 Werckenthin, Christiane, 2116
 Wesche, David L., 1293
 Westin, Katherine, 1437
 Wexler, Hannah M., 984
 Whitcomb, Patricia O., 2391
 White, N. J., 135
 White, Theodore C., 2584, 2932, 3245
 Whitley, Richard J., 1139
 Whittington, William L., 2103
 Wichelhaus, Thomas A., 2817
 Wideburg, Norm, 3218
 Wiener-Kronish, Jeanine P., 3269
 Williams, Byron K., 528
 Williams, D. L., 1853
 Williams, Kerstin J., 795
 Williams, Matt, 647
 Williams, Matthew A., 640, 3234
 Williams, R. Rex, 885
 Williamson, Karen, 487
 Wills, Peter, 772
 Wilson, Aaron J., 3245
 Wilson, Robert, 772
 Wilson, Wyndham, 2391
 Winchester, Gary A., 2682
 Wincker, Patrick, 1771
 Wingard, John R., 3103
 Winstanley, P. A., 164
 Wise, R., 428
 Wise, Richard, 2032
 Wiseman, David J., 45, 2511
 Witvrouw, M., 618
 Wolfe, Joyce N., 184
 Wolff, M., 28
 Wong, Frank A., 885
 Wong, Frankie A., 1098
 Wong, Kim F., 45
 Wong, Wesley, 1646
 Wood, John, 1402
 Wood, P., 1365
 Woodford, Neil, 502
 Woodford, Patricia J., 2919
 Woodnutt, Gary, 3193
 Woolf, Eric, 332
 Wootton, M., 419
 Wretling, Bengt, 3276
- Wright, G. D., 2215
 Wu, Bor Wen, 140
 Wu, Huiwei, 3234
 Wu, Jiunn-Jong, 1319
 Wu, Teresa W., 843
 Wu, Yaming, 1340
 Wubbel, Loretta, 2650
 Wyatt, J. R., 2113
- Xiao, Yan, 712
 Xie, Meng-Yu, 2989
 Ximenez-Fyvie, Laurie Ann, 2595
 Xu, Chen, 956, 2978
 Xu, Jing, 1315
 Xu, Yi, 2883
- Yamada, Hideo, 325
 Yamada, Yasuaki, 2006
 Yamada, Yasuhiro, 2985
 Yamaguchi, Hideyo, 967, 1587
 Yamaguchi, Keizo, 94, 555, 785, 1181, 1858, 2853
 Yamaguchi, Toshiyuki, 698, 2006
 Yamaji, Emiko, 431
 Yamakido, Michio, 1278
 Yamamoto, Hiroshi, 1597
 Yamamoto, Kazuhiko, 1499
 Yamamoto, Koujiro, 691, 1738
 Yamanishi, Koichi, 1666
 Yamano, Katsuhiko, 1738
 Yamatani, S., 3333
 Yamatsu, Isao, 2824
 Yanagihara, Katsunori, 1722
 Yang, Shioh-Shong, 3256
 Yang, Youjun, 1671, 1980
 Yasuda, Hiroshi, 23
 Yasuda, Mitsuru, 433, 3293
 Yasue, Tokutaro, 2678
 Yates, R., 903
 Yeaman, Michael R., 3169
 Yeh, Kuang C., 332
 Yeldandi, Vijay, 2391
 Yogeve, Ram, 1315
 Yokochi, Takashi, 1015
 Yokokawa, Masahiro, 1433
 Yokota, Kenji, 1895
 Yoshida, Masanori, 967
 Yoshida, Ryoji, 698, 2006
 Yoshikawa, Eiji, 431
 Yoshikawa, Susumu, 2745
- Yoshimura, Fuminobu, 2119
 Yoshimura, H., 3333
 Yoshimura, Manabu, 2150
 Yoshinaga, Michiko, 1866
 Yoshioka, Hirofumi, 755
 Yoshizumi, Satoshi, 785
 Youle, Michael S., 293
 Young, Douglas B., 1931
 Young, Lowell S., 180
 Young, Lynnette D., 583
 Yu, Christine Y., 471
 Yu, Yue C., 509
 Yuan, Meifang, 1168
 Yuen, Geoffrey J., 3187
 Yumoto, Noboru, 2745
- Zaat, Sebastian, 1605
 Zagury, Daniel, 2482
 Zaifert, Katie, 3179
 Zakula, Dorothy, 389
 Zalkow, L., 2245
 Zanetti, G., 2966
 Zanetti, Stefania, 3035
 Zarazaga, M., 3279
 Zelenitsky, Sheryl A., 2446
 Zemzoumi, K., 3097
 Zepf, Charlie, 3256
 Zervos, M., 729
 Zervos, Marcus J., 1229, 2710
 Zervos, M. J., 705
 Zeyhle, Eberhard E., 601
 Zhanel, George G., 184, 2427, 2446
 Zhang, Huizhong, 1200
 Zhang, Li, 399, 2225
 Zhang, Lijun, 640, 647
 Zhao, Qixun, 1682, 2225
 Zhao, Xilin, 956, 2978
 Zhong, Zhaojing, 1437
 Zhou, Jianfeng, 956
 Zhou, Weicheng, 2718
 Zhou, Xiao-Jian, 2989
 Zhu, Yong-Lian, 1805
 Ziebuhr, Wilma, 2817
 Ziegelbauer, Karl, 1581, 2197
 Zimmerli, Werner, 895, 2626
 Zinner, Stephen H., 72, 659, 2841, 2848
 Zippel, Uta, 1470
 Zoulim, Fabien, 369
 Zuckerman, Judy, 1815
 Zurenko, Gary E., 947
 Zwinkels, M. G. J., 3266

SUBJECT INDEX

VOLUME 42

- 2-Oxiacephems
E. faecalis, 2943
 OPC-20011, 2943
S. aureus, 2943
S. pneumoniae, 2943
- 2-Pyridones
 ABT-255, 2674
M. tuberculosis, 2674
- 3TC
 AT-61, 3179
 hepatitis B virus, 2128, 3179
 HIV, 2989
 PBMC, 2989
 pharmacodynamics, 2804
 woodchuck hepatitis virus, 2804
- 141W94
 HIV, 2153
 synergy with 1592U89, 2153
- 1592U89
 HIV, 2153
 synergy with 141W94, 2153
- 23S RNA
 clarithromycin, 2749
H. pylori, 2749
- A-5021
 herpes simplex virus, 2095
 herpesvirus
 antiviral activity in cell culture, comparative evaluation, 1666
 varicella-zoster virus, 2095
- aacC3
E. coli, 3173
P. aeruginosa, 3173
- aac(6')-Ij
Acinetobacter sp., 13, 2759
- aac(6')-Iq
K. pneumoniae
 characterization of, 1506
- Abelect
L. donovani, 2722
 versus sodium stibogluconate, 2722
- ABT-255
M. tuberculosis, 2674
- ABT-378
 HIV protease, 3218
 ritonavir, 3218
- Acanthamoeba*
 povidone-iodine, 2232
 propamidine, 2144
- Acanthamoeba castellanii*, 2870
 uptake of *L. pneumophila*, 2870
- Acinetobacter* sp. 13
 aac(6')-Ij, 2759
 IS18, 2759
- Aene vulgaris*
 peroxides, organic, water soluble
 synthesis and antibacterial evaluation, 911
- Actinobacillus actinomycetemcomitans*
 clarithromycin, 3000
 erythromycin, 3000
- Actinomyces viscosus*
 photochemotherapy, 2595
- Acyclovir
 dermatomal herpes zoster
 human immunodeficiency virus-infected patients, 1139
 sorivudine, comparative evaluation, 1139
- EBV TK, 2923
- herpes simplex virus resistance
 northwest England, survey of, 868
- HSV-1 TK, 2923
- mycophenolate mofetil
 potentiation of antiherspesvirus activity, 216
- Adefovir dipivoxil
 human immunodeficiency virus variants
 from AIDS patients after prolonged therapy
 genotypic and phenotypic characterization, 1620
- Acromonas veronii*
 metallo- β -lactamase
 ImS, nucleotide and amino acid sequences, 436
- Albendazole
 microsporidia, 3301
- All-trans-retinoic acid
 lipoprotein distribution
 differences in human, dog, and rat plasma, 1646
- Alpha-toxin
S. aureus, 2817
- Aluminum hydroxide
 pharmacokinetics
 effects on tosufloxacin bioavailability in healthy volunteers, 453
- AmBisome
C. albicans, 2437
L. donovani, 2722
 versus liposomal amphotericin B, 2437
 versus sodium stibogluconate, 2722
- Amikacin
 cefepime, 3304
 ceftazidime, 3304
E. cloacae, 3304
 imipenem, 3304
M. avium, 3006
 liposome encapsulated, prolonged-interval treatment, rationale for and efficacy of, 459
- M. tuberculosis* resistance
 mechanism of, 1295
- pharmacokinetics
 population pharmacokinetic study in febrile, severely neutropenic adults, 849
- Y. enterocolitica*, 3009
- Aminoglycoside acetyltransferases
 aac(6')-Iq
 characterization of, 1506
- E. cloacae*
 altered substrate profile, 209
- Aminoglycoside phosphotransferases
 chromogenic detection, 228
- Aminoglycoside-modifying enzymes
 nomenclature of genes encoding
 letter to the editor, 483
- Aminoglycosides
E. cloacae and *C. freundii* resistance
 aminoglycoside 6'-N-acetyltransferase variants, altered substrate profile, 209
- P. aeruginosa*, mucoid
 diffusion through extracellular polysaccharide, promotion by alginate lyase, 974
- P. stuartii* resistance
 aarE mutations, 959
- pharmacodynamics
 dosing to obtain pharmacodynamic goals in patients with pneumonia, 1892
- pharmacokinetics
 tobramycin MIC changes alter responses of *P. aeruginosa*, 1365
- resistance
 aminoglycoside phosphotransferases, chromogenic detection of, 228
- Amoxicillin
 combination with clavulanate, 2375
H. pylori, 2492
 infection in gnotobiotic piglets, 1549
H. pylori resistance
 risk of development, 1222
 microspheres, 2492
 otitis media, acute
 cefuroxime, comparative evaluation, 1361
S. pneumoniae, penicillin resistant, 1361
S. pneumoniae, 2375
 synergy
 cefotaxime, critical importance of concentrations, 468
 experimental *E. faecalis* endocarditis, 468
- Amoxicillin-clavulanate
H. influenzae, 3193
S. pneumoniae, 3193
S. pneumoniae, penicillin resistant
 activity in experimental respiratory infection model in rats, 813
- AmpC
P. aeruginosa, 3296
- AmpD
P. aeruginosa, 3296
- Amphocil
L. donovani, 2722
 versus sodium stibogluconate, 2722
- Amphotericin B
A. fumigatus, 2569
 aspergillosis
 invasive pulmonary, in mice, 40
- Aspergillus*, 3018
- Aspergillus* and *Fusarium* spp.
 synergy with rifabutin, 509
- Aspergillus* spp., 2726
- C. albicans*, 2431
- Candida*, 3018
- cholesterol, 3146
- colloidal dispersion
 invasive fungal infections in renally impaired patients, 606
- combinations
 flucytosine with or without fluconazole, 528
 murine cryptococcal meningitis, 528
 cryptococcal meningitis
 alone and with flucytosine with or without fluconazole, 528
 cryptococcosis, systemic murine
 Fungizone, Amphotec, AmBisome, and Abelect, comparative evaluation, 899
- dopamine, 3103
- immunoliposomal
 aspergillosis, invasive pulmonary, in mice, 40
- in macrophages, 2569
- L. donovani*, 2722
- L. donovani* promastigotes, resistance in

- mechanism of resistance, 352
L. infantum, 2141
L. major, 3092
 leukemia patients, 3103
 lipid complex
 antifungal activity in vitro and in vivo,
 role of phospholipases, 767
 lipid emulsion
 stability, compatibility, and in vitro anti-
 fungal activity, 762
 lipid nanosphere encapsulated
 C. neoformans, activity against, 1722
 liposomal, 2431, 2437
 liposomes
 blood clearance capacity of the mono-
 nuclear phagocyte system, 1677
 nephrotoxicity, 3103
 neutropenia, 2391
Paecilomyces spp.
 antifungal susceptibilities, 1601
 pharmacodynamics
 assessment of activity against *C. albi-*
 cans by dynamic in vitro mycotic
 infection model, 1382
 pharmacokinetics, 2391, 3146
 distribution in lung tissue after injection
 and inhalation, 1597
 unilamellar liposomal vesicle formula-
 tion, rats, 263
 polyene analog KY-62
 murine candidiasis, treatment of, 147
 synergy
 Aspergillus and *Fusarium* spp., 509
 rifabutin, 509
 transplant patients, 3103
 unilamellar liposomal vesicle formulation
 pharmacokinetics and toxicological pro-
 file in rats, 263
 versus itraconazole, 3018
 versus LY303,366, 2726
 versus sodium stibogluconate, 2722
 versus voriconazole, 3018
 Ampicillin
 combination with LY333328, 2564
 E. faecium, 2564
 Ampicillin-sulbactam
 concentrations in tissues
 bolus injections versus bolus plus con-
 tinuous infusion, 1093
 pharmacodynamics
 in vitro infection model against resis-
 tant *E. coli*, 231
 S. aureus, 3325
 Anaerobes
 cefminox
 comparative in vitro activity, 495
 gatifloxacin, 2459
 skin and soft tissue infections
 levofloxacin, in vitro activities, 984
 Y-688
 in vitro activities, 419
 Antibiotic resistance determinants
 E. hirae penicillin-binding protein 3r
 gene is borne on plasmid carrying other
 antibiotic resistance determinants,
 534
 Antiendotoxin reagents
 polymyxin B-immunoglobulin G conju-
 gate, 583
 Antifungal agents
 cordycepin
 candidiasis, invasive, antifungal activity,
 1424
 nystatin, liposome encapsulated
 four amphotericin B formulations, com-
 parative evaluation, 1412
 time-kill tests
 influence of test conditions on results,
 1207
 Antifungal testing
 filamentous fungi
 in vitro susceptibilities, possible correla-
 tion with outcomes in animal mod-
 els, 282
 Antimalarial agents
 quinoline-ring containing
 S. cerevisiae drug resistance genes, iden-
 tification of, 1034
 Antimony
 L. infantum, 3097
 pentavalent, 3097
 Antimycobacterial agents
 fluorescent protein reporter microplate
 assay
 high-throughput screening of com-
 pounds, 344
 AP-1
 ciprofloxacin, 1923
 Artemether-benflumetol
 falciparum malaria, multidrug resistant
 artesunate-mefloquine, comparative
 evaluation, 135
 Artesunate
 P. falciparum, 2332
 pharmacokinetics, 2332
 thalassemia, 2332
 Artesunate-mefloquine
 falciparum malaria, multidrug resistant
 artemether-benflumetol, comparative
 evaluation, 135
 Aspartic protease inhibition
 cysteine, 2254
 P. falciparum, 2254
 Aspergillosis
 A. fumigatus, amphotericin B susceptible
 and resistant
 LY303366, efficacy in murine model,
 873
 amphotericin B
 immunoliposomal, 40
 pulmonary, invasive
 amphotericin B, immunoliposomal, 40
Aspergillus
 amphotericin B, 2726, 3018
 itraconazole, 2726, 3018
 LY303,366, 2726
 voriconazole, 3018
Aspergillus fumigatus
 amphotericin B, 2569
 immunoliposomal, 40
 invasive pulmonary aspergillosis in
 mice, 40
 amphotericin B susceptible and resistant
 LY303366, efficacy in murine model of
 invasive aspergillosis, 873
 G-CSF, 2299, 2467
 GM-CSF, 2299
 LY303366, 2898
 efficacy in murine model of invasive
 aspergillosis, 873
 monocytes, 2299
 neutrophils, 2299
 rabbits, 2898
 triazoles, 2467
 voriconazole, 2299
Aspergillus spp.
 rifabutin-amphotericin B
 synergy, 509
 AT-61
 3TC, 3179
 hepatitis B virus, 3179
 Atherosclerosis
 C. pneumoniae, 2762
 Atomic force microscopy
 E. coli morphology
 before and after exposure to cefodiz-
 ime, use to investigate, 18
 Atovaquone
 3'-azido-3'-deoxythymidine
 glucuronidation by human liver micro-
 somes, inhibition by, 1592
 cefotaxime
 alone or in combination with minocy-
 cline, 1319
 experimental murine infection, treat-
 ment of, 1319
 minocycline
 alone or in combination with cefo-
 taxime, 1319
 experimental murine infection, treat-
 ment of, 1319
 pharmacokinetics
 zidovudine, glucuronidation by human
 liver microsomes, inhibition by,
 1592
 pharmacokinetics and phase I safety
 human immunodeficiency virus-infected
 infants and children, 1315
 ATP-bioluminescence susceptibility testing
 filamentous cell treatment
 novel test using, 1406
 Aureobasidin A
 S. cerevisiae resistance
 role of ABC transporters, 755
 Autolysis
 E. faecalis, 2883
 Avoparcin
 chickens, 3333
 Enterococcus, 3333
 letter to the editor, 3333
 AY 9944
 HIV, 2482
 3'-Azido-3'-deoxythymidine
 azido-reductase
 activation by ethacrynic acid, dipyr-
 id-
 amole, and indomethacin, 1654
 inhibition by human immunodeficiency
 virus protease inhibitors, 1654
 glucuronidation by human liver micro-
 somes
 inhibition by atovaquone, fluconazole,
 methadone, and valproic acid, 1592
 human immunodeficiency virus-infected
 patients, 1788
 pharmacokinetics
 alone and in combination with ritona-
 vir, 1788
 Azithromycin
 E. coli
 postantibiotic and sub-MIC effects, 414
 H. influenzae, 2385, 3193, 3313
 pharmacodynamics
 in vitro and in vivo, comparison with
 those of erythromycin, 377
 pharmacokinetics, 2385
 bronchopulmonary, letter to the editor,
 481
 S. aureus

- postantibiotic and sub-MIC effects, 414
S. pneumoniae, 2914, 3193
- Azoles**
C. albicans resistance
 cytochrome P-450 lanosterol 14 α -demethylase, amino acid substitutions, 241
 lactoferrin-triazole combinations, synergy, 1587
Candida, 2342
Candida resistance
 13-year evolution and prevalence in cancer patients at a large medical center, 734
 synergy with nitric oxide, 2342
T. cruzi, 3245
- Aztreonam**
 combinations
 ceftazidime, 1610
P. aeruginosa, 1610
P. stuartii resistance
 TEM-60 β -lactamase, 1459
 pharmacodynamics
P. aeruginosa, activity alone and with ceftazidime, 1610
- Babesia divergens*
 drug susceptibilities
 in vitro evaluation, 818
- Bacillus circulans*
 vancomycin, 2055
- Bacteremia**
 bacterial pathogens from
 frequencies of occurrence and antimicrobial susceptibility patterns, 1762
 SENTRY antimicrobial surveillance program, 1762
- Bacterial resistance**
 development in acutely ill patients during therapy
 factors associated with, pharmacodynamic evaluation of, 521
- Bacteroides fragilis*
 norfloxacin efflux, 2119
- Bartonella bacilliformis*
 coumestrol, 2906
gyrB, 2906
- BAY 10-8888**
C. albicans, 2197
 decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
 mechanism of action, 1581
C. tropicalis
 decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
 mechanism of action, 1581
- BAY 12-8039**
 antimycoplasmal activities in vitro, 703
- B. parvaptensis*
 susceptibilities to, letter to the editor, 1868
- B. pertussis*
 susceptibilities to, letter to the editor, 1868
- C. pneumoniae*
 in vitro activity, 951
- BEA005**
 pharmacokinetics, 2174
- Benflumetol**
P. falciparum, 2347
- Benzimidazoles**
 β -tubulin, 2171
C. albicans, 2495, 2503
C. neoformans, 2495, 2503
E. multilocularis metacystodes
 in vitro activities, 1052
 structure-activity relationships, 2495
- Benznidazole**
 IL-12, 2549
T. cruzi, 2549
- β -Lactamase inhibitors**
P. aeruginosa multidrug efflux pumps
 substrates for, 399
 resistant TEM-1 mutants
 selection and characterization of, 1542
- β -Lactamases**
A. veronii ImiS
 nucleotide and amino acid sequences, 436
 AmpC type
P. mirabilis, chromosomally encoded, 1110
bla_{IMP}, 2006
 BLIP, 2893
 carbenicillin-hydrolyzing, 1966
 Caz-hi, 3329
 cefotaxime-hydrolyzing, 1980
 cefotaxime-resistant *Enterobacteriaceae*
 identification of new CTX-M-3 cefotaxime-hydrolyzing enzyme, 827
 ceftazidime, 2576
 class A, cefotaxime hydrolyzing, plasmid mediated
 CTX-M-4, sequence of gene encoding, 1259
 involvement of serine 237 in cephalosporin hydrolysis, 1259
 CTX-M-3, cefotaxime hydrolyzing
 identification of, 827
 DHA-1, 2352
E. coli
 resistance to expanded-spectrum cephalosporins, 1350
 TEM-43, biochemical and genetic properties, 1671
 Toho-2, cloning and sequencing, 1181
Enterobacteriaceae, ceftazidime resistant
 novel TEM and SHV-5 type, isolates from Polish hospitals, 514
 extended spectrum, TEM and SHV-5 type
 ceftazidime resistant *Enterobacteriaceae*
 isolates from Polish hospitals, 514
 extended spectrum, TEM type
 A237T as a modulating mutation, 1042
 FOX-3
 AmpC type, plasmid mediated, characterization of, 464
H. influenzae, 3313
 inhibitor resistant *E. coli*
 discriminatory detection by single-strand conformation polymorphism-PCR, 879
 inhibitor-resistant mutants
 selection and characterization of, 1542
K. oxytoca, 2184
 AmpC type, plasmid mediated, characterization of, 464
K. pneumoniae, 3079
 association with decreased susceptibility to moxalactam, 108
 novel, extended spectrum, TEM type, 108
 outbreak of, epidemiology and successful control, 53
 resistance to expanded-spectrum cephalosporins, 1350
 TEM-43, biochemical and genetic properties, 1671
 L-1 metallo- family
 overexpression, purification, and characterization, 921
S. maltophilia, molecular heterogeneity, 1245
 letter to the editor, 3329
 M13, 2893
M. catarrhalis, 2521
M. morganii, 2125
M. morganii *ampR*, 2352
M. tuberculosis
 β -lactam susceptibilities, contribution to, 1524
 recombinant expression and characterization of, 1375
- minireview
 kinship and diversification, 1
 OXA-16, 3117
 OXA-19, 3113
 OXA-20, 2074
 OXY-2, 2184
P. aeruginosa, 2074, 3113, 3117
P. aeruginosa AmpC, 3296
P. mirabilis
 AmpC type, chromosomally encoded, 1110
 resistance to expanded-spectrum cephalosporins, 1350
- P. stuartii*
 TEM-60, characterization of, 1459
 PSE-4, 2319, 2576
S. aureus *bla_Z*, 3163
S. enteritidis, 2352
S. maltophilia metallo- β -lactamase L1
 molecular heterogeneity, 1245
 overexpression, purification, and characterization, 921
- S. marcescens*
 sequences of, 176
- sanfetrinem, interaction with
 comparison with interactions with imipenem and oral β -lactams, 1168
- SHV-5, 3079
 mutants constructed by substitutions at position 69, properties of, 1281
- sulbactam, 2319
- tazobactam, 2319
- tazobactam, preferential inhibition by
 Toho-2, cloning and sequencing, 1181
- TEM-1, inhibitor resistant
 natural variation and site-directed substitution at Asp276, 1323
- TEM-21, 2125
- TEM-41, 2771
- TEM-47, 3079
- TEM-60
P. stuartii, characterization of, 1459
- TEM-61, 3329
- Toho-2
 cloning and sequencing, 1181
- β -Lactams**
E. coli *hipA*, 3282
M. tuberculosis susceptibilities
 β -lactamases, contribution to, 1524
N. gonorrhoeae *penB*, 2799
S. pneumoniae, 1973, 2914
 release of lipoteichoic and teichoic acids as a result of exposure, 277

- β -Tubulin
 benzimidazoles, 2171
 phenylcarbamates, 2171
 Biapenem
 pharmacokinetics and safety
 elderly subjects, 1433
 Bicyclomycin
 transcription termination factor Rho
 effects on RNA- and ATP-binding ac-
 tivities, 571
 BILD 1633
 herpes simplex virus type 1
 acyclovir resistant, 1629
 Bioavailability
 cephalosporin prodrug esters, 2602
 effect of food, 2295
 stavudine, 2295
 Biocide resistance
 letter to the editor, 2151
 Biofilms
 antibiotic activity
 in vitro and in vivo, impact on, 895
C. albicans, 1900, 2146
 interaction of *S. pneumoniae* and *M. ca-
 tarhalis*, 2521
P. aeruginosa
 levofloxacin, in vitro and in vivo activi-
 ties, 1641
S. epidermidis slime production
 effect on activities of various agents,
 939
 Bioluminescence
S. mutans, 1906
 Biosynthesis
 streptomycin, 2041
 Bis(isopropylmethylcarbonyl)PMPA
 human immunodeficiency virus, drug re-
 sistant
 activity against, 1484
 Bis(isopropylloxycarbonyloxymethyl)-PMPA
 antiretroviral efficacy
 mice, 1568
 pharmacokinetics
 mice, 1568
 Bite wound isolates
 HMR 3004 (RU 64004)
 aerobic and anaerobic human and ani-
 mal bite pathogens, comparative
 evaluation, 1127
 HMR 3647 (RU 66647)
 aerobic and anaerobic human and ani-
 mal bite pathogens, comparative
 evaluation, 1127
bla_{IMP}
P. aeruginosa, 2006
S. marcescens, 2006
Blastomyces dermatitidis
 fluconazole
 susceptibilities of clinical and laboratory
 isolates, 978
 itraconazole
 susceptibilities of clinical and laboratory
 isolates, 978
 ketoconazole
 susceptibilities of clinical and laboratory
 isolates, 978
 BLIP
 M13, 2893
 Blood-brain barrier
 BEA005, 2174
 zalcitabine, 2174
 BM212
M. tuberculosis, 3035
 BM2716
aac(6')-Ij, 2759
 IS18, 2759
 BMS 181184
A. fumigatus, 2399
 neutropenia, 2399
 BMS 181884
 effect of food, 2706
 oral solution, 2706
 pharmacokinetics, 2706
 BMS-200475
 hepadnaviruses, 3200, 3209
 hepatitis B virus, 3209
 triphosphate form, 3200
 BMS-207147
 in vitro antifungal activity, 313
Bordetella parapertussis
 HMR 3004 (RU 64004)
 in vitro activity, comparative evaluation,
 965
 HMR 3647 (RU 66647)
 in vitro activity, comparative evaluation,
 965
 susceptibilities to, letter to the editor,
 1868
Bordetella pertussis
 HMR 3004 (RU 64004)
 in vitro activity, comparative evaluation,
 965
 HMR 3647 (RU 66647)
 in vitro activity, comparative evaluation,
 965
 susceptibilities to, letter to the editor,
 1868
 Brain
 rifampin concentrations, 2626
 Bronchitis
 grepafloxacin
 ciprofloxacin, comparative evaluation,
 114
 efficacy and safety for treatment of
 acute bacterial exacerbations, 114
 Broth microdilution
 penicillin-clindamycin
S. pyogenes, antimicrobial effect, 1266
 Burn patients
 fluconazole pharmacokinetics in, 930
 Caco-2 cells
 sparfloxacin, 2607
 Caco-2/TC-7 cells
 glucose metabolism, 2950
 glutamine metabolism, 2950
 ofloxacin, 2950
S. typhimurium, 2950
Campylobacter fetus
 subsp. *fetus*
 susceptibility testing, 1847
Campylobacter jejuni
 ciprofloxacin, 2106, 3276
dfr, 3059
 erythromycin, 2106
 nalidixic acid, 2106
 ORDR, 3276
 tetracycline, 2106
 trimethoprim, 3059
Candida
 amphotericin B, 3018
 azoles, 2342
 EF-2, 2279
 itraconazole, 3018
 LY303366, 2446
 nitric oxide, 2342
 sordarins, 2274, 2279
 SPA-S-843, 3012
 voriconazole, 3018
Candida albicans
 AmBisome, 2431, 2437
 amphotericin B, 2146, 2431, 2437
 assessment by dynamic in vitro mycotic
 infection model, 1382
 azole resistance
 cytochrome P-450 lanosterol 14 α -de-
 methylase, amino acid substitu-
 tions, 241
 azole resistant
 inhibition of hyphal growth by triazoles
 in presence of lactoferrin, 1587
 BAY 10-8888, 2197
 decreased accumulation or increased
 isoleucyl-tRNA synthetase activity
 confers resistance, 1581
 mechanism of action, 1581
 benzimidazoles, 2495, 2503
 biofilms, 1900, 2146
 carbazoles, 2503
CDR, 2584, 2923
 combinatorial chemistry, 2534
 cyclopeptamines
 A172013, cellular accumulation, local-
 ization, and activity, 389
 decapeptides, 2534
erg6 mutants
 susceptibility studies, 1160
ERG16, 2923
 fluconazole, 2584, 2645, 2923, 2938, 3065
 assessment by dynamic in vitro mycotic
 infection model, 1382
 pharmacodynamics in murine model of
 systemic candidiasis, 1105
 Fungizone, 2431, 2437
 growth rate, 1900
 HIV, 2923
 KY-62
 murine candidiasis, treatment of, 147
 LY303366 photoaffinity analog
 identification of targets, 1187
MDR1, 2923
 murine peritoneal macrophages, 2437
 murine vaginitis, 2434
 neuropeptide Y, 2745
 pentamidine analogues, 2495
 pentoxifylline, 2405
 polycarbophil-econazole, 2434
 SPI-ARGENT II, 2440
 sterol methyltransferase gene
 sequencing, disruption, and character-
 ization, 1160
 terbinafine
 in vitro activities, 1057
 voriconazole
 neutrophils or monocytes, combination
 with, 907
Candida dubliniensis
 fluconazole resistant
 multidrug transporters, identification
 and expression of, 1819
Candida glabrata
 fluconazole resistance
 association with drug efflux and a drug
 transporter gene, *PDHI*, 1695
Candida krusei
 fluconazole, 2645
Candida spp.
 amphotericin B
 lipid complex, role of phospholipases in

- antifungal activity, 767
lipid emulsion, 762
azole resistance
13-year evolution and prevalence in cancer patients at a large medical center, 734
time-kill tests
influence of test conditions on results, 1207
voriconazole
comparative in vitro activity, 161
- Candida tropicalis*
BAY 10-8888
decreased accumulation or increased isoleucyl-tRNA synthetase activity confers resistance, 1581
mechanism of action, 1581
- Candidiasis
antifungal activity, 1424
fluconazole
optimizing correlation between in vitro results and therapeutic outcome, 129
pharmacodynamics in murine model of systemic candidiasis, 1105
- KY-62
treatment of, 147
- CAP18
P. aeruginosa, 3269
- Carbapenems
biapenem
pharmacokinetics and safety in elderly subjects, 1433
- CS-834
in vitro and in vivo activities, 555
pneumonia in mice, 23
S. pneumoniae, penicillin susceptible and resistant, 23
- DA-1131
pharmacokinetics in rats with uranyl nitrate-induced acute renal failure, 1217
- K. pneumoniae* resistance
outer membrane protein profiles, association with, 1636
panipenem, 3136
S-4661
in vitro and in vivo activities, 94
S. aureus, 1996
- Carbazoles
C. albicans, 2503
C. neoformans, 2503
C. parvum, 2877
- Carbenicillin
hydrolyzing β -lactamases, 1966
- Cathelicidins
LL-37, 2206
- Caz-hi β -lactamase
letter to the editor, 3329
- cDNA integration
HIV, 2245
- CDR
C. albicans, 2584
fluconazole resistance, 2584
- Cefazolin
S. aureus, 2449
S. epidermidis, 2449
synergism with PGG-glucan, 2449
- Cefdinir
pharmacokinetics
hemodialysis patients, 1718
S. pyogenes pharyngitis
5-day treatment, efficacy of, 1073
- Cefepime
amikacin, 3304
combinations
aztreonam, 1610
P. aeruginosa, 1610
E. cloacae, 3304
pharmacodynamics
P. aeruginosa, activity alone and with aztreonam, 1610
pneumonia, community acquired
ceftriaxone, comparative evaluation, 729
- Cefminox
anaerobic bacteria
comparative in vitro activity, 495
- Cefodizime
S. pneumoniae, 2527
- Cefoperazone
biliary excretion, 2178
combinations with quinolones, 2002
G-CSF, 2178
S. maltophilia, 2002
- Cefotaxime
Enterobacteriaceae
hospital in Warsaw, identification of new CTX-M-3 cefotaxime-hydrolyzing β -lactamase, 827
hydrolyzing β -lactamase, 1980
S. pneumoniae, 2768
bactericidal activity, letter to the editor, 1869
synergy
amoxicillin, critical importance of concentrations, 468
experimental *E. faecalis* endocarditis, 468
V. vulnificus
alone or in combination with minocycline, 1319
experimental murine infection, treatment of, 1319
- Cefpirome
combinations with quinolones, 2002
comparative evaluation
cefazidime, 28
pneumonia in intensive care patients, empiric treatment of, 28
pharmacokinetics
concentrations in cerebrospinal fluid of children with bacterial meningitis, 199
pneumonia
cefazidime, comparative evaluation, 28
S. maltophilia, 2002
- Ceftazidime
amikacin, 3304
 β -lactamase PSE-4, 2576
combinations with quinolones, 2002
comparative evaluation
cefpirome, 28
pneumonia in intensive care patients, empiric treatment of, 28
E. cloacae, 3304
K. pneumoniae, 3079
lipopolysaccharide release, antibiotic induced
S. typhi, delay between killing and release, 739
P. stuartii resistance
TEM-60 β -lactamase, 1459
pneumonia
cefpirome, comparative evaluation, 28
S. maltophilia, 2002
S. typhi
lipopolysaccharide release, antibiotic induced, delay between killing and release, 739
- Ceftizoxime
pharmacokinetics
continuous infusion in clinically ill adults, 1783
S. pneumoniae
bactericidal activity, letter to the editor, 1869
- Ceftriaxone
assays, 2259
concentration in serum, 2259
pneumonia, community acquired
cefepime, comparative evaluation, 729
S. pneumoniae, penicillin resistant
meropenem, imipenem, and ceftriaxone-vancomycin, comparative activities, 942
versus L-749,345, 2365
Y. enterocolitica, 3009
- Cefuroxime
otitis media, acute
amoxicillin, comparative evaluation, 1361
S. pneumoniae, penicillin resistant, 1361
- Cephalexin
pharmacokinetics
interaction with quinapril, analysis by a nonlinear mixed-effect model, 1463
- Cephalosporins
 β -lactamase CTX-M-4
involvement of serine 237 in cephalosporin hydrolysis, 1259
bioavailability, 2602
E. aerogenes resistance
plasmid mediated, 596
expanded spectrum
 β -lactamase responsible for resistance, characterization of, 1350
K. pneumoniae, *P. mirabilis*, and *E. coli* resistance, 1350
K. pneumoniae resistance
outer membrane protein profiles, association with, 1636
prodrug esters, 2602
S. pneumoniae, 2650
- Cercopin P1, 3320
- Cerulenin
P. aeruginosa resistance
role of efflux systems, novel technique for study, 395
- Children
HIV, 3187
lamivudine, 3187
- China
S. pneumoniae susceptibilities, 2633
- Chlamydia pneumoniae*
atherosclerosis, 2762
azithromycin
microbiologic efficacy, 194
susceptibilities of isolates from patients with community-acquired pneumonia, 194
BAY 12-8039
in vitro activity, 951
HMR 3647 (RU 66647)
activity in vitro, 1515
susceptibilities, 2762
- Chlamydia trachomatis*
chlorhexidine gluconate gel
susceptibility to, 1726
fatty acids, 2290

- gyrase, 2474
 monoglycerides, 2290
 ORDR, 2474
 synthetic lipids adapted from compounds
 in human breast milk
 killing by, 1239
 topoisomerase IV, 2474
- Chloramphenicol
C. difficile resistance
 Tn4453 transposon, 1563
- Chlorocycloguanil
P. falciparum
 in vitro activity, correlation with point
 mutations in the dihydrofolate re-
 ductase domain, 164
- Chlorhexidine gluconate
C. trachomatis
 susceptibility to, 1726
 gel
C. trachomatis, susceptibility to, 1726
- 5-Chloropyrazinamide
Mycobacterium spp.
 in vitro activity, 462
- Cholera toxin
 ciprofloxacin pharmacokinetics
 effect on intestinal elimination in rab-
 bits, 473
- Cholesterol
 amphotericin B, 3146
- Cidofovir
 cytomegalovirus retinitis, 2240
 herpes simplex virus, 2996
- Cimetidine
 clarithromycin
 interaction with, 1578
 pharmacokinetics
 ofloxacin, effects on renal disposition in
 rats, 456
- Ciprofloxacin
 AP-1, 1923
B. paraptensis
 susceptibilities to, letter to the editor,
 1868
B. pertussis
 susceptibilities to, letter to the editor,
 1868
C. jejuni, 3276
 chloramphenicol acetyltransferase, 1923
 combination with gentamicin, 2002
 combinations
 fenbufen, effects on central nervous sys-
 tem, assessment by electroencephalo-
 graphy, 1256
 combinations with cephalosporins, 2002
 foscarnet, interaction with
 neurotoxicodynamics of, 691
H. pylori
 infection in gnotobiotic piglets, 1549
 high-dose pharmacokinetics, 2235
 IL-2, 1923
 liposomal encapsulation
 pharmacokinetics, effect on, 45
 S. typhimurium infection in mice, effect
 on antibacterial efficacy, 45
 Marvelon contraceptive, 3266
N. gonorrhoeae, 2919
N. gonorrhoeae parC, 2103
 NF- κ B, 1923
 orthopedic implants, 3002
 pharmacokinetics, 2841
 cholera toxin, effect on intestinal elimi-
 nation in rabbits, 473
 effects of combination therapy with fen-
- bufen on central nervous system,
 1256
 liposomal encapsulation, effect on, 45
 renal failure in rats, influence on, 289
 prediction of effect, 2848
 prophylaxis in bone marrow transplant
 recipients
 alone and in combination with vanco-
 mycin, comparative evaluation,
 1402
S. aureus *grlA*, *grlB*, *gyrA*, and *gyrB* muta-
 tions
 characterization of and effect on MIC,
 1249
S. multophila, 2002
S. typhimurium
 liposomal encapsulation, effect on infec-
 tion in mice, 45
 severe sepsis, 2235
 viridans streptococci, 2792
Y. enterocolitica, 3009
- Citrobacter freundii*
 aminoglycoside 6'-N-acetyltransferase
 variants
 altered substrate profile, 209
 cefotaxime resistant
 hospital in Warsaw, identification of
 new CTX-M-3 cefotaxime-hydro-
 lyzing β -lactamase, 827
- Clarithromycin
A. actinomycetemcomitans, 3000
 electrocardiographic pharmacodynamics
 after individual or concomitant adminis-
 tration with loratadine, 1176
H. influenzae, 2385, 3193, 3313
H. pylori, 2749
 infection in gnotobiotic piglets, 1549
H. pylori resistance
 risk of development, 1222
Legionella spp.
 activity in vitro, 1520
M. avium, 3006
M. ulcerans, 2070
 pharmacokinetic interactions with rifabu-
 tin
 human immunodeficiency virus-infected
 volunteers, 631
 pharmacokinetics, 2385
 after individual or concomitant adminis-
 tration with loratadine, 1176
 bronchopulmonary, letter to the editor,
 481
 grapefruit juice, effect on, 927
 oral cimetidine prolongs absorption,
 1578
S. pneumoniae, 3193
 tolerance
 human immunodeficiency virus-infected
 volunteers, 631
 clarithromycin and loratadine
 individual or concomitant administration,
 1176
- Clavulanate
 combination with amoxicillin, 2375
S. pneumoniae, 2375
- Clinafloxacin
 bacterial isolates from 10 North American
 centers
 disk diffusion interpretive zone diame-
 ter criteria, 1274
 susceptibility to, 1274
 gram-positive and gram-negative bacteria
 comparative evaluation, 1269
- M. tuberculosis*, 2066
 pharmacokinetics
 inflammatory fluid penetration, 428
S. pneumoniae, 2810
 susceptibility testing
 disk diffusion interpretive zone diame-
 ter criteria, 1274
- Clindamycin
 coryneform bacteria, 3290
 HIV, 3014
 penetration, 3014
S. pneumoniae
 HMR 3647, quinupristin-dalfopristin,
 and erythromycin, comparative ac-
 tivities of and cross-resistance to,
 945
S. pyogenes
 in vitro activity of combinations with
 penicillin, 1266
- Clofazimine
M. avium, 3006
- Clostridium difficile*
 chloramphenicol resistance
 Tn4453 transposon, 1563
- Clostridium* spp.
 nitrofurantoin resistant, nitroreductase
 producing
 isolation from human intestinal tract,
 1121
- Clostridium tetani*
 new pasteurized human tetanus immuno-
 globulin
 safety and pharmacokinetic profile, 298
- CNI-H0294
 human immunodeficiency virus
 inhibition of virus replication in in-
 fected peripheral blood mononu-
 clear cells, 1133
- Co-amoxiclav
S. aureus, heteroresistant
 in vitro activities at concentrations
 achieved in human serum, 1574
- Combinatorial chemistry
C. albicans, 2534
 decapeptides, 2534
- Combinatorial library screening
 two-dimensional agar format, 1447
- Comparative molecular field analysis
 sulfa drugs
 inhibitors of *P. carinii*, 1454
- Contraceptives
 interaction with ciprofloxacin, 3266
- Cordycepin
 antifungal activity, 1424
- Coryneform bacteria
 clindamycin, 3290
 HMR3647, 3290
 macrolides, 3290
- Co-trimoxazole
Staphylococcus, 3086
- Coumarins
grlA, 2109
S. aureus, 2109
S. aureus resistance
 mutations in topoisomerase IV and
 DNA gyrase, effect on, 121
- Coumermycin A₁, 2906
B. bacilliformis *gyrB*, 2906
- Coxiella burnetii*
 trovafloxacin, 2747
- Cryptococcosis
 amphotericin B
 Fungizone, Amphotec, AmBisome, and

- Abelcet, comparative evaluation, 899
- lipid nanosphere encapsulated, activity of, 1722
- Cryptococcus*
- SPA-S-843, 3012
- Cryptococcus neoformans*
- amphotericin B
- alone and with flucytosine with or without fluconazole, 528
- lipid nanosphere encapsulated, activity of, 1722
- murine meningitis, 528
- benzimidazoles, 2495, 2503
- carbrazoles, 2503
- cryptococcosis, systemic murine
- Fungizone, Amphotec, AmBisome, and Abelcet, comparative evaluation, 899
- dolastatin 10, 2961
- fluconazole susceptible and resistant voriconazole versus itraconazole, 471
- furans, 2503
- monoclonal antibody to capsular polysaccharide
- candidate for human therapeutic studies, 1437
- pentamidine analogues, 2495
- triazole TAK-187, 2630
- Cryptosporidiosis
- dinitroanilines
- synthesis and evaluation for treatment, 339
- Cryptosporidium parvum*
- carbrazoles, 2877
- cyclosporin analogs
- inhibition of in vitro growth, 843
- dinitroanilines
- synthesis and evaluation for treatment, 339
- nitazoxanide, 1959, 2877
- paromomycin, 1959, 2877
- CS-834
- in vitro and in vivo activities, 555
- S. pneumoniae*
- penicillin susceptible and resistant, 23
- pneumonia in mice, 23
- CTX-M-5
- cefotaxime, 1980
- S. typhimurium*, 1980
- Cycloheptamines
- A172013
- fungi, cellular accumulation, localization, and activity, 389
- fungi
- A172013, cellular accumulation, localization, and activity, 389
- Cyclosporin
- analogs
- C. parvum*, inhibition of in vitro growth, 843
- C. parvum*
- inhibition of in vitro growth, 843
- cysC
- E. coli*, 3173
- P. aeruginosa*, 3173
- Cysteine inhibition
- aspartic protease, 2254
- P. falciparum*, 2254
- Cytochrome P-450
- ketoconazole, effect on susceptibility, 1756
- Cytokines
- production induced by heat-killed *S. pneumoniae*
- effect of erythromycin and penicillin, 1605
- trovafoxacin
- production by human monocytes, effect on, 1713
- Cytomegalovirus
- cidofovir, 2240
- flow cytometry, 2326
- fomivirsen resistance
- sequence dependent, 971
- foscarnet, 2240
- ganciclovir, 2326
- ganciclovir resistance
- Cys607→Tyr change in UL97 phosphotransferase, 444
- retinitis, 2240
- D0870
- pharmacokinetics
- two multiple-dosing regimens in human immunodeficiency virus-positive patients, 903
- DA-1131
- pharmacokinetics
- rats with uranyl nitrate-induced acute renal failure, 1217
- DABO
- HIV reverse transcriptase, 3225
- Dalfopristin-quinupristin
- E. faecium*, vancomycin resistant in vitro susceptibility, 1088
- Defensins
- conjunctiva, 3328
- letter to the editor, 3328
- Delivery systems
- liposomal
- novel, peptide grafted, 348
- 3'-Deoxyadenosine
- candidiasis, invasive
- antifungal activity, 1424
- 2'-Deoxyguanosine
- D and L enantiomers
- metabolism in human cells, 1045
- Deoxyribonucleoside salvage
- E. coli*, 2620
- Dermaseptin s3
- S. cerevisiae*, 2160
- Dermatome herpes zoster
- acyclovir
- human immunodeficiency virus-infected patients, 1139
- sorivudine, comparative evaluation, 1139
- sorivudine
- acyclovir, comparative evaluation, 1139
- human immunodeficiency virus-infected patients, 1139
- Dextran 70
- PMX-622, 2765
- DHA-1
- M. morganii* ampR, 2352
- S. enteritidis*, 2352
- Diamidoximes
- prodrugs of
- anti-*Pneumocystis* activities, 666
- Diaminomethylpyridopyrimidines
- M. avium* complex, 3315
- Dicaffeoylquinic acid
- human immunodeficiency virus type 1
- selective inhibition of integrase, 140
- Dicaffeoyltartaric acid
- human immunodeficiency virus type 1
- selective inhibition of integrase, 140
- Diclofenac
- panipenem, 3136
- Didanosine
- pharmacokinetics
- human immunodeficiency virus-infected outpatients, 821
- relationship between didanosine exposure and surrogate marker response, 821
- 2',3'-Dideoxy-2',3'-didehydro-β-L(-)-5-fluorocytidine [t(-)-F4dC]
- human immunodeficiency virus type 1
- antiviral activity in combination with β-D(+) nucleoside analogs, 1799
- pharmacokinetics
- metabolism, 1799, 1805
- Dihydrofolate reductase
- diaminomethylpyridopyrimidines, 3315
- M. avium* complex, 3315
- trimethoprim, 2221
- Dihydrofolate reductases
- C. jejuni*, 3059
- trimethoprim, 3059
- Dinitroanilines
- cryptosporidiosis
- evaluation for treatment, 339
- synthesis of, 339
- Dipyridamole
- zidovudine azido-reductase
- activation by, 1654
- Dirithromycin
- H. influenzae*
- effect on infection of the respiratory mucosa, 772
- Disulfiram
- G. lamblia*
- efficacy of, 1488
- DNA gyrase
- S. aureus*
- mutations, novel pleiotropic effects on quinolone and coumarin activity, 121
- DNA gyrase
- cleavage and cell killing
- modulation by ATP, 1022
- E. faecalis* resistance
- alterations in GyrA subunit, association with, 433
- S. marcescens*
- cloning and nucleotide sequence, 190
- mutations in quinolone-resistant isolates, characterization of, 190
- Dolastatin 10
- C. neoformans*, 2961
- Dopamine
- amphotericin B nephrotoxicity, 3103
- Doxycycline
- combination with quinupristin-dalfopristin, 2710
- E. faecium*, 2710
- rickettsiae
- in vitro susceptibilities, 1537
- Doxycycline hyclate
- E. canis*
- experimental canine ehrlichiosis, 362
- ehrlichiosis
- canine, experimental, 362
- DU-6859a
- theophylline metabolism
- effect on, 1751
- E5531
- murine endotoxin response, 2824

- E test
penicillin-clindamycin
S. pyogenes, antimicrobial effect, 1266
- Echinocandins
A. fumigatus, 2898
Aspergillus spp., 2726
Candida, 2446
LY303366, 2446, 2726, 2898
LY303366 photoaffinity analog
C. albicans, identification of targets in, 1187
water soluble
Pneumocystis pneumonia in mice, 37
- Echinococcus granulosus*
oxfendazole
naturally infected animals, treatment of, 601
- Echinococcus multilocularis*
benzimidazoles
metacestodes, activity against, 1052
- Econazole
C. albicans, 2434
combination with polycarbophil, 2434
- EF2
S. cerevisiae, 2694
- Efflux
B. fragilis, 2119
norfloxacin, 2119
P. aeruginosa, 1938, 2225
S. pneumoniae, 2032
- Ehrlichia canis*
doxycycline hyclate
experimental canine ehrlichiosis, 362
- Ehrlichiosis
canine
doxycycline hyclate, 362
E. canis
doxycycline hyclate, 362
- Elderly patients
bacterial infections, serious
meropenem versus cefuroxime-gentamicin, comparative evaluation, 1233
- Encephalitis
T. gondii
trimethoprim-sulfamethoxazole versus pyrimethamine-sulfadiazine, 1346
- Encephalitozoon*
albendazole, 3301
- Endocarditis
E. faecalis
amoxicillin-cefotaxime synergy, critical importance of concentrations, 468
S. aureus
experimental, efficacy of trovafloxacin, 254
S. aureus, methicillin resistant
LY333328, efficacy against, 981
lysothaphin, treatment of, 1335
trovafloxacin, activity against, 1837
- Endotoxin
P. aeruginosa and *E. coli*, antibiotic treated
biological characterization, 1015
- Enterobacter aerogenes*
BM2688, 2557
cephalosporins, expanded spectrum, resistance to
plasmid mediated, 596
In40, 2557
- Enterobacter cloacae*
amikacin, 3304
aminoglycoside 6'-N-acetyltransferase variants
altered substrate profile, 209
cefepime, 3304
ceftazidime, 3304
imipenem, 3304
- Enterobacteriaceae*
 β -lactamases
novel TEM and SHV-5 type, isolates from Polish hospitals, 514
fluoroquinolone resistance, 2661
gyrA, 2661
- Enterococcus faecalis*
auc6-aph2, 2889
autolysin, 2883
 β -lactamase inhibitor combinations
activities and time-kill studies, 857
endocarditis
amoxicillin-cefotaxime synergy, critical importance of concentrations, 468
eperezolid and linezolid
comparative activity and postantibiotic effect, 721
gentamicin, 2889
glycopeptides
activities and time-kill studies, 857
OG1RF, 2883
OPC-20011, 2943
penicillin
activities and time-kill studies, 857
quinolone resistance
alterations in *GyrA* subunit of DNA gyrase and *ParC* subunit of DNA topoisomerase IV, 433
- Enterococcus faecium*
doxycycline, 2710
eperezolid and linezolid
comparative activity and postantibiotic effect, 721
glycopeptide resistance
transferable, plasmid mediated, VanB type, 963
letter to the editor, 3331
LY333328, 2564
quinupristin-dalfopristin, 2188, 2710
satA, 3331
vancomycin, 2150
vancomycin resistance, 2564
vancomycin resistant, 2710
characterization of isolates from United States, 1088
dalfopristin-quinupristin susceptibility in vitro, 1088
vgh, 3331
- Enterococcus hirae*
penicillin-binding protein 3r
gene is borne on plasmid carrying other antibiotic resistance determinants, 534
- Enterococcus* spp.
antimicrobial resistance
turkey flocks fed virginiamycin, 705
avoparcin, 3333
chickens, 3333
gentamicin resistance, high level
aph(2'')-I_d, 1229
glycopeptides, 2215
HMR3647, 3279
letter to the editor, 2463, 3333
pyelonephritis
trovafloxacin-rifampin, contrast with in vitro and in vivo results, 188
South Africa, 2752
susceptibilities, 2752
trovafloxacin
in vitro dynamic model of infection, 72
VanA glycopeptide resistance elements
diversity, human and nonhuman sources, 502
vanA, *vanB*, *vanC-I*, and *vanC-2/3*
DNA sequence variation, 202
vancomycin, 2215
vancomycin resistance, 2463
- Eperezolid
S. aureus, coagulase-negative staphylococci, *E. faecalis*, and *E. faecium*
comparative activity and postantibiotic effect, 721
- Epileptogenic potential
norfloxacin, 2756
pefloxacillin, 2756
- Epstein-Barr virus
acyclovir, 2923
ganciclovir, 2923
thymidine kinase, 2923
- erg6*
C. albicans
sequencing, disruption, and characterization, 1160
- Erythromycin
A. actinomycetemcomitans, 3000
C. jejuni, 2106
cytokine production induced by heat-killed *S. pneumoniae*
effect on, 1605
H. influenzae, 3193, 3313
inhibitory effect on superoxide anion production by human neutrophils
letter to the editor, 1866
L. pneumophila, 3153
pharmacodynamics
in vitro and in vivo, comparison with those of azithromycin, 377
S. aureus, 3024
S. pneumoniae, 2312, 3193
quinupristin-dalfopristin, HMR 3647, and clindamycin, comparative activities of and cross-resistance to, 945
S. pyogenes resistance
emergence in Madrid, letter to the editor, 989
novel methylase gene (*ermTR*), 257
streptococci, group C and G, resistance analysis of different mechanisms of, 1493
- Escherichia coli*
aacC3, 3173
ampicillin-sulbactam
in vitro infection model against strains with various levels of resistance, 231
azithromycin
postantibiotic and sub-MIC effects, 414
 β -lactamase
resistance to expanded-spectrum cephalosporins, 1350
tazobactam, preferential inhibition by, 1181
TEM-43, biochemical and genetic properties, 1671
Toho-2, cloning and sequencing, 1181
 β -lactamase, extended spectrum, TEM type
A237T as a modulating mutation, 1042
 β -lactams, 3282
cefotaxime resistant
hospital in Warsaw, identification of

- new CTX-M-3 cefotaxime-hydrolyzing β -lactamase, 827
- cephalosporins, expanded spectrum, resistance to
- β -lactamase, characterization of, 1350
- cysC*, 3173
- deoxyribonucleoside salvage enzymes, 2620
- DNA gyrase-mediated cleavage and cell killing
- modulation by ATP, 1022
- endotoxins released after antibiotic treatment
- biological characterization, 1015
- enterohemorrhagic O157:H7
- outbreak in Japan, antibiotic susceptibility, 431
- fluoroquinolone resistance, 2089
- fluoroquinolones, 3282
- comparative efficacies, 83
 - continuous or pulsed administration in water, 83
- hipA*, 3282
- isepamicin
- postantibiotic and sub-MIC effects, 414
- linezolid, 3251
- marA*, 2089
- nucleoside analogs, 2620
- postantibiotic effect
- cefotaxime and piperacillin, 78
 - determination with real-time metabolic monitoring, 78
 - physical and biochemical characteristics and dynamics, determination by flow cytometry, 1005
 - screen for HIV variants, 3256
- soxS*, 2089
- SPI-ARGENT II, 2440
- sulfathiazole resistance
- mutations contributing to, characterization of, 88
- Ethacrynic acid
- zidovudine azido-reductase activation by, 1654
- Famciclovir
- herpes simplex virus type 1
 - latency, prevention of, quantitative comparison with valaciclovir, 1555
- Famotidine
- pharmacokinetics
 - effects on tosoflaxacin bioavailability in healthy volunteers, 453
- Fatty acids
- C. trachomatis*, 2290
- Fenbufen
- combinations
 - ciprofloxacin, effects on central nervous system, assessment by electroencephalography, 1256
 - pharmacokinetics
 - effects of combination therapy with ciprofloxacin on central nervous system, 1256
- Ferrocene-chloroquine
- P. falciparum*
 - in vitro activity, 540
- Fleroxacin
- bactericidal activity
 - pefloxacillin, comparative evaluation, 1659
 - pharmacokinetics
 - urinary excretion in healthy volunteers, comparative evaluation, 1659
- Flow cytometry
- postantibiotic effect of methicillin
 - S. aureus*, 1195
- Fluconazole
- 3'-azido-3'-deoxythymidine
 - glucuronidation by human liver microsomes, inhibition by, 1592
- B. dermatitidis*
- susceptibilities of clinical and laboratory isolates, 978
- C. albicans*, 2645, 2923, 2938, 3065
- C. albicans* CDR, 2584
- C. dubliniensis* resistance
- multidrug transporters, identification and expression of, 1819
- C. glabrata* resistance
- association with drug efflux and a drug transporter gene, *PDH1*, 1695
- C. krusei*, 2645
- Candida* resistance
- 13-year evolution and prevalence in cancer patients at a large medical center, 734
- candidiasis, invasive
- optimizing correlation between in vitro results and therapeutic outcome, 129
- Paeclomyces* spp.
- antifungal susceptibilities, 1601
- pharmacodynamics
- assessment of activity against *C. albicans* by dynamic in vitro mycotic infection model, 1382
 - murine model of systemic candidiasis, 1105
- pharmacokinetics
- burn patients, 930
 - rabbis and humans, correlation of AUC and peak levels, 1512
 - zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
- pharmacokinetics of indinavir
- human immunodeficiency virus-infected patients, effect on, 223
- Flucytosine
- Paeclomyces* spp.
 - antifungal susceptibilities, 1601
- 2'-Fluoro-5-methyl- β -L-arabinofuranosyluracil (1-FMAU)
- duck hepatitis B virus
 - inhibition of replication, 369
 - unique metabolism
 - substrate for both thymidine kinase and deoxycytidine kinase, 833
- Fluoroquinolones
- BAY 12-8039
 - antimycoplasmal activities in vitro, 703
 - C-8 substituents, 2978
 - C-8-methoxy
 - S. aureus*, killing by, 956
 - E. coli*, 2089
 - E. coli* *hipA*, 3282
 - E. coli* infection in chickens
 - comparative efficacies, 83
 - continuous or pulsed administration in water, 83
 - efflux, 2032
 - Enterobacteriaceae*, 2661
 - excitatory potencies in central nervous system
 - in vitro model, 1831
- gestational exposure, pregnancy outcome following
- multicenter prospective controlled study, 1336
- gyrA*, 2661
- Haemophilus* spp., 2956
- HSR-903
- respiratory pathogens, in vivo activity, 785
- K. pneumoniae*, quinolone resistant
- energy-dependent accumulation, 1850
- marA*, 2089
- mycobacteria, 2978
- P. aeruginosa*, 2956
- rickettsiae
- in vitro susceptibilities, 1537
- S. aureus* resistance
- letter to the editor, 727
 - selection with ciprofloxacin and trovafloxacin, 727
- S. pneumoniae*, 2032, 2956
- soxS*, 2089
- sulfanilic
- mode of action, 1495
- V. cholerae* resistance
- letter to the editor, 206
 - patients with acute diarrhea in Calcutta, India, 206
- Y-688
- anaerobic bacteria, 419
- Fluoxetine
- ritonavir pharmacokinetics, 3107
- Fomivirsen
- cytomegalovirus resistance
 - sequence dependent, 971
- Food
- pleconaril pharmacokinetics, 2706
- Food and Drug Administration approvals
- 1997, 987
- Foscarnet
- ciprofloxacin, interaction with neurotoxicodynamics of, 691
 - cytomegalovirus retinitis, 2240
 - HIV, 3038
 - pharmacokinetics
 - absolute bioavailability, 293
 - human immunodeficiency virus-seropositive patients, 293
 - zidovudine coresistance, 3038
- Fosfomycin
- S. pyogenes* CD15s-related antigen expression
 - reduction of, 1083
- Fungal infections
- amphotericin B colloidal dispersion
 - renally impaired patients, 606
- Fungi
- amphotericin B
 - lipid emulsion, 762
 - BMS-207147
 - in vitro activity, 313
 - cyclopeptamines
 - A172013, cellular accumulation, localization, and activity, 389
 - filamentous
 - in vitro susceptibilities, possible correlation with outcomes in animal models, 282
 - furanonaphthoquinone analogs
 - antimicrobial activities, 700
- Fungizone
- C. albicans*, 2437
 - versus liposomal amphotericin B, 2437

- Furanonaphthoquinones
analogs
antimicrobial activities, 700
- Furans
C. albicans, 2503
C. neoformans, 2503
- Fusarium* spp.
rifabutin-amphotericin B
synergy, 509
- γ -Glutamylcysteine ethyl ester
human immunodeficiency virus type I
production and propagation, inhibition
of, 1200
- Ganciclovir
cytomegalovirus, 2326
cytomegalovirus resistance
Cys607 \rightarrow Tyr change in UL97 phospho-
transferase, 444
EBV TK, 2923
flow cytometry, 2326
HSV-1 TK, 2923
mycophenolate mofetil
potentiation of antiherpesvirus activity,
216
- Gardnerella vaginalis*
susceptibility testing
continuous-culture biofilm system, 1428
- Gatifloxacin
anaerobes, 2459
E. coli DNA gyrase, 2678
HeLa topoisomerase II, 2678
pharmacodynamics, 2650
S. aureus, 1917
S. aureus topoisomerase IV, 2678
S. pneumoniae, 2650
- G-CSF
A. fumigatus, 2299, 2467
cefoperazone, 2178
voriconazole, 907, 2299
- Genital warts
imiquimod
efficacy and safety in infected patients,
789
- Gentamicin
combinations with quinolones, 2002
delivery into mammalian cells
S. flexneri membrane vesicles, 1476
E. faecalis, 2889
Enterococcus resistance, high level
aph(2'')-Id, 1229
L. monocytogenes, 2511
liposomes, 2511
pharmacokinetics
initial concentration-time profile deter-
mines efficacy against *E. cloacae*,
1370
S. maltophilia, 2002
S. typhimurium, 2511
- Giardia lamblia*
zinc-finger-active drugs
efficacies of, 1488
- gimA*
glycosyl transferase inactivation, 2612
S. amblofaciens, 2612
spiramycin, 2612
- Glucose metabolism
Caco-2/TC-7 cells, 2950
ofloxacin, 2950
S. typhimurium, 2950
- Glutamine metabolism
Caco-2/TC-7 cells, 2950
ofloxacin, 2950
- S. typhimurium*, 2950
- Glutathione prodrugs
 γ -glutamylcysteine ethyl ester
human immunodeficiency virus, inhibi-
tion of production and propaga-
tion, 1200
- Glycopeptides
E. faecalis
activities and time-kill studies, 857
E. faecium resistance
transferable, plasmid mediated, VanB
type, 963
enterococcal resistance
VanA, diversity of, human and nonhu-
man sources, 502
enterococci, 2215
staphylococci, coagulase negative, methi-
cillin resistant
decreased susceptibilities to teicoplanin
and vancomycin, 100
vancomycin, 2215
- Glycosyl transferase
S. amblofaciens gimA, 2612
spiramycin, 2612
- GM-CSF
A. fumigatus, 2299
voriconazole, 907, 2299
- Golgi
megalomycin, 2668
- Gonorrhea
pazufloxacin, reduced clinical efficacy
against
high prevalence of quinolone-resistant
isolates with GyrA mutation, 579
- Gram-negative
clinafloxacin
comparative evaluation, 1269
- Gram-negative organisms
furanonaphthoquinone analogs
antimicrobial activities, 700
- Gram-positive
clinafloxacin
comparative evaluation, 1269
- Gram-positive bacteria
tetracycline resistance
16S rRNA mutation, association with,
1702
- Gram-positive organisms
furanonaphthoquinone analogs
antimicrobial activities, 700
HMR 3647 (RU 66647)
in vitro activity, comparative evaluation,
1028
- Grepafloxacin
antipneumococcal activity
comparative evaluation by time-kill
methodology, 1263
chronic bronchitis, acute bacterial exacer-
bations of
ciprofloxacin, comparative evaluation,
114
efficacy and safety, 114
- grlA*
coumarins, 2109
quinolones, 2109
S. aureus, 236, 1249, 1306, 2109
- grlB*
S. aureus
characterization of mutations and effect
on ciprofloxacin MIC, 1249
- GS 4071
GS 4104 prodrug
influenza virus, protection against infec-
tion in mice and ferrets, 640
oral bioavailability, 647
influenza virus neuraminidase, 3234
- GS 4104
influenza virus
protection against infection in mice and
ferrets, 640
oral bioavailability
comparison with that of GS 4116, 647
- gyrA*
Enterobacteriaceae, 2661
S. aureus
characterization of mutations and effect
on ciprofloxacin MIC, 1249
mutations in, detection in 344 strains,
236
S. pneumoniae, 2193
sparfloxacin, 2193
- Gyrase
B. bacilliformis gyrB, 2906
C. trachomatis, 2474
clinafloxacin, 2810
coumermycin A₁, 2906
E. coli, 2678
gatifloxacin, 2678
letter to the editor, 3051
M. hominis, 2304
mycobacteria, 2084
Mycobacterium sp. *gyrA*, 2978
QRDR, 2474
quinolone resistance, 2084
S. flexneri, 3051
S. pneumoniae, 2810
- gyrB*
S. aureus
characterization of mutations and effect
on ciprofloxacin MIC, 1249
- H2G
herpesvirus, 3285
mycophenolate mofetil, 3285
- Haemophilus*
fluoroquinolones, 2956
- Haemophilus ducreyi*
protegrin, 2690
- Haemophilus influenzae*
amoxicillin-clavulanate, 3193
antimicrobial susceptibility
isolates from respiratory tracts of pa-
tients with cystic fibrosis, 319
azithromycin, 2385, 3193
 β -lactamase production, 3313
clarithromycin, 2385, 3193
dirithromycin
effect on infection of the respiratory
mucosa, 772
erythromycin, 3193
HMR 3647, 2138, 3032
macrolide susceptibility, 3313
- HeLa cells
gatifloxacin, 2678
topoisomerase II, 2678
- Helicobacter pylori*
23S RNA, 1952
amoxicillin, 2492
clarithromycin, 2749
infection in gnotobiotic piglets
antimicrobial therapies, 1549
model for the identification of novel
antimicrobials for treatment, 1549
metronidazole, 2836
metronidazole resistance
effect on bacterial eradication in in-

- infected children, 1334
 miconazole
 letter to the editor, 725
 morphological effects of, 725
 MLS resistance, 1952
 nitazoxanide, 2836
 rebamipide, 1889
 resistance to amoxicillin, clarithromycin,
 and metronidazole
 risk of development, 1222
 Hemofiltration
 meropenem, 2417, 2421
 Hemoglobin degradation
 4-aminoquinolines, 2973
 P. falciparum, 2973
 phenanthrene methanols, 2973
 quinoline methanols, 2973
 Hepatitis
 3TC, 2804
 woodchucks, 2804
 Hepatitis B virus
 3TC, 3179
 AT-61, 3179
 BMS-200475, 3209
 duck
 2'-fluoro-5-methyl- β -L-arabinofuranosyluracil, 369
 2'-fluoro-5-methyl- β -L-arabinofuranosyluracil
 inhibition of replication, 369
 L(-)-Fd4C
 antiviral activity, comparative evaluation, 1805
 PMEA, 3130
 woodchucks, 3209
 Hepatitis viruses
 BMS-200475, 3200, 3209
 lobucavir, 3200
 Hepatitis B virus
 3TC, 2128
 M539V, 2128
 penciclovir, 2132
 Herpes simplex virus
 A-5021, 2095
 acyclovir resistance
 northwest England, survey of, 868
 cidofovir, 2996
 Herpes simplex virus type 1
 acyclovir resistant
 BILD 1633, antiviral activity of, 1629
 latency, prevention of
 famciclovir and valaciclovir, quantitative comparison, 1555
 prevention of latency, quantitative comparison, 1555
 Herpesvirus
 A-5021
 antiviral activity in cell culture, comparative evaluation, 1666
 H2G, 3285
 mycophenolate mofetil, 3285
 potentiation of activity of acyclovir, ganciclovir, and penciclovir, 216
 Hexadecylphosphocholine
 L. infantum infection in mice
 short- and long-term efficacy, 654
hipA
 E. coli, 3282
Histoplasma capsulatum
 MK-991 (L-743,872)
 treatment of, 151
 nikkomycin Z, 2371
 Histoplasmosis
 MK-991 (L-743,872)
 treatment of, 151
 HIV
 141W94, 2153
 1592U/89, 2153
 3TC, 2989
 ABT-378, 3218
 AY 9944, 2482
 bioavailability of stavudine, 2295
 C. albicans, 2923
 children, 3187
 clindamycin, 3014
 DABO derivatives, 3225
 detection of resistance to protease and reverse transcriptase inhibitors
 rapid method for, 269
 dicalcylolquinic and dicalcyltartaric acids
 selective inhibition of integrase, 140
 E. coli screen, 3256
 foscarnet, 3038
 γ -glutamylcysteine ethyl ester
 inhibition of production and propagation, 1200
 indinavir, 3157, 3256
 integrase inhibitors, 2245
 ISIS 5320, 2113
 L(-)-Fd4C
 antiviral activity in combination with β -D(+) nucleoside analogs, 1799
 lamivudine, 3187
 lamivudine triphosphate, 2656
 loviride, 3123
 MDR1, 3157
 minireview, 2775
 MRP1, 3157
 nelfinavir, 2637, 3157
 nuclear importation inhibitors
 CNI-H0294, inhibition of virus replication in infected peripheral blood mononuclear cells, 1133
 PBM, 2989
 PMPA, 612, 1484, 2380
 protease, 3157, 3218, 3256
 protease inhibitors, 478, 2775
 reverse transcriptase, 447, 618, 3038, 3123, 3225
 rifabutin, 2017
 ritonavir, 3157, 3218
 saquinavir, 3157
 S-1153, 1340
 temacrazine
 selective inhibition of replication, 487
 1,1,3-trioxo-2H,4H-thieno[3,4-c][1,2,4]thiadiazine derivatives
 in vitro activity, 618
 TXU (anti-CD7)-pokeweed antiviral protein
 potent inhibition, comparative evaluation, 383
 variants from AIDS patients after prolonged adefovir dipivoxil therapy
 genotypic and phenotypic characterization, 1620
 zidovudine, 2656, 3038
 HMR 3004
 aerobic and anaerobic human and animal bite pathogens
 comparative evaluation, especially macrolides, 1127
 B. pertussis and *B. paraptussis*
 in vitro activity, comparative evaluation, 965
S. pneumoniae
 German isolates, activity against, 1509
 streptococci inducibly resistant to erythromycin
 activity against, 1392
 HMR 3647
 aerobic and anaerobic human and animal bite pathogens
 comparative evaluation, especially macrolides, 1127
 aerobic and facultative non-spore-forming gram-positive bacilli
 in vitro activity, comparative evaluation, 1028
 B. pertussis and *B. paraptussis*
 in vitro activity, comparative evaluation, 965
 C. pneumoniae
 activity in vitro, 1515
 H. influenzae, 2138, 3032
 Legionella spp.
 activity in vitro, 1520
 M. catarrhalis, 3032
 polymorphonuclear neutrophils, 1944
 pneumococci, penicillin and erythromycin susceptible and resistant
 comparative activity, 624
 S. pneumoniae
 German isolates, activity against, 1509
 quinupristin-dalfopristin, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 HMR3647
 coryneform bacteria, 3290
 Enterococcus, 3279
 Homophthalimides
 human rhinovirus
 2A and 3C proteases, dual inhibition of, 916
 HSR-903
 respiratory pathogens
 in vivo activity, 785
 Human papillomavirus
 imiquimod
 efficacy and safety in patients with external genital warts, 789
 Human rhinovirus
 homophthalimides
 2A and 3C proteases, dual inhibition of, 916
 Hydatid disease
 oxfendazole
 naturally infected animals, treatment of, 601
 Hydrocephalus
 meropenem, 2012
 Hydroxamate
 P. falciparum, 2456
 (S)-9-(3-Hydroxy-2-phosphorylmethoxypropyl)adenine [(S)-HPMPA]
 pharmacokinetics
 disposition in liver, 1146
 Hydroxynaphthoquinones
 T. gondii, 2284
 Imidazoles
 NND-502
 Trychophyton spp., in vitro and in vivo activities, comparative evaluation, 967
 S-1153
 human immunodeficiency virus, inhibi-

- tion of replication of drug-resistant strains, 1340
- Imipenem**
 amikacin, 3304
E. cloacae, 3304
 lipopolysaccharide release, antibiotic induced
S. typhi, delay between killing and release, 739
S. pneumoniae, penicillin resistant meropenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
S. typhi
 lipopolysaccharide release, antibiotic induced, delay between killing and release, 739
 versus L-749,345, 2365
- Imipenem-cilastatin**
 versus piperacillin-tazobactam, 2966
- Imiquimod**
 genital warts, external
 efficacy and safety in infected patients, 789
 human papillomavirus
 efficacy and safety in patients with external genital warts, 789
- Implants**
 orthopedic, 3086
Staphylococcus, 3086
- In40**
E. aerogenes In40, 2557
- Indinavir**
 CD4 lymphocyte count and viral load changes
 mathematical modeling of interrelationship, 358
 HIV, 3157
 HIV protease, 3256
 interaction with ritonavir, 2784
 MDR1, 3157
 MRP1, 3157
 pharmacokinetics
 fluconazole, effect on, human immunodeficiency virus-infected patients, 223
 single dose, effect of food, 332
- Indolicin**, 3320
- Indomethacin**
 zidovudine azido-reductase activation by, 1654
- Influenza A virus**
 neuraminidase inhibitor BCX-140 resistant
 generation and characterization of mutant, 801
- Influenza virus**
 GS 4071, 3234
 GS 4104
 protection against infection in mice and ferrets, 640
 neuraminidase, 3234
 neuraminidase inhibitors
 GS 4104, protection against infection in mice and ferrets, 640
- Integrase inhibitors**
 HIV, 2245
- Integrins**
S. enterica, 3053
- Interleukin-2**
 ciprofloxacin, 1923
- Interleukin-10**
P. aeruginosa, 2853
- Interleukin-12**
 benzimidazole, 2549
T. cruzi, 2549
- Intracellular delivery**
 gentamicin
 delivery into mammalian cells by *S. flexneri* membrane vesicles, 1476
- IS/8**
Acinetobacter sp. 13, 2759
- Isepamicin**
E. coli
 postantibiotic and sub-MIC effects, 414
S. aureus
 postantibiotic and sub-MIC effects, 414
- ISIS 5320**
 HIV, 2113
- Isometamidium**
 trypanosomiasis in cattle
 sustained-release device, prophylactic effect, 1012
- Isoniazid**
 combination with rifalazil, 3047
 combination with rifapentine, 3047
M. avium
 activity in beige mice, 712
 amikacin and/or clarithromycin, activity in beige mice, 712
M. tuberculosis, 3047
M. tuberculosis katG, 2443
 mycobacteria
 intracellular activation, role of superoxide, 709
- Itraconazole**
Aspergillus, 3018
Aspergillus spp., 2726
B. dermatitidis
 susceptibilities of clinical and laboratory isolates, 978
 blood-brain barrier, transport across
 P glycoprotein, mediation by, 1738
C. neoformans, fluconazole susceptible and resistant
 comparative efficacy, itraconazole, 471
Candida, 3018
Paccilomyces spp.
 antifungal susceptibilities, 1601
 pharmacokinetics
 blood-brain barrier, transport across, mediation by P glycoprotein, 1738
 enhanced bioavailability in hydroxypropyl- β -cyclodextrin solution, 1858
 repeated dose, infants and children, 404
 versus amphotericin B, 3018
 versus LY303,366, 2726
 versus voriconazole, 3018
- Ivermectin**
 letter to the editor, 2770
 toxocarasis, 2770
- Kanamycin**
M. tuberculosis resistance
 mechanism of, 1295
- katG**
 isoniazid, 2443
M. tuberculosis, 2443
 rifampin, 2443
- Keto-C-glycosides**
 non-small-cell lung cancer cells
 antiproliferative and apoptotic activities, 779
- Ketoconazole**
B. dermatitidis
 susceptibilities of clinical and laboratory isolates, 978
- NADPH cytochrome P-450 oxidoreductase**
 effect on susceptibility, 1756
- Paccilomyces** spp.
 antifungal susceptibilities, 1601
- Ketolides**
 aerobic and facultative non-spore-forming gram-positive bacilli
 in vitro activity, comparative evaluation, 1028
- HMR 3004, 3309**
HMR 3004 (RU 64004)
 aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
B. pertussis and *B. parapertussis*, in vitro activity, comparative evaluation, 965
S. pneumoniae, activity against, 1509
 streptococci inducibly resistant to erythromycin, activity against, 1392
- HMR 3647, 1944, 2138**
HMR 3647 (RU 66647)
 aerobic and anaerobic human and animal bite pathogens, comparative evaluation, 1127
B. pertussis and *B. parapertussis*, in vitro activity, comparative evaluation, 965
C. pneumoniae, in vitro activity, 1515
 gram-positive organisms, comparative evaluation, 1028
 pneumococci, penicillin and erythromycin susceptible and resistant, 624
S. pneumoniae, activity against, 1509
- HMR3647, 3279**
 pneumococci, penicillin and erythromycin susceptible and resistant
 HMR 3647 (RU 66647), 624
- Ketonucleosides**
 non-small-cell lung cancer cells
 antiproliferative and apoptotic activities, 779
- Klebsiella oxytoca**
 β -lactamase
 AmpC type, plasmid mediated, characterization of, 464
 OXY-2, 2184
- Klebsiella pneumoniae**
 antimicrobial resistance
 outer membrane protein profiles, association with, 1636
 β -lactamase
 association with decreased susceptibility to moxalactam, 108
 novel, extended spectrum, TEM type, 108
 resistance to expanded-spectrum cephalosporins, 1350
 TEM-43, biochemical and genetic properties, 1671
 ceftazidime, 3079
 cephalosporins, expanded spectrum, resistance to
 β -lactamase, characterization of, 1350
 extended-spectrum β -lactamase producing outbreak of, epidemiology and successful control, 53
 fluoroquinolones
 energy-dependent accumulation in quinolone-resistant strains, 1850
 outer membrane protein profiles

- antimicrobial resistance, association with, 1636
 SHV-5 β -lactamase, 3079
 TEM-47 β -lactamase, 3079
- KNI-272
 pharmacokinetics
 human immunodeficiency virus-infected children after intravenous and oral dosing, 1815
 nonhuman primates after intravenous dosing, 1815
- KY-62
 candidiasis
 murine, treatment of, 147
 L. amazonensis, 2542
 L. donovani, 2542
- L-743,872
 histoplasmosis
 disseminated, murine model, treatment of, 151
- L-749,345
 versus imipenem, 2365
 versus ceftriaxone, 2365
- Lactacystin
Plasmodium spp., 2731
- Lactobacillus acidophilus*
 susceptibility testing
 continuous-culture biofilm system, 1428
- Lactoferrin
C. albicans, azole resistant
 inhibition of hyphal growth, 1587
 synergy with triazoles, 1587
- Lamivudine
 children, 3187
 HIV, 3187
 pharmacokinetics, 3187
- Lamivudine triphosphate
 HIV, 2656
 in PBMC, 2656
- Lantibiotics
 mersacidin
 peptidoglycan synthesis, inhibition by targeting lipid II, 154
- Legionella pneumophila*
A. castellanii, 2870
 ampicillin, 2870
 ciprofloxacin, 2870
 erythromycin, 2870, 3153
 imipenem, 2870
 levofloxacin, 3153
 monocytes, 3153
 rifampin, 3153
 U937 cells, 2870
- Legionella* spp.
 newer antimicrobial agents
 activity in vitro, 1520
- Leishmania amazonensis*
 KY62, 2542
- Leishmania donovani*
 amphotericin B, 2722
 amphotericin B resistance
 promastigotes, mechanism of, 352
 KY62, 2542
 megalomicin, 2668
 sodium stibogluconate, 2722
- Leishmania infantum*
 amphotericin B, 2141
 hexadecylphosphocholine
 established infection in mice, short- and long-term efficacy, 654
 pentavalent antimony, 3097
- Leishmania major*
 amphotericin B, 3092
 megalomicin, 2668
- Leishmania* spp.
 meglumine antimonate
 characterization of, 1076
- Leishmania tarentolae*
 sodium stibogluconate resistant
 gene amplification, 1689
- Leishmania viannia panmensis*
 pentavalent antimony, 1990
- Leishmaniasis
 hexadecylphosphocholine
 established infection in mice, short- and long-term efficacy, 654
 liposomal delivery system, peptide grafted macrophages, targeting to, 348
- Leprosy
 ofloxacin-minocycline, with or without rifampin
 bactericidal activity in mice and lepromatous patients, 1115
- Letters to the Editor
 aminoglycoside-modifying enzymes
 nomenclature of genes encoding, 483
 avoparcin, 3333
B. paraptussis
 BAY 12-8039, trovafloxacin, and ciprofloxacin, susceptibilities to, 1868
B. pertussis
 BAY 12-8039, trovafloxacin, and ciprofloxacin, susceptibilities to, 1868
 beta-defensins, 3328
 biocide resistance, 2151
 Caz-hi β -lactamase, 3329
 cefotaxime
 S. pneumoniae, activity against, 1869
 ceftizoxime
 S. pneumoniae, activity against, 1869
E. faecium
 satB, 3331
 vgb, 3331
Enterococcus, 3333
 erythromycin
 inhibitory effect on superoxide anion production by human neutrophils, 1866
 glycopeptide usage
 Europe, 3049
 U.S., 3049
H. pylori
 miconazole, morphological effects of, 725
 ivermectin, 2770
M. leprae, 3334
 miconazole
 H. pylori, morphological effects on, 725
 pharmacokinetics
 azithromycin and clarithromycin, bronchopulmonary, 481
S. aureus, fluoroquinolone and methicillin resistant
 selection with ciprofloxacin and trovafloxacin, 727
S. aureus, mupirocin resistant
 isolates from different geographic areas, characterization of, 1305
S. aureus, quinolone resistant
 gla mutations, analysis of, 1306
S. pneumoniae
 ceftizoxime and cefotaxime, activities against, 1869
 synergistic activity of trovafloxacin and ceftriaxone or vancomycin, 991
- S. pyogenes*, erythromycin resistant, clindamycin susceptible
 emergence in Madrid, letter to the editor, 989
- S. rimosus* OtrB, 3050
- TEM-41, 2771
- toxocariasis, 2770
- V. cholerae* fluoroquinolone resistance
 patients with acute diarrhea in Calcutta, India, 206
- vancomycin
 historical yearly usage, 1303
 vancomycin resistance, 3049
 vancomycin-resistant *E. faecium*, 2150
 vancomycin-resistant enterococci, 2463
- Leukemia
 amphotericin B nephrotoxicity, 3103
- Levofloxacin
 anaerobes from skin and soft tissue infections
 in vitro activities, 984
 combination with gentamicin, 2002
 combinations with cephalosporins, 2002
L. pneumophila, 3153
P. aeruginosa
 determination of activities by checkerboard and time-kill methodology, 953
 synergy, 953
P. aeruginosa, biofilm producing
 in vitro and in vivo activities, 1641
 pharmacokinetics
 double-blind evaluation in healthy volunteers, 885
 population pharmacokinetics and demographic model for prediction of individual drug clearance, 1098
 pneumococci
 postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
 postantibiotic effect and postantibiotic sub-MIC effect
 pneumococci, comparative evaluation, 1253
S. maltophilia, 2002
 safety
 double-blind evaluation in healthy volunteers, 885
- L-FMAU
 duck hepatitis B virus
 inhibition of replication, 369
- Linezolid
E. coli, 3251
 inhibition of protein synthesis, 3251
S. aureus, 3251
S. aureus, coagulase-negative staphylococci, *E. faecalis*, and *E. faecium*
 comparative activity and postantibiotic effect, 721
- Lipid A
 E5531, 2824
- Lipopolysaccharides
 CAP18, 3269
P. aeruginosa, 3269
- Lipoproteins
 nystatin, 1878
- Liposomal agents
 pharmacokinetics
 blood clearance capacity of the mononuclear phagocyte system, 1677

- Liposomes
gentamicin, 2511
- Lipoteichoic acid
S. aureus, 3073
- Listeria monocytogenes*
gentamicin, 2511
- LL-37
antimicrobial activities, 2206
- Lobucavir
hepadnaviruses, 3200
triphosphate form, 3200
- Lomefloxacin
photosensitivity, 3141
- Loratadine
electrocardiographic pharmacodynamics
after individual or concomitant administration with clarithromycin, 1176
pharmacokinetics, steady state
after individual or concomitant administration with clarithromycin, 1176
- Loviride
HIV reverse transcriptase, 3123
- Luciferase
S. mutans, 1906
- Lumefantrine
P. falciparum, 2347
- LY303366
A. fumigatus, 2898
A. fumigatus, amphotericin B susceptible and resistant
efficacy in murine model of invasive aspergillosis, 873
Aspergillus spp., 2726
Candida, 2446
pharmacokinetics, 2898
photoaffinity analog
C. albicans, identification of targets in, 1187
susceptibility testing
endpoints, evaluation of, 1387
versus amphotericin B, 2726
versus itraconazole, 2726
- LY333328
combination with ampicillin, 2564
E. faecium, 2564
multidrug resistance, 2452
postantibiotic effects, 2564
S. aureus, 2427
S. aureus, methicillin resistant
experimental endocarditis, efficacy against, 981
vancomycin resistance, 2564
versus teicoplanin, 2452
versus vancomycin, 2452
- Lysostaphin
S. aureus, methicillin resistant
aortic valve endocarditis, treatment of, 1335
- M13
BLIP, 2893
- Macrolides
coryneform bacteria, 3290
M. avium resistance
emergence during experimental chemotherapy, 180
pneumococci
postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
postantibiotic effect and postantibiotic sub-MIC effect
pneumococci, comparative evaluation, 1253
- Macrophages
liposomal delivery system, peptide grafted, 348
- Magainin, 3320
- Magainins
analogs
MSI-78, in vitro antimicrobial activity, 1213
- Malaria
ferrocene-chloroquine
in vitro activity, 540
P. falciparum, multidrug resistant
artesunate-mefloquine versus artemether-benflumetol, 135
P. falciparum, sulfadoxine-pyrimethamine resistant
molecular basis for, 1811
WR 238605
prophylaxis in a human challenge model, 1293
- Mannich agents
disposition, 2410
malaria, 2410
pharmacology, 2410
toxicology, 2410
- marA*
E. coli, 2089
fluoroquinolone resistance, 2089
- Marvelon
ciprofloxacin, 3266
- Mathematical modeling
indinavir
CD4 lymphocyte count and viral load changes, 358
- MDR1
HIV, 3157
indinavir, 3157
nelfinavir, 3157
ritonavir, 3157
saquinavir, 3157
- mec*
S. aureus, introduction in
alteration of in vitro functional activities of fibrinogen and fibronectin adhesins, 564
- mecA*
coagulase-negative staphylococci
mecA and *gvrA*, chromosomal relationship, 306
S. aureus and *S. epidermidis*, methicillin resistant
diversity of mutations, analysis of, 717
- mecI*
S. aureus and *S. epidermidis*, methicillin resistant
diversity of mutations, analysis of, 717
- Megalomicin
Leishmania, 2668
Trypanosoma, 2668
- Meglumine antimunate
characterization of, 1076
- Membrane-active peptides
cercopin P1, 3320
indolicin, 3320
magainin, 3320
ranalexin, 3320
- Meningitis
amphotericin B
alone and with flucytosine with or without fluconazole, 528
cryptococcal
amphotericin B, alone and with flucytosine with or without fluconazole, 528
- pneumococci, penicillin resistant
moxifloxacin, activity against, 1706
- S. pneumoniae*
moxifloxacin, activity, 1397
- S. pneumoniae*, penicillin resistant
meropenem, imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
- Meropenem
bacterial infections in elderly patients
cefuroxime-gentamicin, comparative evaluation, 1233
hydrocephalus, 2012
pharmacokinetics, 2417, 2421
hemofiltration, 2417, 2421
S. pneumoniae, penicillin resistant
imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
ventriculostomy, 2012
- Mersacidin
peptidoglycan synthesis
inhibition by targeting lipid II, 154
- Methadone
3'-azido-3'-deoxythymidine
glucuronidation by human liver microsomes, inhibition by, 1592
pharmacokinetics
zidovudine, glucuronidation by human liver microsomes, inhibition by, 1592
- Methicillin
coagulase negative staphylococci, resistance
mecA and *gvrA*, chromosomal relationship, 306
postantibiotic effect
S. aureus, flow cytometric assessment of, 1195
S. aureus, 2817
S. aureus resistance
introduction of *mec* alters in vitro functional activities of fibrinogen and fibronectin adhesins, 564
letter to the editor, 727
mecA and *mecI*, diversity of mutations, analysis of, 717
selection with ciprofloxacin and trovafloxacin, 727
S. epidermidis resistance
mecA and *mecI*, diversity of mutations, analysis of, 717
- 8-Methoxyquinolones
BAY 12-8039
C. pneumoniae, in vitro activity, 951
moxifloxacin
meningitis due to penicillin-resistant pneumococci, efficacy against, 1706
- Metronidazole
H. pylori resistance
effect on bacterial eradication in infected children, 1334
risk of development, 1222
- Miconazole
H. pylori
letter to the editor, 725
morphological effects of, 725
Pacilomyces spp.
antifungal susceptibilities, 1601
- Micrococci
P. falciparum

- potent inhibition of growth and protein synthesis, 715
- Microdialysis
rifampin in brain, 2626
- Microspheres
rifampin, 2682
- Microsporidia
albendazole, 3301
- Minireviews
 β -lactamases
 kinship and diversification, 1
HIV, 2775
P. carinii
 pneumonia, treatment of, 1309
 prevention of infection, 995
penicillin-binding proteins
 kinship and diversification, 1
protease inhibitors, 2775
Tn916, 1871
two-component signal transduction
 target for microbial anti-infective therapy, 1529
- Minocycline
letter to the editor, 3334
M. leprae, 3334
 combination with ofloxacin, with or without rifampin, 1115
ofloxacin, with or without rifampin
 bactericidal activity in mice and lepromatous patients, 1115
- V. vulnificus*
alone or in combination with cefotaxime, 1319
experimental murine infection, treatment of, 1319
- MK-826
S. aureus, 1996
- MK-991
histoplasmosis
 disseminated, murine model, treatment of, 151
P. carinii, 1985
- MLS resistance
H. pylori 23S RNA, 1952
S. pneumoniae, 2312, 2425
- Monoclonal antibodies
C. neoformans capsular polysaccharide
 candidate for human therapeutic studies, 1437
- Monocytes
A. fumigatus, 2299
 combination with voriconazole, 2299
novobiocin, 1911
- Monoglycerides
C. trachomatis, 2290
- Moraxella catarrhalis*
 β -lactamase BRO-1, 2521
biofilms, 2521
HMR 3647, 3032
interaction with *S. pneumoniae*, 2521
- Morganella morganii*
ampR, 2352
S. enteritidis DHA-1, 2352
TEM-21, 2125
- Moxalactam
K. pneumoniae, decreased susceptibility
 novel, extended-spectrum, TEM-type
 β -lactamase, 108
- Moxifloxacin
M. tuberculosis, 2066
meningitis
 penicillin-resistant pneumococcus, activity against, 1706
 pharmacokinetics, 2060
 coadministration of dexamethasone,
 effect on penetration into cerebrospinal fluid, 1397
pneumococci, penicillin resistant
 activity against, 1706
S. pneumoniae meningitis
 activity against, 1397
- MRP1
HIV, 3157
indinavir, 3157
nelfinavir, 3157
ritonavir, 3157
saquinavir, 3157
- MSI-78
in vitro antimicrobial activity
 comparative evaluation, 1213
- Multidrug efflux pumps
P. aeruginosa
 β -lactamase inhibitors, substrates for, 399
 expression in multidrug-sensitive *E. coli* strain, 65
 resistance to fatty acid biosynthesis inhibitors, novel technique for study, 395
S. aureus QacA
 comparative analysis of resistance to diamidines, biguanidines, and guanthyldrazones, 475
V. parahaemolyticus NorM
 cloning and sequencing, 1778
- Mupirocin
S. aureus resistance
 characterization of isolates from different geographic areas, letter to the editor, 1305
- Murine gamma herpesvirus 68
in vitro and in vivo susceptibilities, 170
- Mycobacteria
fluoroquinolones, 2978
gyrA, 2978
gyrB, 2084
quinolone resistance, 2084
- Mycobacterium aurum*
norfloxacin
 accumulation in, 795
- Mycobacterium avium*
amikacin, 3006
amikacin, liposome encapsulated
 prolonged-interval treatment, rationale for and efficacy of, 459
clarithromycin, 3006
clofazimine, 3006
isoniazid
 activity in beige mice, 712
 amikacin and/or clarithromycin, activity in beige mice, 712
macrolide resistance
 emergence during experimental chemotherapy, 180
rifampin, 3006
TNF- α , 2336
triple infection with *T. gondii* and *P. carinii* in rat model
 drug evaluation, 1068
- Mycobacterium avium* complex
diaminomethylpyridopyrimidines, 3315
dihydrofolate reductase, 3315
postantibiotic effect
 CO₂ generation versus viable-count method for determination, 184
- Mycobacterium leprae*
letter to the editor, 3334
minocycline, 3334
ofloxacin, 3334
ofloxacin-minocycline, with or without rifampin
 bactericidal activity in mice and lepromatous patients, 1115
rifampin, 3334
- Mycobacterium smegmatis*
norfloxacin
 accumulation in, 795
tet(V), 1931
- Mycobacterium* spp.
5-chloropyrazinamide
 in vitro activity, 462
isoniazid action
 catalase-peroxidase mediated, role of superoxide, 709
- Mycobacterium tuberculosis*
ABT-255, 2674
amikacin and kanamycin resistance
 mechanism of, 1295
 β -lactamases
 β -lactam susceptibilities, contribution to, 1524
 recombinant expression and characterization of, 1375
- BM212, 3035
clinafloxacin, 2066
isoniazid, 2443, 3047
katG, 2443
macrophages, 2682
moxifloxacin, 2066
rifalazil, 3047
rifampin, 2443, 2682
rifamycin resistance
 rpoB mutations, contribution to, 1853
rifapentine, 3047
screening of antimycobacterial compounds
 fluorescent protein reporter microplate assay, 344
- Mycobacterium ulcerans*
clarithromycin, 2070
- Mycophenolate mofetil
antiherpesvirus activity of acyclovir, ganciclovir, and penciclovir
 potentiation of, 216
H2G, 3285
herpesvirus, 3285
- Mycoplasma hominis*
DNA gyrase, 2304
ofloxacin, 2304
sparfloxacin, 2304
topoisomerase IV, 2024, 2304
- Mycoplasma pneumoniae*
quinupristin-dalfopristin
 comparative in vitro activity, 698
RPR 106972
 comparative in vitro activity, 698
- Mycoplasma* spp.
BAY 12-8039
 in vitro activities, 703
- Nalidixic acid
C. jejuni, 2106
- Neisseria gonorrhoeae*
 β -lactams, 2799
ciprofloxacin, 2103, 2919
parC, 2103
pazufloxacin, reduced clinical efficacy against
 high prevalence of quinolone-resistant

- isolates with GyrA mutation, 579
penB porin, 2799
 tetracycline, 2799
- Nelfinavir
 HIV, 2637, 3157
 MDR1, 3157
 MRP1, 3157
- Neuraminidase inhibitors
 influenza A virus resistance
 generation and characterization of resistant mutant, 801
- Neuraminidases
 GS 4071, 3234
 influenza virus, 3234
- Neuropeptide Y
C. albicans, 2745
- Neutropenia
 amphotericin B, 2391
 BMS 181184, 2399
- Neutrophils
A. fumigatus, 2299
 combination with voriconazole, 2299
 LL-37, 2206
- NF- κ B
 ciprofloxacin, 1923
- Nikkomycin Z
H. capsulatum, 2371
- Nitazoxanide
C. parvum, 1959, 2877
H. pylori, 2836
- Nitric oxide
Candida, 2342
 synergy with azoles, 2342
- Nitrofurantoin
Clostridium resistance
 nitroreductase-producing strains, isolation from human intestinal tract, 1121
- NND-502
Trychophyton spp.
 in vitro and in vivo activities, comparative evaluation, 967
- Non-small-cell lung cancer cells
 keto-C-glycosides
 antiproliferative and apoptotic activities, 779
 ketonucleosides
 antiproliferative and apoptotic activities, 779
- NorA
S. aureus, 3317
- Norfloracin
B. fragilis, 2119
 efflux, 2119
 epileptogenic potential, 2756
M. aurum
 accumulation in, 795
M. smegmatis
 accumulation in, 795
V. parahaemolyticus resistance
 NorM multidrug efflux protein, cloning and sequencing, 1778
- Novobiocin
 monocyte functions, 1911
- Nucleoside analogs
E. coli, 2620
- 1-Nucleoside analogs
 unique metabolism, substrate for both thymidine kinase and deoxycytidine kinase, 833
- Nystatin
 free and liposome encapsulated
 four amphotericin B formulations, comparative evaluation, 1412
 high-density lipoproteins, 1878
- Ofloxacin
 Caco-2/TC-7 cells, 2950
 glucose metabolism, 2950
 glutamine metabolism, 2950
 letter to the editor, 3334
M. hominis, 2304
M. leprae, 3334
 combination with minocycline, with or without rifampin, 1115
 minocycline, with or without rifampin
 bactericidal activity in mice and lepromatous patients, 1115
 osteomyelitis
 prophylaxis with absorbable, ofloxacin-impregnated beads, 840
 pharmacokinetics
 disposition in human head, axillary, and pubic hairs, 1298
 probenecid and cimetidine, effects on renal disposition in rats, 456
S. typhimurium, 2950
 urinary tract infection, 2262
- OPC-20011
E. faecalis, 2943
S. aureus, 2943
S. pneumoniae, 2943
- oprM*
P. aeruginosa antibiotic resistance
 contribution to independent of MexAB, 1682
- Orthopedic implants
 susceptibilities of isolates, 3002
- Osteomyelitis
 ofloxacin-impregnated beads, absorbable prophylaxis with, 840
- Otitis media
 acute
 antimicrobial-resistant pathogens in middle ear fluid, prevalence of, 589
S. pneumoniae, penicillin resistant
 amoxicillin versus cefuroxime, 1361
- OXA-16
P. aeruginosa, 3117
- OXA-19
P. aeruginosa, 3113
- OXA-20
P. aeruginosa, 2074
- Oxacillin
S. aureus, methicillin resistant,
 reduction of oxacillin resistance by ciba-cron blue F3GA, 1278
- Oxazolidinones
 linezolid, 3251
S. aureus resistance
 biochemical basis and mechanism of action, 947
- Oxfendazole
E. granulosus
 naturally infected animals, treatment of, 601
 hydatid disease, cystic
 naturally infected animals, treatment of, 601
- OXY-2
K. oxytoca, 2184
- Paclitaxel
T. gondii, 2032
- Paeclomyces* spp.
 antifungal susceptibilities, 1601
- Panipenem
 diclofenac, 3136
 valproic acid, 3136
- parC*
 ciprofloxacin, 2103
N. gonorrhoeae, 2103
S. pneumoniae, 2193
 sparfloxacin, 2193
- Paromomycin
C. parvum, 1959, 2877
- Pasteurella multocida*
 tetracycline, 2116
 Tn5706, 2116
- Pazufloxacin
 gonorrhea, reduced clinical efficacy
 against
 high prevalence of quinolone-resistant isolates with GyrA mutation, 579
- Pefloxacin
 bactericidal activity
 fleroxacin, comparative evaluation, 1659
 epileptogenic potential, 2756
 pharmacokinetics
 concentration in plasma and tissue after administration as surgical prophylaxis, 425
 urinary excretion in healthy volunteers, comparative evaluation, 1659
- penB*
N. gonorrhoeae, 2799
- Peniclovir
 hepatitis B virus, 2132
 mycophenolate mofetil
 potentiation of antiherpetic activity, 216
- Penicillanic acid sulfones
 PSE-4, 2319
- Penicillin
 cytokine production induced by heat-killed *S. pneumoniae*
 effect on, 1605
S. pneumoniae, high-level resistance
 penicillin-binding protein 1A, alterations in responsible for, 1329
S. pneumoniae PBP 1A, 2262
S. pyogenes
 in vitro activity of combinations with clindamycin, 1266
- Penicillin-binding proteins
 1A
 alterations in essential for high-level penicillin resistance in *S. pneumoniae*, 1329
E. hirae
 3r gene, borne on plasmid carrying other antibiotic resistance determinants, 534
- minireview
 kinship and diversification, 1
S. pneumoniae
 affinity for, 173
 alterations in PBP 1A essential for high-level penicillin resistance, 1329
- Penicillins
E. faecalis
 activities and time-kill studies, 857
- Pentamidine
C. albicans, 2495
C. neoformans, 2495
 structure-activity relationships, 2495
- Pentavalent antimony
L. infantum, 3097

- L. viannia panmensis*, 1990
- Pentoxifylline
C. albicans, 2405
 pharmacokinetics, 2405
- Peptidoglycan
S. aureus, 3073
- Peroxides
 organic, water soluble
 synthesis and antibacterial evaluation, 911
- PGG glucan, 545
Staphylococcus spp.
 prophylactic activity in a guinea pig
 model of wound infection, 545
- PGG-glucan
S. aureus, 2449
S. epidermidis, 2449
 synergism with cefazolin, 2449
- P-glycoprotein
 sparfloxacin, 2607
- Pharmacodynamics
 aminoglycosides
 dosing to obtain pharmacodynamic
 goals in patients with pneumonia,
 1892
- amphotericin B
 assessment of activity against *C. albi-*
cans by dynamic in vitro mycotic
 infection model, 1382
- ampicillin-sulbactam
 in vitro model against resistant *E. coli*,
 231
- antimicrobial pharmacodynamic indices
 and bacterial killing
 comparisons by the Zhi model, 1731
- azithromycin
 in vitro and in vivo, comparison with
 those of erythromycin, 377
S. aureus and *E. coli*, postantibiotic and
 sub-MIC effects, 414
- bacterial resistance, development in
 acutely ill patients during therapy
 factors associated with, 521
- cefepime-aztreonam
P. aeruginosa, 1610
- co-amoxiclav
S. aureus, in vitro activities at concen-
 trations achieved in human serum,
 1574
- combination therapy, prediction of effi-
 cacy
 fractional inhibitory concentration ki-
 netics, 744
- erythromycin
 in vitro and in vivo, comparison with
 those of azithromycin, 377
- fluconazole
 assessment of activity against *C. albi-*
cans by dynamic in vitro mycotic
 infection model, 1382
 murine model of systemic candidiasis,
 1105
- fractional inhibitory concentration kinetics
 combination therapy, prediction of effi-
 cacy, 744
- isepamicin
S. aureus and *E. coli*, postantibiotic and
 sub-MIC effects, 414
- 1(-)-JF4C
 comparative evaluation, 1805
- trovafloxacin
 enterococci, in vitro dynamic model of
 infection, 72
- Pharmacokinetics
 amikacin
 population pharmacokinetic study in
 febrile, severely neutropenic adults,
 849
- amphotericin B, 2391
 distribution in lung tissue after injection
 and inhalation, 1597
 unilamellar liposomal vesicle formula-
 tion, rats, 263
- ampicillin-sulbactam
 concentrations in tissues after bolus
 injections versus bolus plus contin-
 uous infusion, 1093
- antimicrobial effect, prediction of
 in vitro dynamic model, quinolones, 659
- artesunate, 2332
- atovaquone, micronized
 human immunodeficiency virus-infected
 infants and children, phase I safety,
 1315
- azithromycin, 2385
 BEA005, 2174
- biapenem
 pharmacokinetics and safety in elderly
 subjects, 1433
- bis(isopropylloxycarbonyloxymethyl)-
 PMPA
 mice, 1568
 BMS 181184, 2700
- bronchopulmonary, letter to the editor,
 481
- cefdinir
 hemodialysis patients, 1718
- cefpime
 concentrations in cerebrospinal fluid of
 children with bacterial meningitis,
 199
- ceftizoxime
 continuous infusion in clinically ill
 adults, 1783
- cephalexin
 interaction with quinapril, analysis by a
 nonlinear mixed-effect model, 1463
- ciprofloxacin, 2235, 2841
 cholera toxin, effect on intestinal elimi-
 nation in rabbits, 473
 foscarnet, neurotoxicodynamics of inter-
 action in mice, 691
 liposomal encapsulation, effect on, 45
 renal failure in rats, influence on, 289
- ciprofloxacin-fenbufen
 effects on central nervous system, as-
 sessment by electroencephalogra-
 phy, 1256
- clarithromycin, 2385
 bronchopulmonary, letter to the editor,
 481
 grapefruit juice, effect on, 927
 interactions with rifabutin in human
 immunodeficiency virus-infected
 volunteers, 631
 oral cimetidine prolongs absorption,
 1578
- clarithromycin and loratadine
 individual or concomitant administra-
 tion, 1176
- clinafloxacin
 pharmacokinetics and inflammatory
 fluid penetration, 428
- D0870
 two multiple-dosing regimens in human
 immunodeficiency virus-positive
 patients, 903
- DA-1131
 rats with uranyl nitrate-induced acute
 renal failure, 1217
- didanosine
 human immunodeficiency virus-infected
 outpatients, 821
- floxacin
 urinary excretion in healthy volunteers,
 comparative evaluation, 1659
- fluconazole
 burn patients, 930
 effect on indinavir pharmacokinetics in
 human immunodeficiency virus-
 infected patients, 223
 rabbits and humans, correlation of
 AUC and peak levels, 1512
- foscarnet
 absolute bioavailability, 293
 ciprofloxacin, neurotoxicodynamics of
 interaction in mice, 691
 human immunodeficiency virus-seropos-
 itive patients, 293
- gentamicin
 delivery into mammalian cells by *S. flex-*
neri membrane vesicles, 1476
 initial concentration-time profile deter-
 mines efficacy against *E. cloacae*,
 1370
- GS 4104
 oral bioavailability, 647
- human immunodeficiency virus-infected
 patients, 1788
- (S)-9-(3-hydroxy-2-phosphonylme-
 thoxypropyl)adenine [(S)-HPMPA]
 disposition in liver, 1146
- hydroxyitraconazole
 repeated dose, infants and children, 404
- indinavir, 2784
 fluconazole, effect on, human immuno-
 deficiency virus-infected patients,
 223
 single dose, effect of food, 332
- itraconazole
 blood-brain barrier, transport across,
 mediation by P glycoprotein, 1738
 enhanced bioavailability in hydroxypro-
 pyl- β -cyclodextrin solution, 1858
 repeated dose, infants and children, 404
- KNI-272
 human immunodeficiency virus-infected
 children after intravenous and oral
 dosing, 1815
 nonhuman primates after intravenous
 dosing, 1815
- lamivudine, 3187
- levofloxacin
 population pharmacokinetics and demo-
 graphic model for prediction of
 individual drug clearance, 1098
 safety and pharmacokinetics, double-
 blind evaluation in healthy volun-
 teers, 885
- 1(-)-JF4C
 metabolism, 1799, 1805
- liposomal agents
 blood clearance capacity of the mono-
 nuclear phagocyte system, 1677
- Mannich agents, 2410
- meropenem, 2417, 2421
- moxifloxacin, 2060
 coadministration of dexamethasone,
 effect on penetration into cerebro-

- spinal fluid, 1397
- new pasteurized human tetanus immunoglobulin
- safety and pharmacokinetic profile, 298
- ofloxacin
- disposition in human head, axillary, and pubic hairs, 1298
- probenecid and cimetidine, effects on renal disposition in rats, 456
- pefloxacacin
- concentration in plasma and tissue after administration as surgical prophylaxis, 425
- urinary excretion in healthy volunteers, comparative evaluation, 1659
- pentoxifylline, 2405
- 9-*R*-(2-phosphonomethoxypropyl)adenine (PMPA)
- pharmacokinetics and bioavailability in dogs, 687
- pleconaril, 2706
- PMPA, 2380
- population
- levofloxacin, 1098
- positron emission tomography, 2048
- quinapril
- interaction with cephalexin, analysis by a nonlinear mixed-effect model, 1463
- rifabutin, 2017
- interactions with clarithromycin in human immunodeficiency virus-infected volunteers, 631
- ritonavir, 2784, 3107
- alone and in combination with zidovudine, 1788
- human immunodeficiency virus-infected patients, 1788
- sparfloxacin
- chondrotoxicity and toxicokinetics in juvenile rats, 1470
- physicochemical properties that regulate penetration of quinolones, 1412
- serum and vitreous humor in rabbits, 1417
- sulbenicillin
- stereoselective disposition in humans, 325
- theophylline, 2359
- terbinafine, effect on in healthy volunteers, 695
- tobramycin
- MIC changes alter responses of *P. aeruginosa*, 1365
- tosufloxacin
- aluminum hydroxide and famotidine, effects on bioavailability, 453
- trovafloxacin, 2048, 2841
- zalcitabine, 2174
- application of radioimmunoassay to population pharmacokinetics, 409
- zidovudine
- alone and in combination with ritonavir, 1788
- premature infants exposed to human immunodeficiency virus, 808
- Pharyngitis
- S. pyogenes*
- cefclindir treatment, 5 day, 1073
- Phenylcarbamates
- β -tubulin, 2171
- Phospholipases
- amphotericin B lipid complex
- role in antifungal activity, 767
- 9-*R*-(2-Phosphonomethoxypropyl)adenine (PMPA)
- human immunodeficiency virus, drug resistant
- activity against, 1484
- pharmacokinetics and bioavailability
- dogs, 687
- prodrug
- human immunodeficiency virus, activity and cellular metabolism, 612
- 9-*R*-(2-Phosphonomethoxypropyl)adenine (PMPA)
- antiretroviral efficacy in mice, 1568
- pharmacokinetics in mice, 1568
- Photochemotherapy
- A. viscosus*, 2595
- P. gingivalis*, 2595
- Photosensitivity
- lomefloxacin, 3141
- Piperacillin-tazobactam
- versus imipenem-cilastatin, 2966
- Plasmodium*
- lactacystin, 2731
- Mannich agents, 2410
- Plasmodium falciparum*
- 4-aminoquinolines, 2973
- artesunate, 2332
- aspartic protease inhibition, 2254
- chlorocyclohexanil
- in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164
- cysteine inhibition, 2254
- ferrocene-chloroquine
- in vitro activity, 540
- heme polymerization, inhibition of, and drug accumulation
- drug activity, relationship between, 682
- hemoglobin degradation, 2973
- hydroxamate, 2456
- lumefantrine, 2347
- malaria, multidrug resistant
- artesunate-mefloquine versus artemether-benflumetol, 135
- megalomicin, 2668
- micrococin
- potent inhibition of growth and protein synthesis, 715
- phenanthrene methanols, 2973
- polyhydroxyphenyl, 2456
- pyrimethamine
- in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164
- quinoline methanols, 2973
- sulfadoxine-pyrimethamine resistance
- molecular basis for, 1811
- thalassemia, 2332
- WR 238605
- prophylaxis in a human challenge model, 1293
- Platelets
- S. aureus*, 3169
- Pleconaril
- effect of food, 2706
- oral solution, 2706
- pharmacokinetics, 2706
- PMEA
- hepatitis B virus, 3130
- PMPA
- HIV, 2380
- pharmacokinetics, 2380
- PMX-622
- antimicrobial activity, 2765
- combinations, 2765
- Pneumocandins
- MK-991, 1985
- MK-991 (L-743,872)
- histoplasmosis, murine model, treatment of, 151
- P. carinii*, 1985
- Pneumococci
- grefaploxacacin
- in vitro activity, comparative evaluation, 1263
- HMR 3647 (RU 66647)
- comparative activity, 624
- levofloxacin
- postantibiotic effect, comparative evaluation, 1253
- macrolides
- postantibiotic effect, comparative evaluation, 1253
- penicillin resistant
- moxifloxacin, activity against, 1706
- quinolones
- postantibiotic effect, comparative evaluation, 1253
- trovafloxacin
- postantibiotic effect, 1503
- Pneumocystis carinii*
- echinocandins
- water soluble, pneumonia in mice, 37
- MK-991, 1985
- pneumonia
- echinocandins, water soluble, 37
- sulfamethoxypyridazine, efficacy in murine model, 934
- treatment of, minireview, 1309
- prevention of infection
- minireview, 995
- sordarins, 2863
- sulfa drugs
- quantitative structure-activity relationship studies, 1454
- sulfamethoxypyridazine
- efficacy in murine model, 934
- triple infection with *T. gondii* and *M. avium* in rat model
- drug evaluation, 1068
- Pneumocystis* spp.
- aromatic diamidoxime prodrugs
- activities in rats, 666
- Pneumonia
- aminoglycosides
- dosing to obtain pharmacodynamic goals in patients with pneumonia, 1892
- C. pneumoniae*
- susceptibilities of isolates from patients with community-acquired pneumonia, 194
- cefepime
- ceftriaxone, comparative evaluation, 729
- cefpime
- ceftazidime, comparative evaluation, 28
- ceftazidime
- cefpime, comparative evaluation, 28
- ceftriaxone
- cefepime, comparative evaluation, 729
- community acquired
- cefepime versus ceftriaxone, compara-

- tive evaluation, 729
- P. carinii*
echinocandins, water soluble, 37
sulfamethoxypyridazine, efficacy in murine model, 934
treatment of, minireview, 1309
- S. pneumoniae*
CS-834, 23
penicillin susceptible and resistant, 23
S. pneumoniae, penicillin susceptible and multidrug-resistant
trovafloxacin, efficacy in mouse pneumonia model, 862
- Pneumonic plague
antibiotic treatments
comparative evaluation, 675
- Pokeweed antiviral protein
TXU anti-CD7 monoclonal antibody
human immunodeficiency virus, potent inhibition, 383
- Poland
K. pneumoniae, 3079
- Polycarboxyl
C. albicans, 2434
combination with econazole, 2434
- Polynes
SPA-S-843, 3012
- Polyhydroxyphenyl
P. falciparum, 2456
- Polymorphonuclear neutrophils
HMR 3647, 1944
- Polymyxin B
covalent conjugate with human immunoglobulin G
antidotoxin reagent, 583
PMX-622, 2765
- Population pharmacokinetics
HIV, 2017
rifabutin, 2017
- Porins
N. gonorrhoeae penB, 2799
- Porphyromonas gingivalis*
photochemotherapy, 2595
susceptibilities, 3022
- Positron emission tomography
trovafloxacin, 2048
- Postantibiotic effect
azithromycin
S. aureus and *E. coli*, 414
bacterial populations
characteristics and dynamics, determination by flow cytometry, 1005
CO₂ generation versus viable-count method for determination, 184
- E. coli*
cefotaxime and piperacillin, 78
determination with real-time metabolic monitoring, 78
- E. faecium*, 2188
- isepamicin
S. aureus and *E. coli*, 414
- levofloxacin
pneumococci, comparative evaluation, 1253
- M. avium* complex
CO₂ generation versus viable-count method for determination, 184
- macrolides
pneumococci, comparative evaluation, 1253
- methicillin
S. aureus, flow cytometric assessment of, 1195
- quinolones
pneumococci, comparative evaluation, 1253
quinupristin-dalfopristin, 2188, 3028
- tobramycin
dosing interval, relation to duration and clinical relevance, 749
- trovafloxacin
gram-positive and -negative organisms, 1503
- Povidone-iodine
Acanthamoeba, 2232
- Pradimicin
A. fumigatus, 2399
BMS 181184, 2399
- Pradimicins
BMS 181184, 2700
- Prediction of effect
ciprofloxacin, 2848
MIC based, 2848
- Prevotella intermedia*
susceptibilities, 3022
- Prevotella nigrescens*
susceptibilities, 3022
- Probenecid
pharmacokinetics
ofloxacin, effects on renal disposition in rats, 456
- Propamidine
Acanthamoeba 18S rRNA, 2144
- Prostheses
S. aureus, 2830
- Protease inhibitors
HIV, 2775
homophthalimides
human rhinovirus 2A and 3C proteases, dual inhibition of, 916
human immunodeficiency virus type 1 resistance
detection of, rapid method for, 269
estimate of frequency in unselected virus populations in vitro, 478
KNI-272
pharmacokinetics in nonhuman primates and human immunodeficiency virus-infected children, 1815
minireview, 2775
zidovudine azido-reductase inhibition by, 1654
- Proteasomes
lactacystin, 2731
Plasmodium, 2731
- Protegrin
H. ducreyi, 2690
- Proteus mirabilis*
β-lactamase
AmpC type, chromosomally encoded, 1110
resistance to expanded-spectrum cephalosporins, 1350
cephalosporins, expanded spectrum, resistance to
β-lactamase, characterization of, 1350
- Providencia stuartii*
aarE mutations
high-level aminoglycoside resistance and reduced expression of the chromosomal aminoglycoside 2'-N-acetyltransferase, 959
aminoglycoside resistance
aarE mutations, 959
ceftazidime and aztreonam resistance
β-lactamase, TEM derived, extended spectrum, 1459
- PSE-4
ceftazidime, 2576
sulbactam, 2319
tazobactam, 2319
- Pseudomonas aeruginosa*
aacC3, 3173
aminoglycosides
diffusion through extracellular polysaccharide, promotion by alginate lyase, 974
AmpC β-lactamase, 3296
ampD, 3296
biofilm producing
levofloxacin, in vitro and in vivo activities, 1641
bla_{IMP}, 2006
CAP18, 3269
cefepime-aztreonam
activity against, 1610
cysC, 3173
efflux, 2225
endotoxins released after antibiotic treatment
biological characterization, 1015
fluoroquinolones, 2956
gut-derived sepsis, 2853
interleukin-10, 2853
levofloxacin
determination of activities by checkerboard and time-kill methodology, 953
in vitro and in vivo activities against biofilm-producing isolates, 1641
synergy, 953
MexC-MexD-OprJ, 1938
multidrug efflux pumps
β-lactamase inhibitors, substrates for, 399
expression in multidrug-sensitive *E. coli* strain, 65
novel technique for study of, 395
role in resistance to fatty acid biosynthesis inhibitors, 395
nfxB mutants, 1938
oprM
antibiotic resistance, contribution to independent of MexAB, 1682
OXA-19 β-lactamase, 3113
OXA-20 β-lactamase, 2074
postantibiotic effect
physical and biochemical characteristics and dynamics, determination by flow cytometry, 1005
SPI-ARGENT II, 2440
tobramycin postantibiotic effect
dosing interval, relation to duration and clinical relevance, 749
TonB, 2225
Pylonephritis
enterococcal
trovafloxacin-rifampin, contrast with in vitro and in vivo results, 188
- Pyrimethamine
P. falciparum
in vitro activity, correlation with point mutations in the dihydrofolate reductase domain, 164
- Pyrrrole
BM12, 3035
M. tuberculosis, 3035

QRDR

- C. jejuni*, 3276
- C. trachomatis*, 2474
- Enterobacteriaceae*, 2661
- gyrA*, 2661
- gyrase, 2472
- letter to the editor, 3051
- mycobacteria, 2084
- S. epidermidis*, 3293
- S. flexneri*, 3051
- topoisomerase IV, 2474
- viridans streptococci, 2792
- Quantitative structure-activity relationship studies
 - sulfa drugs
 - inhibitors of *P. carinii*, 1454
- Quinapril
 - pharmacokinetics
 - interaction with cephalexin, analysis by a nonlinear mixed-effect model, 1463
- Quinolones
 - antimicrobial effect, prediction of
 - in vitro dynamic model, 659
 - ciprofloxacin, 1923
 - clinafloxacin
 - bacterial isolates from 10 North American centers, activity against, 1274
 - disk diffusion interpretive zone diameter criteria, 1274
 - gram-positive and gram-negative bacteria, activity against, 1269
- DU-6859a
 - theophylline metabolism, effect on, 1751
- E. faecalis* resistance
 - alterations in GyrA subunit of DNA gyrase and ParC subunit of DNA topoisomerase IV, 433
- gatifloxacin, 1917
- gestational exposure, pregnancy outcome following
 - multicenter prospective controlled study, 1336
- grlA*, 2109
- pharmacokinetics
 - physicochemical properties that regulate penetration, 1412
- pneumococci
 - postantibiotic effect and postantibiotic sub-MIC effect, comparative evaluation, 1253
 - postantibiotic effect and postantibiotic sub-MIC effect
 - pneumococci, comparative evaluation, 1253
- S. aureus*, 2109
- S. aureus* resistance
 - grlA* mutations, analysis of, letter to the editor, 1306
 - mutations in topoisomerase IV and DNA gyrase, effect on, 121
- S. marcescens* resistance
 - DNA gyrase, mutations in, 190
- sitafloxacin
 - antibacterial activities, 1284
 - type II topoisomerases, inhibitory effects on, 1284
- Y-688, 1889
- Quinupristin-dalfopristin
 - combination with doxycycline, 2710
- E. faecium*, 2188, 2710
- M. pneumoniae*

- comparative in vitro activity, 698
- postantibiotic effect, 2188, 3028
- S. pneumoniae*
 - HMR 3647, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 - release of lipoteichoic and teichoic acids as a result of exposure, 277
 - time-kill curve, 2188

- Radioimmunoassays
 - population pharmacokinetics
 - zalcitabine, 409
- Ranalexin, 3320
- Rebamipide
 - H. pylori*, 1889
- Resistance studies
 - bacteremia, bacterial pathogens from frequencies of occurrence and antimicrobial susceptibility patterns, 1762
 - SENTRY antimicrobial surveillance program, 1762
- Respiratory infections
 - H. influenzae*
 - dirithromycin, effect on infection of the respiratory mucosa, 772
 - S. pneumoniae*, penicillin resistant
 - amoxicillin-clavulanate, activity in rat model, 813
- Respiratory pathogens
 - HSR-903
 - in vivo activity, 785
- Reverse transcriptase inhibitors
 - human immunodeficiency virus resistance
 - detection of, rapid method for, 269
 - S-1153, inhibition of replication, 1340
 - 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine derivatives
 - anti-human immunodeficiency virus activity, 618
- Ribonucleotide reductase inhibitors
 - herpes simplex virus, acyclovir resistant
 - BILD 1633, activity of, 1629
- Rickettsia* spp.
 - in vitro susceptibilities
 - 13 antimicrobial agents, 1537
- Rickettsia typhi*
 - rifampin resistant
 - rpoB*, point mutations in, 1845
- Rifabutin
 - Aspergillus* and *Fusarium* spp.
 - synergy with amphotericin B, 509
 - HIV, 2017
 - pharmacokinetic interactions with clarithromycin
 - human immunodeficiency virus-infected volunteers, 631
 - population pharmacokinetics, 2017
 - synergy
 - amphotericin B, 509
 - Aspergillus* and *Fusarium* spp., 509
 - tolerance
 - human immunodeficiency virus-infected volunteers, 631
- Rifalazil
 - combination with isoniazid, 3047
 - M. tuberculosis*, 3047
- Rifampin
 - brain concentrations, 2626
 - CD1b expression by human peripheral blood monocytes
 - cytokine induced, increase of, 550
 - L. pneumophila*, 3153

- Legionella* spp.
 - activity in vitro, 1520
 - letter to the editor, 3334
 - M. avium*, 3006
 - M. leprae*, 3334
 - M. tuberculosis*, 2682
 - M. tuberculosis katG*, 2443
 - microspheres, 2682
 - pyelonephritis, enterococcal
 - combination with trovafloxacin, contrast with in vitro and in vivo results, 188
 - R. typhi* resistance
 - rpoB*, point mutations in, 1845
 - S. aureus rpoB*, 2590
 - trovafloxacin
 - enterococcal pyelonephritis, contrast with in vitro and in vivo results, 188
- Rifamycin
 - M. tuberculosis* resistance
 - rpoB* mutations, contribution to, 1853
- Rifamycins
 - S. pneumoniae*
 - release of lipoteichoic and teichoic acids as a result of exposure, 277
- Rifapentine
 - combination with isoniazid, 3047
- Legionella* spp.
 - activity in vitro, 1520
- M. tuberculosis*, 3047
- Ritonavir
 - ABT-378, 3218
 - fluoxetine, 3107
 - HIV, 3157
 - HIV protease, 3218
 - human immunodeficiency virus-infected patients, 1788
 - interaction with indinavir, 2784
 - MDR1, 3157
 - MRP1, 3157
 - pharmacokinetics, 3107
 - alone and in combination with zidovudine, 1788
- Roxithromycin
 - cytokine production by and neutrophil attachment to bronchial epithelial cells
 - inhibition of, 1499
- rpoB*
 - rifampin resistance, 2590
 - S. aureus*, 2590
- RPR 106972
 - M. pneumoniae*
 - comparative in vitro activity, 698
- Rufloxacin
 - interaction with theophylline, 2359
- S-1153
 - human immunodeficiency virus, drug resistant
 - inhibition of replication, 1340
- S-4661
 - in vitro and in vivo activities, 94
- Saccharomyces*
 - SPA-S-843, 3012
- Saccharomyces cerevisiae*
 - aureobasidin A resistance
 - role of ABC transporters, 755
 - dermaseptin s3, 2160
 - EF2, 2694
 - quinoline-ring containing antimalarial drugs

- resistance genes, identification of, 1034
sordarins, 2694
Salmonella enterica
 IncFI plasmid, 3053
 IncLM plasmid, 3053
 tetracycline resistance
 subsp. *enterica* serovar Dublin, 1288
Salmonella enteritidis
 DHA-1, 2352
 M. morganii *ampR*, 2352
Salmonella typhi
 lipopolysaccharide release, antibiotic induced
 delay between killing by ceftazidime and imipenem and release, 739
Salmonella typhimurium
 Caco-2/TC-7 cells, 2950
 CTX-M-5, 1980
 gentamicin, 2511
 glucose metabolism, 2950
 glutamine metabolism, 2950
 ofloxacin, 2950
Salvage kinases
 E. coli, 2620
Sanfetrinem
 β -lactamases, interaction with
 comparison with interactions with imipenem and oral β -lactams, 1168
 polymorphonuclear granulocytes, entry into, 1745
 prodrugs
 sanfetrinem cilexetil, in vivo activities, 1858
 S. pneumoniae
 in vitro activity and affinity for penicillin-binding proteins, 173
 S. pneumoniae, penicillin resistant
 intracellular, activity against, 1745
Sanfetrinem cilexetil
 in vivo activities, comparative evaluation, 1858
Saquinavir
 HIV, 3157
 MDR1, 3157
 MRP1, 3157
SCH 56592
 A. fumigatus, 2467
 T. cruzi
 antiproliferative effects and mechanism of action, 1771
Screening
 combinatorial chemical libraries
 two-dimensional agar format, 1447
SENTRY antimicrobial surveillance program
 bacteremia, bacterial pathogens from
 frequencies of occurrence and antimicrobial susceptibility patterns, 1762
Serratia marcescens
 β -lactamases
 homologous, sequences of, 176
 bla_{IMP}, 2006
 DNA gyrase
 cloning and nucleotide sequence, 190
 mutations in quinolone-resistant isolates, characterization of, 190
Serum
 ceftriaxone concentrations, 2259
Shigella flexneri
 antimicrobial resistance
 Hong Kong, 1986 to 1995, 440
 gentamicin
 delivery into mammalian cells by *S. flexneri* membrane vesicles, 1476
 gyrase, 3051
 letter to the editor, 3051
 topoisomerase IV, 3051
Shigella sonnei
 antimicrobial resistance
 Hong Kong, 1986 to 1995, 440
Silver
 SPI-ARGENT II, 2440
Single-strand conformation polymorphism-PCR
 β -lactamases, inhibitor resistant
 discriminatory detection, 879
SIPI 1029
 T. brucei, 2718
Sifalofloxacin
 antibacterial activities, 1284
 type II topoisomerases
 inhibitory effects on, 1284
Sodium stibogluconate
 L. donovani, 2722
 L. tarentolae resistance
 gene amplification, 1689
 versus amphotericin B, 2722
Sordarins
 Candida, 2274, 2279
 fungi, 2863
 P. carinii, 2863
 S. cerevisiae EF2, 2694
 yeasts, 2863
Sorivudine
 dermatomal herpes zoster
 acyclovir, comparative evaluation, 1139
 human immunodeficiency virus-infected patients, 1139
South Africa
 Enterococcus, 2752
soxS
 E. coli, 2089
 fluoroquinolone resistance, 2089
Spain
 P. gingivalis, 3022
 P. intermedia, 3022
 P. nigrescens, 3022
Sparfloxacin
 M. hominis, 2304
 P-glycoprotein, 2607
 pharmacokinetics
 chondrotoxicity and toxicokinetics in juvenile rats, 1470
 physicochemical properties that regulate penetration of quinolones, 1412
 serum and vitreous humor in rabbits, 1417
 photodegradation
 defluorinated sparfloxacin as a photoproduct, 1151
 liquid chromatography coupled with UV detection and tandem mass spectrometry, 1151
 S. pneumoniae, 2193
 secretion from Caco-2 cells, 2607
 urinary tract infection, 2262
SPA-S-843
 Candida, 3012
 Cryptococcus, 3012
 Saccharomyces, 3012
 versus amphotericin B, 3012
SPI-ARGENT II
 C. albicans, 2440
 E. coli, 2440
 P. aeruginosa, 2440
S. aureus, 2440
silver, 2440
Spiramycin
 S. ambofaciens *gimA*, 2612
St. Petersburg
 M. tuberculosis, 2443
Staphylococcus
 co-trimoxazole, 3086
 orthopedic implants, 3086
Staphylococcus aureus
 alpha-toxin, 2817
 ampicillin-sulbactam, 3325
 antibiotic susceptibility
 increase overall in *femAB* null mutants, 936
 azithromycin
 postantibiotic and sub-MIC effects, 414
 cefazolin, 2449
 ciprofloxacin sensitive, 3325
 co-amoxiclav
 in vitro activities at concentrations achieved in human serum, 1574
 coumarins, 2109
 DNA gyrase
 mutations in, novel pleiotropic effects on quinolone and coumarin activity, 121
 endocarditis
 trovafloxacin, 1837
 trovafloxacin, efficacy of, 254
 endocarditis, aortic valve
 lysostaphin, treatment of experimental infection, 1335
 eperezolid and linezolid
 comparative activity and postantibiotic effect, 721
 eperezolid resistance
 conferred by ribosomes from an oxazolidinone-resistant mutant, 947
 erythromycin, 3024
 femAB null mutants
 increased overall antibiotic susceptibility, 936
 fluoroquinolone and methicillin resistant
 letter to the editor, 727
 selection with ciprofloxacin and trovafloxacin, 727
 fluoroquinolone resistance, 3317
 fluoroquinolone resistant, methicillin susceptible and resistant
 topoisomerase mutations, 197
 gatifloxacin, 1917
 grlA, 2109
 grlA, *grlB*, *gvrA*, and *gvrB* mutations
 characterization of and effect on ciprofloxacin MIC, 1249
 grlA and *gvrA*
 mutations in, detection in 344 strains, 236
 GrIB, 3044
 isepamicin
 postantibiotic and sub-MIC effects, 414
 joint prostheses, 2830
 linezolid, 3251
 lipoteichoic acid, 3073
 LY333328, 2427
 lysostaphin
 aortic valve endocarditis, treatment of, 1335
 mec element, introduction of
 alteration of in vitro functional activities of fibrinogen and fibronectin adhesins, 564

- methicillin, 2817
 postantibiotic effect, flow cytometric assessment of, 1195
 methicillin resistance, 3317
 methicillin resistant, 3325
 LY333328, efficacy against, 981
 mecA and *mecI*, diversity of mutations, analysis of, 717
 triazine dye cibacron blue F3GA decreases oxacillin resistance, 1278
 C-8-methoxy fluoroquinolones
 killing by, 956
 MK-826, 1996
 multidrug efflux pump
 QacA, comparative analysis of resistance to diamidines, biguanidines, and guanylhydrazones, 875
 mupirocin resistant
 characterization of isolates from different geographic areas, letter to the editor, 1305
norA, 1917, 3317
 OPC-20011, 2943
 osteomyelitis
 prophylaxis with absorbable, ofloxacin-impregnated beads, 840
 oxacillin resistant
 trovafloxacin, activity in experimental endocarditis, 1837
 oxazolidinone resistance
 biochemical basis and mechanism of action, 947
 peptidoglycan, 3073
 PGG-glucan, 2449
 platelets, 3169
 quinolone resistant
 griA mutations, analysis of, letter to the editor, 1306
 quinolones, 2109
 rifampin, 2590
rpoB, 2590
 SPI-ARGENT II, 2440
 teicoplanin, 2830
 tobramycin postantibiotic effect
 dosing interval, relation to duration and clinical relevance, 749
 topoisomerase, 2109, 2122
 topoisomerase IV
 mutations in, novel pleiotropic effects on quinolone and coumarin activity, 121
 trovafloxacin, 2122, 3325
 experimental endocarditis, efficacy of, 254
 type B β -lactamase, 3163
 vancomycin, 3325
 vancomycin pharmacodynamics, 2739
 Y-688, 1889
Staphylococcus epidermidis
 biofilm formation
 antibiotic activity in vitro and in vivo, impact on, 895
 cefazolin, 2449
 methicillin resistant
 mecA and *mecI*, diversity of mutations, analysis of, 717
 PGG-glucan, 2449
 QRDR, 3293
 slime production
 effect on activities of various agents, 939
 vancomycin pharmacodynamics, 2739
Staphylococcus spp.
 coagulase negative
 eperezolid and linezolid, comparative activity and postantibiotic effect, 721
 slime production, effect on activities of various agents, 939
 coagulase negative, methicillin resistant
 decreased susceptibilities to teicoplanin and vancomycin, 100
 mecA and *gyrA*, chromosomal relationship, 306
 streptogramin A and B resistance
 plasmid carrying two resistance genes, characterization of, 1788
 trovafloxacin
 postantibiotic effect, 1503
 Stavudine
 bioavailability, 2295
 effect of food, 2295
 HIV, 2295
Stenotrophomonas maltophilia
 cephalosporins, 2002
 gentamicin, 2002
 metallo- β -lactamase L-1
 molecular heterogeneity, 1245
 overexpression, purification, and characterization, 921
 quinolones, 2002
 Stepwise mutations
 S. aureus NorA, 3317
 Sterol methyltransferase genes
 C. albicans
 sequencing, disruption, and characterization, 1160
Streptococcus mutans
 bioluminescence, 1906
Streptococcus pneumoniae
 acute otitis media
 antimicrobial-resistant pathogens in middle ear fluid, prevalence of, 589
 amoxicillin, 2375
 amoxicillin-clavulanate, 2375, 3193
 azithromycin, 2914, 3193
 β -lactams, 1973, 2914
 biofilms, 2521
 cefodizime, 2527
 cefotaxime, 2768
 bactericidal activity, letter to the editor, 1869
 ceftizoxime
 bactericidal activity, letter to the editor, 1869
 cephalosporin resistant, 2650
 clarithromycin, 3193
 clinafloxacin, 2810
 clindamycin
 HMR 3647, quinupristin-dalfopristin, and erythromycin, comparative activities of and cross-resistance to, 945
 erythromycin, 2312, 3193
 quinupristin-dalfopristin, HMR 3647, and clindamycin, comparative activities of and cross-resistance to, 945
 fluoroquinolones, 2032, 2956
 gatifloxacin pharmacodynamics, 2650
 grepafloxacin
 in vitro activity, comparative evaluation, 1263
 gyrA, 2193
 gyrase, 2810
 HMR 3004, 3309
 HMR 3004 (RU 64004)
 German isolates, activity against, 1509
 HMR 3647 (RU 66647)
 German isolates, activity against, 1509
 quinupristin-dalfopristin, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 interaction with *M. catarrhalis*, 2521
 meningitis
 moxifloxacin, activity, 1397
 MLS resistance, 2312, 2425
 OPC-20011, 2943
 otitis media, acute
 amoxicillin versus cefuroxime, 1361
parC, 2193
 PBP 1A, 2262
 penicillin resistance, high level
 penicillin-binding protein 1A, alterations in responsible for, 1329
 penicillin resistant
 acute otitis media, amoxicillin versus cefuroxime, 1361
 amoxicillin-clavulanate, activity in rat respiratory infection model, 813
 meropenem, imipenem, ceftriaxone, and ceftriaxone-vancomycin, comparative activities, 942
 penicillin resistant, intracellular sanfetrinem, activity against, 1745
 penicillin susceptible and resistant
 CS-834, treatment of experimental pneumonia, 23
 trovafloxacin, efficacy in mouse pneumonia model, 862
 penicillin-binding protein 1A
 high-level penicillin resistance, alterations responsible for, 1329
 quinupristin-dalfopristin
 HMR 3647, erythromycin, and clindamycin, comparative activities of and cross-resistance to, 945
 release of lipoteichoic and teichoic acids drug exposure, result of, 277
 sanfetrinem
 in vitro activity and affinity for penicillin-binding proteins, 173
 sparfloxacin, 2193
 susceptibilities in China, 2633
 Thr-371, 2267
 Tn917, 2312
 topoisomerase IV, 2810
 trovafloxacin
 efficacy in mouse pneumonia model, 862
 synergistic activity with ceftriaxone or vancomycin, letter to the editor, 991
Streptococcus pyogenes
 CD15s-related antigen expression
 reduction of after treatment with fosfomycin, 1083
 erythromycin resistance
 novel methylase gene (*ermTR*), 257
 erythromycin resistant, clindamycin susceptible isolates
 emergence in Madrid, letter to the editor, 989
 fosfomycin
 CD15s-related antigen expression, reduction of, 1083
 penicillin-clindamycin

- in vitro activity by E test, broth microdilution, and time-kill studies, 1266
- pharyngitis
- cefdirin treatment, 5 day, 1073
- sulfonamide resistance
- chromosomal dihydropteroate synthase, differences in amino acid sequence, 1062
- Streptococcus* spp.
- group B
- susceptibilities of isolates from patients with bacteremia or meningitis, 1517
- group C and G
- erythromycin resistance mechanisms, analysis of different, 1493
- HMR 3004 (RU 64004)
- activity against strains inducibly resistant to erythromycin, 1392
- Streptogramins
- RPR 106972
- M. pneumoniae*, comparative in vitro activity, 698
- staphylococcal resistance
- plasmid carrying two resistance genes, characterization of, 1788
- Streptomyces ambifaciens*
- gimA*, 2612
- glycosyl transferase inactivation, 2612
- spiramycin, 2612
- Streptomyces rimosus*
- letter to the editor, 3050
- OtrB, 3050
- Tet347, 3050
- tetracycline efflux, 3050
- Streptomyces virginiae*
- virginiamycin *M₁* reductase, 2985
- Streptomycin
- biosynthesis, 2041
- Sulbactam
- combinations
- ampicillin, pharmacodynamics in in vitro infection model, 231
- pharmacodynamics
- with ampicillin, in vitro infection model against resistant *E. coli*, 231
- PSE-4, 2319
- Sulbenicillin
- pharmacokinetics
- stereoselective disposition in humans, 325
- stereoselective disposition
- humans, 325
- Sulfa drugs
- P. carinii*
- quantitative structure-activity relationship studies, 1454
- Sulfadoxine-pyrimethamine
- P. falciparum* resistance
- molecular basis for, 1811
- Sulfamethoxypyridazine
- P. carinii* pneumonia
- efficacy in murine model, 934
- Sulfanilic acid
- mode of action, 1495
- Sulfathiazole
- E. coli* resistance
- mutations contributing to, characterization of, 88
- Sulfonamides
- S. pyogenes* resistance
- chromosomal dihydropteroate synthase, differences in amino acid sequence, 1062
- Susceptibility testing
- ATP-bioluminescence method
- novel test using filamentous cell treatment, 1406
- C. fetus* subsp. *fetus*, 1847
- clinafloxacin
- disk diffusion interpretive zone diameter criteria, 1274
- continuous-culture biofilm system
- G. vaginalis*, 1428
- L. acidophilus*, 1428
- G. vaginalis*
- continuous-culture biofilm system, 1428
- L. acidophilus*
- continuous-culture biofilm system, 1428
- LY303366
- endpoints, evaluation of, 1387
- U. urealyticum*
- neonatal respiratory isolates, 1290
- TAK-187
- C. neoformans*, 2630
- Tazobactam
- PSE-4, 2319
- Teicoplanin
- S. aureus*, 2830
- versus LY333328, 2452
- TEM-21
- M. organii*, 2125
- TEM-41
- letter to the editor, 2771
- TEM-61 β -lactamase
- letter to the editor, 3329
- Temacrazine
- human immunodeficiency virus type 1
- selective inhibition of replication, 487
- Terbinafine
- C. albicans*
- in vitro activities, 1057
- pathogenic yeasts
- in vitro activities, 1057
- Tet(M)
- tetracycline resistance
- host mutations reduce resistance, 59
- Tet(O)
- tetracycline resistance
- host mutations reduce resistance, 59
- Tetanus
- new pasteurized immunoglobulin
- safety and pharmacokinetic profile, 298
- Tetracycline
- C. jejuni*, 2106
- efflux, 3050
- letter to the editor, 3050
- N. gonorrhoeae* *penB*, 2799
- P. multocida* Tn5706, 2116
- resistance in *M. smegmatis*, 1931
- resistance, Tet(O) mediated
- host mutations reduce resistance, 59
- S. rimosus* OtrB, 3050
- Tetracyclines
- resistance in a gram-positive bacterium
- 16S rRNA mutation, association with, 1702
- S. enterica* subsp. *enterica* serovar Dublin
- resistance in, 1288
- Thalassemia
- artesunate, 2332
- P. falciparum*, 2332
- Theophylline
- DU-6859a
- metabolism, effect on, 1751
- interaction with rifloxacin, 2359
- pharmacokinetics, 2359
- terbinifine, effect on in healthy volunteers, 695
- Thiamphenicol
- rickettiae
- in vitro susceptibilities, 1537
- Thiazolides
- H. pylori*, 2836
- nitazoxanide, 2836
- Thiolactomycin
- P. aeruginosa* resistance
- role of efflux systems, novel technique for study, 395
- Thymidine kinase
- acyclovir, 2923
- Epstein-Barr virus, 2923
- ganciclovir, 2923
- herpes simplex virus, 2923
- Time-kill curve
- E. faecium*, 2188
- quinupristin-dalfopristin, 2188
- Time-kill studies
- antifungal
- influence of test conditions on results, 1207
- grepafloxacin
- antipneumococcal activity, comparative evaluation, 1263
- penicillin-clindamycin
- S. pyogenes*, antimicrobial effect, 1266
- Tn916
- mini-review, 1871
- Tn5706
- P. multocida*, 2116
- tetracycline, 2116
- TNF- α
- M. avium*, 2336
- Tobramycin
- pharmacokinetics
- MIC changes alter responses of *P. aeruginosa*, 1365
- postantibiotic effect
- dosing interval, relation to duration and clinical relevance, 749
- TonB
- P. aeruginosa*, 2225
- Topoisomerase
- griA*, 2109
- S. aureus*, 2109, 2122
- Topoisomerase II
- gatifloxacin, 2678
- HeLa cells, 2678
- Topoisomerase IV
- C. trachomatis*, 2474
- clinafloxacin, 2810
- gatifloxacin, 2678
- letter to the editor, 3051
- M. hominis*, 2024, 2304
- parC*, 2024
- parE*, 2024
- QRDR, 2474
- S. aureus*, 2678
- S. aureus* GrIB, 3044
- S. flexneri*, 3051
- S. pneumoniae*, 2810
- Topoisomerases
- E. faecalis* resistance
- alterations in ParC subunit, association with, 433
- inhibitors
- rapid throughput in vivo screen for, 889

- S. aureus*
 mutations, novel pleiotropic effects on
 quinolone and coumarin activity, 121
S. aureus, fluoroquinolone resistant, meth-
 icillin susceptible and resistant
 mutations, 197
 type II
 sitafloxacin, inhibitory effects on, 1284
 Tosufloxacin
 pharmacokinetics
 aluminum hydroxide and famotidine,
 effects on bioavailability, 453
 Toxicity
 sparflaxacin
 chondrotoxicity and toxicokinetics in
 juvenile rats, 1470
 Toxocariasis
 ivermectin, 2770
 letter to the editor, 2770
Toxoplasma gondii
 encephalitis
 trimethoprim-sulfamethoxazole versus
 pyrimethamine-sulfadiazine, 1346
 NSC 113452, 2284
 NSC 113455, 2284
 paclitaxel, 2032
 triple infection with *P. carinii* and *M.*
avium in rat model
 drug evaluation, 1068
 Transcription termination factor Rho
 bicyclomycin
 effects on RNA- and ATP-binding ac-
 tivities, 571
 Transplant patients
 amphotericin B nephrotoxicity, 3103
 Triazine dyes
 cibacron blue F3GA
 reduction of oxacillin resistance in me-
 thicillin-resistant *S. aureus*, 1278
 Triazines
 SIPI 1029, 2718
T. brucei, 2718
 Triazoles
A. fumigatus, 2467
 BMS-207147
 in vitro activity, 313
C. neoformans, 2630
 D0870
 pharmacokinetics of two multiple-dos-
 ing regimens in human immunode-
 ficiency virus-positive patients, 903
 SCH 56592
T. cruzi, antiproliferative effects and
 mechanism of action, 1771
 SCH56592, 2467
 TAK-187, 2630
 Trimethoprim
C. jejuni dfr, 3059
 dihydrofolate reductase, 2221
 Trimethoprim-sulfamethoxazole
 toxoplasmic encephalitis
 patients with AIDS, randomized trial,
 1346
 pyrimethamine-sulfadiazine, compara-
 tive evaluation, 1346
 1,1,3-Trisoxo-2H,4H-thieno[3,4-
 e][1,2,4]thiadiazine (T1D) derivatives
 anti-human immunodeficiency virus ac-
 tivity, 618
 Trovafloxacin
B. paraperitussis
 susceptibilities to, letter to the editor,
 1868
B. pertussis
 susceptibilities to, letter to the editor,
 1868
C. burnetii, 2747
 combination with gentamicin, 2002
 combinations with cephalosporins, 2002
 cytokine production by human monocytes
 effect on, 1713
 endocarditis
S. aureus, oxacillin resistant, activity
 against, 1837
 enterococci
 activity in an in vitro dynamic model of
 infection, 72
 pharmacodynamics
 in vitro dynamic model of infection, 72
 pharmacokinetics, 2048, 2841
 postantibiotic effect
 gram-positive and -negative organisms,
 1503
 pyelonephritis, enterococcal
 combination with rifampin, contrast
 with in vitro and in vivo results,
 188
 rifampin
 enterococcal pyelonephritis, contrast
 with in vitro and in vivo results,
 188
S. aureus, 2122, 3325
S. aureus endocarditis
 experimental, efficacy of, 254
S. aureus, oxacillin resistant
 endocarditis, 1837
S. maltophilia, 2002
S. pneumoniae
 release of lipoteichoic and teichoic ac-
 ids as a result of exposure, 277
 synergistic activity with ceftriaxone or
 vancomycin, letter to the editor,
 991
S. pneumoniae, penicillin susceptible and
 multiresistant
 efficacy in mouse pneumonia model,
 862
 topoisomerase, 2122
 Trybazine hydrochloride
 trypanosomes, 2858
 Trychophyton spp.
 NND-502
 lanconazole and terbinafine, compara-
 tive evaluation, 967
Trypanosoma brucei
 megalomicin, 2668
 SIPI 1029, 2718
Trypanosoma cruzi
 azole resistance, 3245
 benzimidazole, 2549
 IL-12, 2549
 megalomicin, 2668
 SCH 56592
 antiproliferative effects and mechanism
 of action, 1771
 Trypanosomes
 trybazine hydrochloride, 2858
 Trypanosomiasis
 isometamidium, sustained-release device
 prophylactic effect, 1012
 Turkey
P. aeruginosa OXA-16, 3117
 Two-component signal transduction
 target for microbial anti-infective therapy
 minireview, 1529
 TXU (anti-CD7)-pokeweed antiviral protein
 human immunodeficiency virus type 1
 potent inhibition, comparative evalua-
 tion, 383
 U937 cells
 uptake of *L. pneumophila*, 2870
Ureaplasma urealyticum
 susceptibility testing
 neonatal respiratory isolates, 1290
 Urinary tract infection
 community acquired, 2262
 ofloxacin, 2262
 sparflaxacin, 2262
 Valaciclovir
 herpes simplex virus type 1
 latency, prevention of, quantitative
 comparison with famciclovir, 1555
 Valproic acid
 3'-azido-3'-deoxythymidine
 glucuronidation by human liver micro-
 somes, inhibition by, 1592
 panipenem, 3136
 pharmacokinetics
 zidovudine, glucuronidation by human
 liver microsomes, inhibition by,
 1592
 VanA
 glycopeptide resistance elements
 diversity, human and nonhuman
 sources, 502
 vanB
 glycopeptide resistance
E. faecium, transferable, plasmid medi-
 ated, 963
 Vancomycin
B. cirulans, 2055
 combinations
 ciprofloxacin, prophylaxis in bone mar-
 row transplant recipients, 1402
E. faecium, 2150, 2564, 2710
E. faecium resistance
 characterization of isolates from United
 States, 1088
 dalopristin-quinupristin susceptibility in
 vitro, 1088
 enterococci, 2215
 Enterococcus resistance
 van genes, DNA sequence variation,
 202
 glycopeptides, 2215
 historical yearly usage
 letter to the editor, 1303
 letter to the editor, 2463
 LY333328, 2564
 orthopedic implants, 3002
 pharmacodynamics, 2739
 resistant enterococci, 2463
S. aureus, 2739, 3325
S. epidermidis, 2739
 versus LY333328, 2452
 Varicella-zoster virus
 A-5021, 2095
 acyclovir
 human immunodeficiency virus-infected
 patients, 1139
 sorivudine, comparative evaluation,
 1139
 sorivudine
 acyclovir, comparative evaluation, 1139
 human immunodeficiency virus-infected
 patients, 1139

- Venovenous hemofiltration
meropenem, 2417
- Ventriculostomy
meropenem, 2012
- Vibrio cholerae*
fluoroquinolone resistance
letter to the editor, 206
patients with acute diarrhea in Calcutta,
India, 206
- Vibrio parahaemolyticus*
NorM multidrug efflux protein
cloning and sequencing, 1778
- Virginiamycin M₁
S. virginiae reductase, 2985
- Viridans streptococci
ciprofloxacin, 2792
ORDR, 2792
- Voriconazole
A. fumigatus, 2299
Aspergillus, 3018
C. albicans
neutrophils or monocytes, combination
with, 907
C. neoformans, fluconazole susceptible
and resistant
comparative efficacy, itraconazole, 471
Candida, 3018
Candida spp.
comparative in vitro activities, 161
G-CSF, 2299
GM-CSF, 2299
in combination with monocytes, 2299
in combination with neutrophils, 2299
neutrophils or monocytes, combination with
C. albicans, 907
versus amphotericin B, 3018
versus itraconazole, 3018
- Woodchucks
hepatitis B virus, 3209
WR 238605
P. falciparum malaria
prophylaxis in a human challenge
model, 1293
- Y-688
anaerobic bacteria
in vitro activities, 419
S. aureus, 1889
- Yeasts
terbinafine
in vitro activities, 1057
- Yersinia enterocolitica*
amikacin, 3009
ceftriaxone, 3009
ciprofloxacin, 3009
O9, 3009
- Yersinia pestis*
pneumonic plague, experimental
antibiotic treatments, comparative eval-
uation, 675
- Zalcitabine
pharmacokinetics, 2174
application of radioimmunoassay to
population pharmacokinetics, 409
- Zidovudine
foscarnet coresistance, 3038
HIV, 3038
pharmacokinetics
premature infants exposed to human
immunodeficiency virus, 808
- Zinc-finger-active drugs
G. lamblia
efficacy of, 1488

